
<html lang="en"     class="pb-page"  data-request-id="258430bc-f920-425a-a3a2-f7de0f3e0284"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01520;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure–Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides" /></meta><meta name="dc.Creator" content="Wenhu  Zhan" /></meta><meta name="dc.Creator" content="Pradeep K.  Singh" /></meta><meta name="dc.Creator" content="Yi  Ban" /></meta><meta name="dc.Creator" content="Xiaoping  Qing" /></meta><meta name="dc.Creator" content="Marie Dominique  Ah Kioon" /></meta><meta name="dc.Creator" content="Hao  Fan" /></meta><meta name="dc.Creator" content="Quanju  Zhao" /></meta><meta name="dc.Creator" content="Rong  Wang" /></meta><meta name="dc.Creator" content="George  Sukenick" /></meta><meta name="dc.Creator" content="Jane  Salmon" /></meta><meta name="dc.Creator" content="J. David  Warren" /></meta><meta name="dc.Creator" content="Xiaojing  Ma" /></meta><meta name="dc.Creator" content="Franck J.  Barrat" /></meta><meta name="dc.Creator" content="Carl F.  Nathan" /></meta><meta name="dc.Creator" content="Gang  Lin" /></meta><meta name="dc.Description" content="The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic β5i subunit of i-20S inhibi..." /></meta><meta name="Description" content="The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic β5i subunit of i-20S inhibi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 23, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01520" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01520" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01520" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01520" /></link>
        
    
    

<title>Structure–Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01520" /></meta><meta property="og:title" content="Structure–Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0015.jpeg" /></meta><meta property="og:description" content="The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic β5i subunit of i-20S inhibits T cell activation, B cell proliferation, and dendritic cell differentiation in vitro and suppresses immune responses in animal models of autoimmune disorders and allograft rejection. However, cytotoxicity to immune cells has accompanied the use of covalently reactive β5i inhibitors, whose activity against the constitutive proteasome (c-20S) is cumulative with the time of exposure. Herein, we report a structure–activity relationship study of a class of noncovalent proteasome inhibitors with picomolar potencies and 1000-fold selectivity for i-20S over c-20S. Furthermore, these inhibitors are specific for β5i over the other five active subunits of i-20S and c-20S, providing useful tools to study the functions of β5i in immune responses. The potency of these compounds in inhibiting human T cell activation suggests that they may have therapeutic potential." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01520"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01520">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01520&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01520&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01520&amp;href=/doi/10.1021/acs.jmedchem.0c01520" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 13103-13123</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01494" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01555" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure–Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wenhu Zhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhu Zhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhu++Zhan">Wenhu Zhan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7095-7081" title="Orcid link">http://orcid.org/0000-0002-7095-7081</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pradeep K. Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pradeep K. Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, Milstein Chemistry Core Facility, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pradeep+K.++Singh">Pradeep K. Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi Ban</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi Ban</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Ban">Yi Ban</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoping Qing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoping Qing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoping++Qing">Xiaoping Qing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marie Dominique Ah Kioon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie Dominique Ah Kioon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie+Dominique++Ah+Kioon">Marie Dominique Ah Kioon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Fan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Fan">Hao Fan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Quanju Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Quanju Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Quanju++Zhao">Quanju Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, Room 1735, New York, New York 10065-6007, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Wang">Rong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">George Sukenick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">George Sukenick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, Room 1735, New York, New York 10065-6007, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=George++Sukenick">George Sukenick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jane Salmon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jane Salmon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jane++Salmon">Jane Salmon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. David Warren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. David Warren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, Milstein Chemistry Core Facility, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+David++Warren">J. David Warren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaojing Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojing Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojing++Ma">Xiaojing Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Franck J. Barrat</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Franck J. Barrat</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div><div class="loa-info-affiliations-info">Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Franck+J.++Barrat">Franck J. Barrat</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carl F. Nathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carl F. Nathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carl+F.++Nathan">Carl F. Nathan</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Gang Lin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3057515c02000005705d55541e535f425e555c5c1e555445"><span class="__cf_email__" data-cfemail="bbdcdad7898b8b8efbd6dedf95d8d4c9d5ded7d795dedfce">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Lin">Gang Lin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4797-7073" title="Orcid link">http://orcid.org/0000-0003-4797-7073</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01520&amp;href=/doi/10.1021%2Facs.jmedchem.0c01520" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 13103–13123</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 23, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 August 2020</li><li><span class="item_label"><b>Published</b> online</span>23 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01520</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13103%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWenhu%2BZhan%252C%2BPradeep%2BK.%2BSingh%252C%2BYi%2BBan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c01520%26title%3DStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNoncovalent%2BImmunoproteasome%2B%25CE%25B25i-Selective%2BDipeptides%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13123%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01520"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">683</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01520" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure–Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wenhu&quot;,&quot;last_name&quot;:&quot;Zhan&quot;},{&quot;first_name&quot;:&quot;Pradeep&quot;,&quot;last_name&quot;:&quot;K. Singh&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Ban&quot;},{&quot;first_name&quot;:&quot;Xiaoping&quot;,&quot;last_name&quot;:&quot;Qing&quot;},{&quot;first_name&quot;:&quot;Marie&quot;,&quot;last_name&quot;:&quot;Dominique Ah Kioon&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Quanju&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Sukenick&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;Salmon&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;David Warren&quot;},{&quot;first_name&quot;:&quot;Xiaojing&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Franck&quot;,&quot;last_name&quot;:&quot;J. Barrat&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;F. Nathan&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Lin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13103-13123&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01520&quot;},&quot;abstract&quot;:&quot;The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic β5i subunit of i-20S inhibits T cell activation, B cell proliferation, and dendritic cell differentiation in vitro and suppresses immune responses in animal models of autoimmune disorders and allograft rejection. However, cytotoxicity to immune cells has accompanied the use of covalently reactive β5i inhibitors, whose activity against the constitutive proteasome (c-20S) is cumulative with the time of exposure. Herein, we report a structure–activity relationship study of a class of noncovalent proteasome inhibitors with picomolar potencies and 1000-fold selectivity for i-20S over c-20S. Furthermore, these inhibitors are specific for β5i over the other five active subunits of i-20S and c-20S, providing useful tools to study the functions of β5i in immune responses. The potency of these compounds in inhibiting human T cell activation suggests th&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01520&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01520" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01520&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01520" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01520&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01520" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01520&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01520&amp;href=/doi/10.1021/acs.jmedchem.0c01520" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01520" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01520" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01520%26sid%3Dliteratum%253Aachs%26pmid%3D33095579%26genre%3Darticle%26aulast%3DZhan%26date%3D2020%26atitle%3DStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNoncovalent%2BImmunoproteasome%2B%25CE%25B25i-Selective%2BDipeptides%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D13103%26epage%3D13123%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292569" title="Acid and base chemistry">Acid and base chemistry</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic β5i subunit of i-20S inhibits T cell activation, B cell proliferation, and dendritic cell differentiation in vitro and suppresses immune responses in animal models of autoimmune disorders and allograft rejection. However, cytotoxicity to immune cells has accompanied the use of covalently reactive β5i inhibitors, whose activity against the constitutive proteasome (c-20S) is cumulative with the time of exposure. Herein, we report a structure–activity relationship study of a class of noncovalent proteasome inhibitors with picomolar potencies and 1000-fold selectivity for i-20S over c-20S. Furthermore, these inhibitors are specific for β5i over the other five active subunits of i-20S and c-20S, providing useful tools to study the functions of β5i in immune responses. The potency of these compounds in inhibiting human T cell activation suggests that they may have therapeutic potential.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the approval of Bortezomib for the treatment of once largely untreatable multiple myeloma, components of the ubiquitin proteasome system (UPS) of protein degradation have become attractive drug targets for various malignancies and autoimmune disorders. The UPS degrades cellular proteins via a highly regulated process by which protein substrates are polyubiquitinated through a cascade of reactions catalyzed by a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3). Polyubiquitinated proteins are recognized, unfolded, and translocated by the proteasome regulatory particle (19S) into the 20S core particle for degradation by three proteolytic β subunits in the 20S core: β1, β2, and β5.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Through this ordered degradation process, the UPS regulates numerous cellular activities ranging from the removal of unfolded or damaged proteins to cell cycle progression, transcription factor activation, and immune surveillance by providing antigenic peptides for presentation by MHC class I molecules.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Pan-proteasome inhibitors limit the supply of peptides for MHC class I molecules and thus block antigen presentation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Bortezomib is highly toxic to plasma cells<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and has been used to prevent antibody-mediated graft rejection of transplanted kidneys, although the effect is modest at the limited doses that are considered tolerable in patients who do not have an incurable malignancy.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Species-selective inhibitors of proteasomes of pathogenic microbes have been developed for the treatment of infections by <i>Mycobacterium tuberculosis</i>,<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9−12)</a><i>Plasmodia</i>,<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a><i>Leishmania</i>, and <i>Trypanosoma</i>,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> suggesting further potential therapeutic utility of proteasome inhibitors.</div><div class="NLM_p">To harness the benefit of proteasome inhibitors in the therapy of autoimmune disorders without the toxicity of pan-proteasome inhibition, it is necessary to develop proteasome inhibitors that selectively target one or more of the proteasome subunits that predominate in the immune system rather than those expressed in nonimmune cells. There are two major isoforms of proteasome in humans that differ in each of the three proteolytically active subunits: constitutive proteasome (c-20S) and immunoproteasome (i-20S). Recent proteomic studies have found that i-20S predominates in the cells of the human innate and adaptive immune systems.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The i-20S is also upregulated in other cells at sites of inflammation and upon exposure to interferon-γ.</div><div class="NLM_p">Selective inhibitors of i-20S β5i over c-20S β5c have been reported, such as the peptide epoxyketone ONX0914, which produced similar immunoregulatory effects in mice as BTZ but with much reduced toxicity.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26">(20−26)</a> A recent study reported an improvement in ONX0914 with up to 600-fold selectivity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Reports on ONX0914 were followed by reports of other selective i-20S inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>); due to space limitations, only reviews and the most recent primary publications are cited.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33">(27−33)</a> Most reported inhibitors are peptide epoxyketones or sulfonyl fluorides that act covalently and irreversibly with the active site. Irreversible covalent binding can result in unpredictable liver toxicity, even if off-target binding occurs at a low level,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and irreversible inhibitors often show diminished selectivity over time.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Compounds reported in patents also include amino boronates from Merck-Serono and substituted thiazoles and peptide α-keto amides from Roche (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). These three classes of i-20S inhibitors are either covalent but reversible or noncovalent. They represent alternative directions for developing i-20S-selective inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of some reported immunoproteasome inhibitors. ONX0914 was previously named PR957.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Merck-Serono β5i-selective inhibitor 76, Ro19, and Roche compound 21 were reported in a patent review.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> HT2004, DPLG3, and PKS21221 were recently reported as β5i-selective inhibitors.<a onclick="showRef(event, 'ref35 ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref38">(35,36,38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recently, our labs reported three new classes of immunoproteasome inhibitors (IPIs): 1,3,4-oxathiazol-2-ones,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> β-amino acid-based <i>N</i>,<i>C</i>-capped dipeptidomimetics,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and <i>N</i>,<i>C</i>-capped dipeptides.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> We also discovered asparagine-ethylenediamine IPIs (AsnEDAs) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The latter three classes are noncovalent inhibitors and highly β5i-selective. We have demonstrated that compounds from each class inhibit β5i in cells and restrict immunological responses of plasmacytoid dendritic cells, B cells, and T cells in vitro.<a onclick="showRef(event, 'ref35 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref38">(35,38)</a> We reported that DPLG3 prolonged the survival of MHC-mismatched mouse cardiac allografts in a heterotopic heart transplant model.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, DPLG3 lacks drug-like properties. Herein, we report our further structure–activity relationship (SAR) studies of the <i>N</i>,<i>C</i>-capped dipeptides.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design Rationale</h3><div class="NLM_p">DPLG3 was developed based on DPLG2, which was designed for species-selective inhibition of the <i>M. tuberculosis</i> proteasome (Mtb20S) over i-20S and c-20S.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> We have shown that i-20S and Mtb20S share similar substrate preferences, especially at the S1 site (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which prefers bulky hydrophobic moieties as visualized in the structures of Mtb20S and i-20S.<a onclick="showRef(event, 'ref9 ref10 ref12 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref12 ref38 ref39">(9,10,12,38,39)</a> We postulated that by anchoring a bulky P1 (<i>N</i>-cap) in the <i>N</i>,<i>C</i>-capped dipeptide, we could explore the P2 (R<sub>2</sub>), P3 (R<sub>3</sub>), and <i>N</i>-cap positions to improve potency and in the meantime maintain selectivity and improve pharmacokinetic properties.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Illustration of <i>N</i>-cap, R<sub>2</sub>, R<sub>3</sub>, and <i>C</i>-cap and their binding sites in the β5 active subunits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">DPLG3 is a highly selective immunoproteasome β5i inhibitor with single-digit nanomolar potency but it suffers from poor physicochemical properties and cell permeability.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> We reported that replacing P2 <i>p</i>-F-phenylalanine of DPLG3 with <i>O</i>-methyl-serine (PKS2086) maintained potency, but the isoform selectivity (β5c/β5i) over c-20S was reduced to 68-fold. Replacing P2 <i>O</i>-methyl-serine in PKS2086 with P2 Ala (PKS2058) improved isoform selectivity (β5c/β5i = 230) and maintained comparable inhibition activity. These preliminary structure–activity analyses suggested that even partially exposing S2 to the solvent could be used to tune the physicochemical properties and selectivity profile of <i>N</i>,<i>C</i>-capped dipeptides, inviting further SAR studies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibition IC<sub>50</sub> Values of Compounds with P4 Amides against Human c-20S β5c and i-20S β5i</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0013.gif" alt="" id="fx2" /></img><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <i>C</i>-Cap Optimization</h3><div class="NLM_p last">The <i>C</i>-cap binds to the S1 pocket, which is immediately adjacent to the active site. Structural studies of i-20S and c-20S have revealed that this S1 site dictates the selectivity of an inhibitor between β5i and β5c. We have shown that the P1 naphthyl ring is the selectivity driver, but the naphthyl ring is hydrophobic. To improve solubility and microsomal stability, we replaced the naphthalenemethyl ring in PKS2058 with the following substituents: 4-quinolinmethyl (PKS2068), 5-quinolinmethyl (PKS2073), and 4-indolemethyl (PKS2083). Quinolinyl analogues eliminated inhibitory activity against both β5i and β5c, while the indolyl analogue decreased the potency against β5i and increased the activity against β5c. Replacing 1-naphthalenemethyl on the <i>C</i>-cap of PKS2086 with 8-quinolinmethyl (PKS2220) and 8-tetrahydroquinolinmethyl (PKS2226) led to 19-fold and 114-fold reductions in β5i activities, respectively, further suggesting that a basic P1 moiety is detrimental to its interaction with the hydrophobic S1 pocket of β5i. Using substituted benzyl groups as <i>C</i>-caps, as in PKS2160 and PKS2211, abolished selectivity. Therefore, we kept the naphthalenemethyl moiety as the <i>C</i>-cap for further SAR studies.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>N</i>-Cap Optimization</h3><div class="NLM_p last">Subsequent exploration of the <i>N</i>-cap with small, focused libraries revealed that a hydrophobic <i>N</i>-cap helps maintain selectivity. Extending the phenylpropionate group on the <i>N</i>-cap of PKS2058 yielded PKS2127. Phenylbutanoate-bearing PKS2127 was >5076-fold-selective for β5i over β5c and yet with only 3-fold lower potency than PKS2058. Likewise, the abridged analogue PKS2142 showed a 1840-fold preference for β5i. Replacement of phenylpropionate in PKS2058 with the smaller trifluoroacetate in PKS2106 resulted in diminished activity with decent selectivity (β5c/β5i = 229). Conversely, polar <i>N</i>-caps were not tolerated, as exemplified by the pyrazine PKS2098, the morpholine PKS2099, the thiazole PKS2102, and the isoxazole PKS2105, all of which suffered a significant reduction in β5i inhibitory potency and compromised selectivity compared to PKS2058.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> R3 Optimization</h3><div class="NLM_p">We have detailed the role of the defined S3 pocket in the species-selective binding of <i>N</i>,<i>C</i>-capped dipeptide inhibitors to the Mtb20S,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> but we have found no reports exploring interactions with the S3 pocket for improving β5i potency and selectivity for β5i over β5c. Accordingly, we changed R3 from branched chain amino acids to asparagine and glutamine. Replacing the R3 Asn-O<i><sup>t</sup></i>Bu with <i>O</i>-methyl-Ser (PKS2048) or Asn (PKS21083) abolished the inhibitory activities against both β5i and β5c, whereas the Asn-neopentyl analogue (PKS21066) was tolerated, suggesting that Asn coupled with a bulky moiety on the side chain would be a potency driver for <i>N</i>,<i>C</i>-capped dipeptide proteasome inhibitors. Replacement of R3 Asn-O<i><sup>t</sup></i>Bu with Asn-oxetane (PKS2130) reduced potency against β5i over 100-fold compared to PKS2058, further testifying to the critical role of the bulky O<i><sup>t</sup></i>Bu group in the inhibition of β5i activity. Replacing the R3 Asn-O<i><sup>t</sup></i>Bu (PKS2086) with Asn amide with a fully substituted N atom (PKS2209, 2230BP, 2205, and 2208) resulted in a significant loss of affinity for both β5i and β5c. However, the bulky Asn piperidine in PKS2206 did not impose a great loss in potency and retained selectivity. Removal of the O atom from Asn-O<i><sup>t</sup></i>Bu of PKS2086 provided PKS2230. While their potencies and selectivity profiles are similar, the physicochemical properties of “amide” PKS2230 would be presumably better than those of the “<i>N</i>-alkoxyamide” PKS2086. Improvement in β5i potency was observed for the R3 Gln-<i><sup>t</sup></i>Bu analogue PKS2243 (IC<sub>50</sub> = 0.0023 μM), suggesting that Gln-O<i><sup>t</sup></i>Bu fits the S3 pocket better than Asn-O<i><sup>t</sup></i>Bu, despite their comparable lengths. The trend was further attested by the observation that replacing R3 Asn-O<i><sup>t</sup></i>Bu of PKS2058 (IC<sub>50</sub> = 0.0057 μM) with Gln-O<i><sup>t</sup></i>Bu (PKS2255, IC<sub>50</sub> = 0.0015 μM) boosted β5i potency by 3.8-fold. However, the potency against β5c was enhanced slightly more, impairing β5i selectivity by 2- to 3-fold (PKS2255 vs PKS2058, PKS2243 vs PKS2086). We thus chose Asn-<sup>t</sup>Bu (selectivity) or Gln-<i><sup>t</sup></i>Bu (potency) as R3 for further optimization.</div><div class="NLM_p">Introduction of a 4-F substituent on the <i>C</i>-cap naphthalenemethyl of PKS2255, which was expected to block metabolism, gave PKS21210, an equipotent β5i inhibitor with about 2-fold improvement in selectivity relative to PKS2255. The isoform selectivity (β5c/β5i = 204) of PKS21271, a hybrid compound incorporating both the 4-F naphthalenemethyl group and the R3 Asn-<sup><i>t</i></sup>Bu, was slightly improved relative to that of PKS2255 (β5c/β5i = 152), whereas the potency was compromised by over 30-fold. Because 3-indoleglyoxylate was reported to be an optimal <i>N</i>-cap for dipeptide inhibitors of the human 20S proteasome with a P3 threonine residue,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> we incorporated it into the scaffold of the current β5i inhibitor. Combining 3-indoleglyoxylate <i>N</i>-cap with R3 Asn-<sup><i>t</i></sup>Bu yielded a β5i inhibitor with pM IC<sub>50</sub> and over 100-fold selectivity (PKS3053). Additionally, we revisited the 5-methylisoxazole-3-carboxylate <i>N</i>-cap with an aim to further improve the selectivity profile. Replacing the phenylpropionate group of PKS21210 and PKS21217 with 5-methylisoxazole-3-carboxylate improved selectivity indices from 152- and 204-fold to 508- (PKS21272) and 984-fold (PKS21213) and, unexpectedly, also improved β5i inhibition by 1.3- and 2.7- fold. Still better, 765- and 1187-fold isoform selectivities were recorded for two R2 <i>O</i>-methyl-serine analogues, PKS21245 and PKS21244. A 4-F substituent on the <i>C</i>-cap naphthalenemethyl contributed over 4-fold improvement to the noteworthy isoform selectivity of PKS21244 compared to that of PKS2244.</div><div class="NLM_p">Next, we assessed the influence of a sulfonyl <i>N</i>-cap on asparagine and glutamine derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We replaced phenylpropionate with tosyl on the <i>N</i>-cap of PKS2255, yielding PKS2256. IC<sub>50</sub> values were determined to be 400 pM against β5i and 424 nM against β5c, affording 3 orders of magnitude of selectivity. As in compounds with the selectivity-enhancing 4-F substituents described above, a further 2-fold improvement in selectivity was observed for PKS21209 (β5c/β5i = 2329). However, PKS21209 exhibited a 6-fold reduction in potency against β5i compared to PKS2256. Again, replacing the Gln-<i><sup>t</sup></i>Bu of PKS21209 with Asn-<sup><i>t</i></sup>Bu (PKS21206) lost 6.8-fold in potency of inhibition of β5i but improved the selectivity to 3274-fold over the inhibition of β5c. This pattern of impact on β5i activity was reinforced in the R2 <i>O</i>-methyl-serine analogues PKS21265 and PKS21266, where the Gln-<i><sup>t</sup></i>Bu PKS21265 (IC<sub>50</sub> = 0.8 nM) exhibited a 70-fold greater activity over Asn-<sup><i>t</i></sup>Bu PKS21266 (IC<sub>50</sub> = 56 nM) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of β5i and β5c by select dipeptides. (A) Dose-dependent inhibition of β5i and β5c by compounds indicated in the <i>x</i>-axis. (B) <i>K</i><sub>i</sub> of PKS21265 was also determined with varying concentrations of PKS21265 and substrate suc-LLVY-AMC. The Lineweaver–Burk plot was shown on the left. The plot of slopes against the inhibitor concentration yields a <i>K</i><sub>i</sub> of 3.1 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition of IC<sub>50</sub> Values of Compounds with P4 Tosyl against Human c-20S β5c and i-20S β5i</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0014.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data were taken from ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>.</p></div></div><div></div></div><div class="NLM_p">We further determined β1 or β2 activities of six select compounds in either i-20S or c-20S, and all exhibited <50% inhibition against β1i, β1c, β2i, or β2c at a concentration of 33.3 μM, suggesting that they are <i>bona fide</i> β5i-specific inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_p last">Blackburn and others have shown that <i>N</i>,<i>C</i>-capped dipeptides are generally specific inhibitors of proteasome over a panel of proteases.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We next tested these compounds against α-chymotrypsin, cathepsin L, and trypsin with the compounds at 100, 33.3, and 11.1 μM. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf" class="ext-link">Table S2</a>, all of the compounds were inactive against all three proteases, except for weak inhibition of α-chymotrypsin and cathepsin L by PKS3053. Thus, in agreement with the previous study,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> these compounds were highly specific for proteasome inhibition.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Inhibition Kinetics of i-20S β5i</h3><div class="NLM_p last">The kinetics of proteasome inhibition can be complicated by the duplication of each active site in different rings of the proteasome.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> We have observed that an active site binding inhibitor can behave like a noncompetitive inhibitor.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We selected PKS21265 for elucidation of the kinetics of inhibition of β5i. The Lineweaver–Burk plot of 1/<i>V</i> versus 1/<i>S</i> in the presence of different concentrations of PKS21265 yielded a series of straight lines that had the same <i>x</i>-intercept, suggesting a typical noncompetitive inhibition kinetics (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Intracellular Proteasome Inhibition</h3><div class="NLM_p">To investigate if these <i>N</i>,<i>C</i>-capped dipeptides are cell-permeable, we selected three compounds with <i>N</i>-cap amides and three compounds with <i>N</i>-cap sulfonamides and tested their intracellular proteasome inhibition in Karpas-1106P cells (which express i-20S but not c-20S) and HeLa cells (which express c-20S but not i-20S). These compounds dose-dependently inhibited i-20S β5i in Karpas-1106P and c-20S β5c in Hela cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), and in situ potencies were correlated well with their activities determined in vitro with purified enzymes (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In situ inhibition of i-20S β5i in Karpas-1106P and c-20S β5c in Hela cells and dose-dependent inhibition of T cell activation in peripheral blood mononuclear cells (PBMCs) stimulated by anti-CD3 antibody. All experiments were repeated three times. Representative results are shown and data are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibition of i-20S β5i in Karpas-1106P and c-20S β5c in Hela Cells by Select Compounds and Their Inhibition of T Cell Proliferation in PBMCs upon Stimulation by Anti-CD3 Antibody</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">Karpas-1106P</th><th class="colsep0 rowsep0" align="center" char=".">HELA</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS3053</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.293</td><td class="colsep0 rowsep0" align="char" char=".">0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS21210</td><td class="colsep0 rowsep0" align="char" char=".">0.039</td><td class="colsep0 rowsep0" align="char" char=".">2.031</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS21272</td><td class="colsep0 rowsep0" align="char" char=".">0.053</td><td class="colsep0 rowsep0" align="char" char=".">4.306</td><td class="colsep0 rowsep0" align="char" char=".">0.073</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS21209</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">3.030</td><td class="colsep0 rowsep0" align="char" char=".">0.039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS21265</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="char" char=".">1.861</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKS21266</td><td class="colsep0 rowsep0" align="char" char=".">0.197</td><td class="colsep0 rowsep0" align="char" char=".">22.56</td><td class="colsep0 rowsep0" align="char" char=".">0.073</td></tr></tbody></table></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibition of T Cell Activation and Proliferation</h3><div class="NLM_p last">We have shown that β5i-selective β-amino acid-based dipeptides inhibit the activation and proliferation of human T cells in peripheral blood mononuclear cells.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> We tested the same six compounds as above for their inhibitory activity against primary human T cells stimulated by anti-CD3 antibody (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). PKS3053 was two times more active than PKS21210 and >3 times more active than PKS21272 and the activity tracked with their IC<sub>50</sub> values against β5i. With its <i>N</i>-cap sulfonamide, PS21265 was the most potent compound, with 2-fold greater potency compared to PKS21209 and 5-fold compared to PKS21266 (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of dipeptide analogues with different <i>N</i>-caps is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. PKS2058 was synthesized by condensation of PKS21059<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> with PKS2026.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The reaction gave a poor yield (6%) due to intramolecular cyclization of PKS21059 giving <i>N</i>-<i>tert</i>-butoxysuccinimide byproduct. Other <i>N</i>-cap analogues were synthesized from PKS21054.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Debenzylation of PKS21054 and coupling with Ala-OBn followed by debenzylation and coupling with 1-methylnaphthylamine gave PKS2095. Finally, BOC-deprotection and coupling with appropriate carboxylic acids gave the <i>N</i>-cap analogues. <i>C</i>-cap analogues were synthesized from PKS21059 (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Coupling of PKS21059 with Ala-OBn and subsequent debenzylation gave PKS2067. Different amines were coupled with PKS2067 to give <i>C</i>-cap analogues. PKS2048 was synthesized from PKS2032<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> by BOC-deprotection and coupling with 3-phenylpropanoic acid.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Cap Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, HOBt, Hünig’s base; (b) 10% Pd on carbon, methanol, H<sub>2</sub> balloon, 98%; (c) <i>O</i>-benzylalanine hydrochloride, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), HOAt, Hünig’s base, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 59%; (d) 1-naphthylmethylamine, HATU, HOAt, Hünig’s base, DMF; (e) 20% trifluoroacetic acid (TFA) in dichloromethane (DCM); and (f) RCOOH, HATU, HOAt, Hünig’s base, DMF.</p></p></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>C</i>-cap Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) 10% Pd on carbon, H<sub>2</sub> balloon, EtOH; (c) TFA, DCM; and (d) 3-phenylpropanoic acid, EDC, HOBt, Hünig’s base, DMF.</p></p></figure><div class="NLM_p">The synthesis of compounds where P2 is methylserine is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The commercially available <i>O</i>-methylserine was coupled with 3-methoxybenzyl amine and subsequent BOC-deprotection gave compound PKS2158. The condensation of PKS21059 with PKS2158 provided compound PKS2160. Similarly, compound PKS2220 was synthesized starting from <i>O</i>-methylserine and 8-quinolinmethylamine. Compound PKS2211 was synthesized by condensation of <i>O</i>-methylserine with 2,3-dimethoxybenzyl amine. The condensation product was subjected to BOC-deprotection and coupled with BOC-Asp(OBn)-OH to give PKS2191. Again, BOC-deprotection and coupling with 3-phenylpropanoic acid yielded PKS2200. The debenzylation of PKS2200 and condensation with <i>O</i>-tertbutylhydroxylamine gave compound PKS2211. Similarly, following the same set of reactions, compound PKS2226 was synthesized starting from <i>O</i>-methylserine and 8-quinolinmethylamine. Condensation of PKS2124<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> with 3-aminooxetane yielded compound PKS2130. Similarly, compounds PKS2230 and PKS2209 were synthesized by condensation of PKS2201<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> with <i>tert</i>-butylamine and azetidine, respectively. PKS2244 was synthesized from PKS2131<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> by converting to <i>tert</i>-butyl amide followed by BOC-deprotection and coupling with 5-methylisoxazole-3-carboxylic acid.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Various P2 (Methylserine) Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) TFA, DCM; (c) BOC-Asp(OBn)-OH, HATU, HOAt, Hünig’s base, DMF; (d) 3-phenylpropanoic acid, HATU, HOAt, Hünig’s base, DMF; (e) 10% Pd on carbon, methanol; (f) <i>O</i>-tert-butyl hydroxylamine, HATU, HOAt, Hünig’s base, DMF; (g) <i>tert</i>-butylamine or 3-aminooxetane, HATU, HOAt, Hünig’s base, DMF; (h) <i>tert</i>-butylamine, HATU, HOAt, Hünig’s base, DMF; and (i) 5-methylisoxazole-3-carboxylic acid, HATU, HOAt, Hünig’s base, DMF.</p></p></figure><div class="NLM_p">Condensation of BOC-Glu-OBn with <i>tert</i>-butylamine followed by BOC-deprotection gave <b>PKS2233</b>. It was then coupled with 3-phenylpropanoic acid and subsequent debenzylation gave PKS2239. PKS21202 was synthesized by condensation of BOC-Ala-OSu with 4-fluoromethyl-1-naphthylmethylamine and subsequent BOC-deprotection. Condensation of PKS2239 with PKS2082,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> PKS2026, and PKS21202 gave compounds PKS2243, PKS2255, and PKS21210, respectively (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). PKS3052<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> was coupled with PKS2026 and PKS21013<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was coupled with PKS21202 to provide compounds PKS3035 and PKS21271, respectively. <i>O</i>-Methylserine was coupled with 4-fluoromethyl-1-naphthylmethylamine and subsequently BOC was deprotected to give compound PKS21238. PKS21178<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> was coupled with PKS21202 and PKS21238 to give compounds PKS21213 and PKS21244, respectively. 5-Methylisoxazole-3-carboxylic acid was subjected to condensation with PKS2233 and subsequent debenzylation furnished compound PKS21233. PKS21233 was coupled with PKS21202 and PKS21238 to give compounds PKS21272 and PKS21245, respectively (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Finally, compounds with <i>N</i>-sulfonyl cap were synthesized by HATU-mediated amide formation of corresponding acids and amines (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Various P3-P4 Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butylamine, EDC, HOBt, Hünig’s base; (b) TFA, DCM; (c) 3-phenylpropanoic acid, HATU, HOAt, Hünig’s base, DMF; (d) 10% Pd on carbon, methanol, hydrogen balloon; (e) triethylamine, DCM; and (f) HATU, HOAt, Hünig’s base, DMF.</p></p></figure><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Various P2-P3 Analogues with an <i>N</i>-cap 5-methylisoxazole-3-carboxamide</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) TFA, DCM; and (c) 10% Pd on carbon, methanol, hydrogen balloon.</p></p></figure><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds with <i>N</i>-Sulfonyl Cap</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We found that several factors significantly contribute to potency and selectivity of <i>N</i>,<i>C</i>-capped dipeptides: (1) for inhibition, neither β5i nor β5c prefers benzopyridinyl at P1, but an indole moiety is acceptable, suggesting the hydrophobic nature of the S1 pocket and H-bond acceptor presented; (2) a bulky P1 (<i>C</i>-cap) is the major determinant of selective inhibition of β5i over β5c; (3) P3 glutamine with <sup><i>t</i></sup>-butyl amide side chain generally improved potency by 3- to 50-fold for β5i and by 30- to 40-fold for β5c compared to P3 asparagine, without affecting the selectivity; (4) a hydrophobic <i>N</i>-cap is generally preferred; and (5) these inhibitors act only on the chymotryptic β5 subunits.</div><div class="NLM_p last">Recent studies of β5i-selective inhibitors have presented several observations: (1) inhibition of both β5i and β5c without the inhibition of β2i/c and β1i/c can kill cancer cells;<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> however, whether inhibition of only β5i or β5c can induce cell death is still understudied; (2) selective inhibition of β5i by peptide boronates does not lead to cell death of plasma cells and pDCs;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (3) inhibition of both β5 and β2 was synergistic for the death of breast cancer cell line cells, and inhibition of both β5 and β1 was additive.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> In contrast, noncytotoxic inhibition of β5i with compounds that showed no inhibitory activity against β2c, β2i, β1c, or β1i sufficed to inhibit human T cell proliferation and might afford partial inhibition of the function of many types of immune cells with the cumulative effect of therapeutic efficacy in chronic autoimmune states.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Suc-LLVY-AMC, Ac-ANW-AMC, Z-VLR-AMC, Ac-LLE-AMC, Ac-PAL-AMC, human c-20S (RBC), and i-20S (PBMC) were from Boston Biochem (Cambridge, MA). Enzymatic assays were recorded on a Molecular Devices SpectraMax M5 plate readers. The human blood samples were sourced ethically and their research use was in accord with the terms of the informed consent. The purity of all final compounds was >95%.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthetic Methods</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Chemicals and Spectroscopy</h4><div class="NLM_p last">All commercially available materials were purchased from Bachem, Sigma-Aldrich, P3 BioSystems, or other vendors and were used as received unless stated otherwise. All nonaqueous reactions were performed under argon in oven-dried glassware. Reactions were monitored using a Waters Acquity Ultra Performance Liquid Chromatography (UPLC). All HPLC purifications were done by a Varian PrepStar HPLC system or Waters Autopure (mass-directed purification system) using a Prep C18 5 μm OBD (19 mm × 150 mm) column. <sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired on a Bruker DRX-500 spectrometer. Chemical shifts δ are expressed in parts per million, with the solvent resonance as an internal standard (chloroform-<i>d</i>, <sup>1</sup>H: 7.26; <sup>13</sup>C: 77.16 ppm; DMSO-d6, <sup>1</sup>H: 2.50 ppm; <sup>13</sup>C: 39.52 ppm). Hexafluorobenzene was used as the internal standard for <sup>19</sup>F NMR. NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad), coupling constant, and integration. We followed our reported procedure for HATU- or EDC-mediated amide bond formation, <i>boc</i>-deprotection, and <i>O</i>-debenzylation.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> All final compounds are >95% pure.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> PKS2058</h4><div class="NLM_p last">Synthesized by following the general procedure for EDC-mediated amide bond formation. Yield = 6%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.46 (t, <i>J</i> = 5.8 Hz, 1H), 8.20–8.16 (m, 1H), 8.15 (d, <i>J</i> = 7.2 Hz, 1H), 8.10–8.02 (m, 1H), 7.96–7.90 (m, 1H), 7.86–7.80 (m, 1H), 7.56–7.50 (m, 2H), 7.47–7.41 (m, 2H), 7.28–7.24 (m, 2H), 7.20–7.13 (m, 3H), 4.70–4.67 (m, 2H), 4.62–4.56 (m, 1H), 4.29–4.22 (m, 1H), 2.82–2.75 (m, 2H), 2.55–2.48 (m, 1H), 2.44–2.38 (m, 2H), 2.36–2.30 (m, 1H), 1.24 (d, <i>J</i> = 7.2 Hz, 3H), 1.22 and 1.10 (s, rotamers, 9H). LCMS calcd for C<sub>31</sub>H<sub>39</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 547.3. Found: 547.4.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> PKS2076</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS21054</b> (592 mg, 1.5 mmol). After completion of reaction (5 h), the mixture was filtered through celite and the filtrate was evaporated to give the product (450 mg, 98%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 9.28 and 8.98 (s, rotamers, 1H), 6.92 and 5.76 (b, rotamers, 1H), 4.59–4.47 (m, 1H), 3.22–2.69 (m, 2H), 1.44 (s, 9H), 1.27 and 1.24 (s, rotamers, 9H). LCMS calcd for C<sub>13</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub> [M – H]<sup>−</sup>: 303.2. Found: 303.5.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> PKS2081</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2076</b> (304 mg, 1 mmol) and <i>O</i>-benzylalanine hydrochloride (237 mg, 1.1 mmol). The isolated crude product was purified by recrystallization with ethanol-water to give a pure product (276 mg, 59%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.20 (s, 1H), 7.51–7.34 (m, 6H), 6.13 and 5.89 (b, rotamers, 1H), 5.20 (d, <i>J</i> = 12.4 Hz, 1H), 5.15 (d, <i>J</i> = 12.4 Hz, 1H), 4.60–4.45 (m, 2H), 2.79–2.66 (m, 1H), 2.49–2.45 (m, 1H), 1.46 (s, 9H), 1.41 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (s, 9H). LCMS calcd for C<sub>23</sub>H<sub>36</sub>N<sub>3</sub>O<sub>7</sub> [M + H]<sup>+</sup>: 466.3. Found: 466.5.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> PKS2092</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS2081</b> (150 mg, 0.32 mmol). After completion of reaction, the mixture was filtered through celite and evaporated to give the product (120 mg, quant.). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.96 (b, 1H), 10.37 (s, 1H), 7.94 (d, <i>J</i> = 6.7 Hz, 1H), 7.01 (d, <i>J</i> = 6.6 Hz, 1H), 4.28–4.23 (m, 1H), 4.10–4.04 (m, 1H), 2.39 (dd, <i>J</i> = 14.4, 4.4 Hz, 1H), 2.27 (dd, <i>J</i> = 14.4, 9.9 Hz, 1H), 1.37 (s, 9H), 1.23 (d, <i>J</i> = 7.2 Hz, 3H), 1.14 (s, 9H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> PKS2095</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS2092</b> (120 mg, 0.32 mmol) and 1-naphthylmethylamine (56 μL, 0.38 mmol). After completion of reaction (6 h), the mixture was precipitated with water. The precipitate was filtered and dried to give the product (153 mg, 93%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 8.47 (t, <i>J</i> = 5.7 Hz, 1H), 8.06–8.04 (m, 1H), 8.01 (d, <i>J</i> = 7.4 Hz, 1H), 7.96–7.94 (m, 1H), 7.86–7.84 (m, 1H), 7.57–7.52 (m, 2H), 7.48–7.43 (m, 2H), 6.94 (d, <i>J</i> = 8.1 Hz, 1H), 4.74 (d, <i>J</i> = 5.8 Hz, 2H), 4.32–4.26 (m, 2H), 2.46 (dd, <i>J</i> = 14.6, 5.5 Hz, 1H), 2.29 (dd, <i>J</i> = 14.6, 8.5 Hz, 1H), 1.37 (s, 9H), 1.24 (d, <i>J</i> = 7.0 Hz, 3H), 1.13 (s, 9H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> PKS2097</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2095</b> (118 mg, 0.23 mmol). The isolated crude was triturated with diethyl ether to give the product (120 mg, 98%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 8.71 (d, <i>J</i> = 7.3 Hz, 1H), 8.58 (t, <i>J</i> = 5.7 Hz, 1H), 8.16 (s, 3H), 8.07–8.05 (m, 1H), 7.97–7.95 (m, 1H), 7.87–7.85 (m, 1H), 7.58–7.53 (m, 2H), 7.49–7.44 (m, 2H), 4.79–4.71 (m, 2H), 4.39–4.34 (m, 1H), 4.13 (m, 1H), 2.70 (dd, <i>J</i> = 16.4, 4.9 Hz, 1H), 2.56 (dd, <i>J</i> = 16.4, 8.1 Hz, 1H), 1.28 (d, <i>J</i> = 7.0 Hz, 3H), 1.15 (s, 9H). LCMS calcd for C<sub>22</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 415.2. Found: 415.5.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> PKS2098</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of pyrazine-2-carboxylic acid (2.5 mg, 0.02 mmol) and <b>PKS2097</b> (10.6 mg, 0.02 mmol). The crude was purified by HPLC to give 10.3 mg (99%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ10.45 (s, 1H), 9.19 (d, <i>J</i> = 1.4 Hz, 1H), 8.94 (d, <i>J</i> = 8.1 Hz, 1H), 8.92 (d, <i>J</i> = 2.5 Hz, 1H), 8.78 (t, <i>J</i> = 2.0 Hz, 1H), 8.50 (t, <i>J</i> = 5.8 Hz, 1H), 8.37 (d, <i>J</i> = 7.3 Hz, 1H), 8.07–8.05 (m, 1H), 7.95–7.93 (m, 1H), 7.85–7.83 (m, 1H), 7.56–7.52 (m, 2H), 7.48–7.44 (m, 2H), 4.85–4.81 (m, 1H), 4.75 (d, <i>J</i> = 5.8 Hz, 2H), 4.36–4.30 (m, 1H), 2.68 (dd, <i>J</i> = 14.7, 7.2 Hz, 1H), 2.63 (dd, <i>J</i> = 14.7, 5.2 Hz, 1H), 1.27 (d, <i>J</i> = 7.1 Hz, 3H), 1.06 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.3, 170.2, 168.0, 162.8, 148.3, 144.5, 143.9, 134.9, 133.7, 131.2, 128.9, 127.9, 126.6, 126.2, 125.8, 125.6, 123.8, 81.1, 50.5, 49.2, 40.6, 35.4, 26.6, 18.4. LCMS calcd for C<sub>27</sub>H<sub>33</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 521.3. Found: 521.5.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> PKS2099</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of morpholine-4-acetic acid (3.0 mg, 0.02 mmol) and <b>PKS2097</b> (10.6 mg, 0.02 mmol). The crude was purified by HPLC to give 10.6 mg (98%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.50 (t, <i>J</i> = 5.8 Hz, 1H), 8.20 (d, <i>J</i> = 7.3 Hz, 1H), 8.08–8.06 (m, 1H), 7.98–8.02 (m, 1H), 7.96–7.94 (m, 1H), 7.85 (dd, <i>J</i> = 7.0, 2.6 Hz, 1H), 7.57–7.52 (m, 2H), 7.48–7.44 (m, 2H), 4.73 (d, <i>J</i> = 5.7 Hz, 2H), 4.62–4.57 (m, 1H), 4.31–4.27 (m, 1H), 3.61 (t, <i>J</i> = 4.6 Hz, 4H), 2.94 (s, 2H), 2.50–2.43 (m, 6H), 1.25 (d, <i>J</i> = 7.2 Hz, 3H), 1.11 (s, 9H). LCMS calcd for C<sub>28</sub>H<sub>40</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 542.3. Found: 542.5.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> PKS2102</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of 2-methylthiazole-3-carboxylic acid (2.9 mg, 0.02 mmol) and <b>PKS2097</b> (10.6 mg, 0.02 mmol). The crude was purified by HPLC to give 8.4 mg (77%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H), 8.52 (t, <i>J</i> = 5.8 Hz, 1H), 8.32 (d, <i>J</i> = 7.3 Hz, 1H), 8.29 (d, <i>J</i> = 8.1 Hz, 1H), 8.12 (s, 1H), 8.08–8.06 (m, 1H), 7.96–7.94 (m, 1H), 7.84 (dd, <i>J</i> = 7.0, 2.5 Hz, 1H), 7.56–7.52 (m, 2H), 7.48–7.44 (m, 2H), 4.78–4.74 (m, 3H), 4.35–4.29 (m, 1H), 2.71 (s, 3H), 2.63 (dd, <i>J</i> = 14.6, 7.3 Hz, 1H), 2.58 (dd, <i>J</i> = 14.6, 5.3 Hz, 1H), 1.26 (d, <i>J</i> = 7.1 Hz, 3H), 1.07 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 170.4, 168.0, 166.7, 160.4, 149.2, 134.9, 133.7, 131.3, 128.9, 127.9, 126.6, 126.2, 125.9, 125.6, 124.7, 123.8, 81.1, 50.3, 49.1, 40.6, 35.6, 26.6, 19.2, 18.5. LCMS calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: 540.2. Found: 540.5.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> PKS2105</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of 5-methylisoxazole-3-carboxylic acid (2.5 mg, 0.02 mmol) and <b>PKS2097</b> (10.6 mg, 0.02 mmol). The crude was purified by HPLC to give 10.2 mg (97%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 8.62 (d, <i>J</i> = 8.0 Hz, 1H), 8.48 (t, <i>J</i> = 5.8 Hz, 1H), 8.27 (d, <i>J</i> = 7.4 Hz, 1H), 8.06–8.04 (m, 1H), 7.96–7.94 (m, 1H), 7.85 (dd, <i>J</i> = 7.4, 1.9 Hz, 1H), 7.56–7.52 (m, 2H), 7.48–7.43 (m, 2H), 6.54 (s, 1H), 4.79–4.76 (m, 1H), 4.74 (d, <i>J</i> = 5.8 Hz, 2H), 4.34–4.28 (m, 1H), 2.60 (dd, <i>J</i> = 14.7, 5.5 Hz, 1H), 2.55 (dd, <i>J</i> = 14.7, 8.0 Hz, 1H), 2.47 (s, 3H), 1.25 (d, <i>J</i> = 7.1 Hz, 3H), 1.09 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.9, 171.4, 169.7, 167.5, 158.4, 158.4, 134.4, 133.2, 130.8, 128.5, 127.5, 126.2, 125.8, 125.4, 125.2, 123.4, 101.3, 80.6, 50.0, 48.6, 40.1, 34.6, 26.2, 18.1, 11.8. LCMS calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 524.3. Found: 524.5.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> PKS2106</h4><div class="NLM_p last">Substrate (<b>PKS2097</b>) (10.6 mg, 0.02 mmol) was dissolved in 1 mL tetrahydrofuran, and the solution was cooled to 0 °C. The mixture was basified with <i>N</i>-methylmorpholine (4.4 mL, 0.04 mmol). Trifluoroacetic anhydride (2.8 mL, 0.02 mmol) was added, and the mixture was stirred for 1 h at 0 °C. The solvent was evaporated, and the crude was purified by HPLC to give a pure product (8.3 mg, 81%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 9.67 (b, 1H), 8.48 (t, <i>J</i> = 5.7 Hz, 1H), 8.41 (d, <i>J</i> = 7.3 Hz, 1H), 8.06–8.04 (m, 1H), 7.96–7.94 (m, 1H), 7.85 (d, <i>J</i> = 7.6 Hz, 1H), 7.57–7.53 (m, 2H), 7.48–7.43 (m, 2H), 4.74–4.70 (m, 3H), 4.33–4.27 (m, 1H), 2.63 (dd, <i>J</i> = 15.2, 5.0 Hz, 1H), 2.54–2.49 (m, 1H), 1.26 (d, <i>J</i> = 7.1 Hz, 3H), 1.12 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 169.5, 167.4, 134.9, 133.7, 131.2, 128.9, 127.9, 126.6, 126.2, 125.9, 125.6, 123.8, 81.1, 50.7, 49.2, 40.6, 34.6, 26.6, 18.5. <sup>19</sup>F NMR (471 MHz, DMSO, C<sub>6</sub>F<sub>6</sub> external reference) δ −71.81. LCMS calcd for C<sub>24</sub>H<sub>30</sub>F<sub>3</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 511.2. Found: 511.4.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> PKS2127</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of 4-phenylbutanoic acid (5.4 mg, 0.033 mmol) and <b>PKS2097</b> (17.3 mg, 0.033 mmol). The crude was purified by HPLC to give 15.7 mg (85%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.46 (t, <i>J</i> = 5.9 Hz, 1H), 8.11–8.06 (m, 3H), 7.95–7.93 (m, 1H), 7.85–7.83 (m, 1H), 7.56–7.52 (m, 2H), 7.45 (d, <i>J</i> = 5.0 Hz, 2H), 7.28–7.25 (m, 2H), 7.19–7.16 (m, 3H), 4.75 (dd, <i>J</i> = 15.3, 5.9 Hz, 1H), 4.70 (dd, <i>J</i> = 15.3, 5.7 Hz, 1H), 4.60–4.56 (m, 1H), 4.30–4.24 (m, 1H), 2.56–2.50 (m, 3H), 2.34 (dd, <i>J</i> = 14.8, 7.8 Hz, 1H), 2.13 (t, <i>J</i> = 7.4 Hz, 2H), 1.80–1.74 (m, 2H), 1.24 (d, <i>J</i> = 7.0 Hz, 3H), 1.10 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 172.4, 171.0, 168.1, 142.3, 134.9, 133.7, 131.3, 128.9, 128.8, 128.7, 127.9, 126.6, 126.2, 126.2, 125.8, 125.7, 123.8, 81.00, 50.2, 49.0, 35.2, 35.1, 35.0, 27.5, 26.7, 18.5. LCMS calcd for C<sub>32</sub>H<sub>41</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 561.3. Found: 561.5.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> PKS2142</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of phenylacetic acid (4.9 mg, 0.036 mmol) and <b>PKS2097</b> (17.3 mg, 0.033 mmol). The crude was purified by HPLC to give 12.1 mg (68%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.47 (t, <i>J</i> = 5.9 Hz, 1H), 8.36 (d, <i>J</i> = 7.9 Hz, 1H), 8.18 (d, <i>J</i> = 7.4 Hz, 1H), 8.09–8.07 (m, 1H), 7.95–7.93 (m, 1H), 7.85–7.83 (m, 1H), 7.56–7.52 (m, 2H), 7.45 (d, <i>J</i> = 5.0 Hz, 2H), 7.29–7.19 (m, 5H), 4.76 (dd, <i>J</i> = 15.3, 6.0 Hz, 1H), 4.69 (dd, <i>J</i> = 15.3, 5.8 Hz, 1H), 4.60–4.56 (m, 1H), 4.29–4.23 (m, 1H), 3.46 (s, 2H), 2.56–2.51 (m, 1H), 2.37 (dd, <i>J</i> = 14.9, 7.3 Hz, 1H), 1.22 (d, <i>J</i> = 7.1 Hz, 3H), 1.10 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 170.9, 170.5, 168.1, 136.6, 134.9, 133.7, 131.3, 129.5, 128.9, 128.6, 127.9, 126.8, 126.6, 126.2, 125.8, 125.7, 123.9, 81.0, 50.2, 49.1, 42.4, 40.6, 35.3, 26.7, 18.4. LCMS calcd for C<sub>30</sub>H<sub>37</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 533.3. Found: 533.5.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> PKS2063</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS21059</b> (33.6 mg, 0.1 mmol) and H-Ala-OBn·HCl (21.5 mg, 0.1 mmol). After completion of reaction, the mixture was precipitated by the addition of cold water. The precipitate was filtered and dried to give the product (27 mg, 54%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (s, 1H), 8.31 (d, <i>J</i> = 7.0 Hz, 1H), 8.07 (d, <i>J</i> = 8.2 Hz, 1H), 7.40–7.32 (m, 5H), 7.28–7.25 (m, 2H), 7.20–7.15 (m, 3H), 5.11 (s, 2H), 4.66 (td, <i>J</i> = 9.0, 4.9 Hz, 1H), 4.33–4.27 (m, 1H), 2.80–2.76 (m, 2H), 2.41–2.37 (m, 3H), 2.26 (dd, <i>J</i> = 14.8, 9.5 Hz, 1H), 1.29 (d, <i>J</i> = 7.2 Hz, 3H), 1.14 (s, 9H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> PKS2067</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS2063</b> (25.0 mg, 0.05 mmol). After completion of reaction (5 h), the mixture was filtered through celite. The filtrate was evaporated and dried under vacuum to give the product (20 mg, quant.). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (b, 1H), 9.75 (b, 1H), 7.80 (b, 1H), 7.20–7.17 (m, 2H), 7.12–7.09 (m, 1H), 7.01 (d, <i>J</i> = 7.4 Hz, 2H), 4.32–4.28 (m, 1H), 3.67–3.61 (m, 1H), 2.67–2.58 (m, 2H), 2.43–2.37 (m, 1H), 2.34–2.28 (m, 1H), 2.23–2.21 (m, 2H), 1.15 (d, <i>J</i> = 6.8 Hz, 3H), 1.12 (s, 9H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> PKS2068</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2067</b> (5.0 mg, 0.0123 mmol) and quinolin-4-ylmethylamine dihydrochloride (2.8 mg, 0.0123 mmol). The crude was purified by HPLC to give 2.0 mg (30%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.84 (d, <i>J</i> = 4.5 Hz, 1H), 8.60 (t, <i>J</i> = 6.0 Hz, 1H), 8.29 (d, <i>J</i> = 7.1 Hz, 1H), 8.19–8.15 (m, 2H), 8.05 (dd, <i>J</i> = 8.5, 1.3 Hz, 1H), 7.80–7.76 (m, 1H), 7.66–7.63 (m, 1H), 7.40 (d, <i>J</i> = 4.4 Hz, 1H), 7.27–7.24 (m, 2H), 7.20–7.15 (m, 3H), 4.80–4.78 (m, 2H), 4.64–4.59 (m, 1H), 4.30–4.27 (m, 1H), 2.80–2.77 (m, 2H), 2.56–2.51 (m, 1H), 2.44–2.40 (m, 2H), 2.35 (dd, <i>J</i> = 14.9, 7.1 Hz, 1H), 1.29 (d, <i>J</i> = 7.1 Hz, 3H), 1.06 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 171.4, 170.7, 167.7, 150.1, 147.3, 144.6, 141.2, 129.4, 129.3, 128.3, 128.1, 126.6, 125.9, 125.8, 123.5, 118.9, 80.5, 64.9, 49.6, 48.8, 36.7, 34.8, 30.9, 26.2, 17.7. HRMS calcd for C<sub>30</sub>H<sub>38</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 548.2873. Found: 548.2857.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> PKS2073</h4><div class="NLM_p last">The title compound was prepared by following the general procedure for HATU-mediated coupling of <b>PKS2067</b> (5.0 mg, 0.0123 mmol) and quinolin-5-ylmethylamine (2.0 mg, 0.0123 mmol). The crude was purified by HPLC to give 4.7 mg (70%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.92–8.91 (m, 1H), 8.55 (d, <i>J</i> = 8.6 Hz, 1H), 8.51 (t, <i>J</i> = 6.0 Hz, 1H), 8.18–8.15 (m, 2H), 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.70 (dd, <i>J</i> = 8.5, 7.0 Hz, 1H), 7.57–7.54 (m, 2H), 7.27–7.24 (m, 2H), 7.19–7.15 (m, 3H), 4.79 (dd, <i>J</i> = 15.4, 6.1 Hz, 1H), 4.70 (dd, <i>J</i> = 15.4, 5.7 Hz, 1H), 4.61–4.56 (m, 1H), 4.27–4.21 (m, 1H), 2.80–2.76 (m, 2H), 2.53–2.48 (m, 1H), 2.43–2.39 (m, 2H), 2.33 (dd, <i>J</i> = 14.8, 7.2 Hz, 1H), 1.23 (d, <i>J</i> = 7.1 Hz, 3H), 1.10 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 171.9, 171.0, 168.1, 150.6, 148.4, 141.7, 136.0, 132.5, 129.4, 128.9, 128.7, 128.6, 126.4, 126.3, 126.2, 121.7, 81.0, 70.2, 50.0, 49.1, 37.2, 35.3, 31.4, 26.7, 18.3. HRMS calcd for C<sub>30</sub>H<sub>38</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 548.2867. Found: 548.2879.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> PKS2083</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2067</b> (5.0 mg, 0.0123 mmol) and 4-(aminomethyl)indole (1.8 mg, 0.0123 mmol). The crude was purified by HPLC to give 5.8 mg (88%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.10 (s, 1H), 10.35 (s, 1H), 8.36 (t, <i>J</i> = 5.9 Hz, 1H), 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 8.05 (d, <i>J</i> = 7.4 Hz, 1H), 7.32–7.25 (m, 4H), 7.20–7.16 (m, 3H), 7.01 (t, <i>J</i> = 7.6 Hz, 1H), 6.89 (d, <i>J</i> = 7.1 Hz, 1H), 6.52–6.51 (m, 1H), 4.61–4.48 (m, 3H), 4.28–4.24 (m, 1H), 2.81–2.77 (m, 2H), 2.53–2.49 (m, 1H), 2.46–2.38 (m, 2H), 2.33 (dd, <i>J</i> = 14.8, 7.6 Hz, 1H), 1.23 (d, <i>J</i> = 7.1 Hz, 3H), 1.13 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.1, 171.8, 170.8, 168.1, 141.7, 136.2, 130.5, 128.7, 128.6, 128.6, 126.6, 126.3, 125.3, 121.1, 117.8, 110.8, 81.0, 50.1, 49.0, 41.0, 37.2, 35.3, 31.4, 26.7, 18.7. HRMS calcd for C<sub>29</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 558.2687. Found: 558.2698.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> PKS2038</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2032</b> (95 mg, 0.22 mmol). After completion of reaction, dichloromethane and excess trifluoroacetic acid were evaporated and the crude was triturated with diethyl ether. The mixture was filtered to give the product (60 mg, 61%) as a white powder. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73 (d, <i>J</i> = 7.6 Hz, 1H), 8.51 (t, <i>J</i> = 5.7 Hz, 1H), 8.18 (b, 3H), 8.05–8.03 (m, 1H), 7.97–7.95 (m, 1H), 7.87 (d, <i>J</i> = 8.0 Hz, 1H), 7.58–7.54 (m, 2H), 7.49–7.43 (m, 2H), 4.80–4.72 (m, 2H), 4.45–4.39 (m, 1H), 4.03 (m, 1H), 3.65 (dd, <i>J</i> = 10.7, 3.8 Hz, 1H), 3.56 (dd, <i>J</i> = 10.7, 7.2 Hz, 1H), 3.25 (s, 3H), 1.28 (d, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> PKS2048</h4><div class="NLM_p last">Synthesized following the general procedure for EDC coupling of 3-phenylpropanoic acid (16.5 mg, 0.11 mmol) with <b>PKS2038</b> (44.3 mg, 0.1 mmol). The crude was purified by silica gel column chromatography to give 44.1 mg (87%) of product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24–8.18 (m, 2H), 8.15 (d, <i>J</i> = 7.8 Hz, 1H), 8.04–8.02 (m, 1H), 7.96–7.94 (m, 1H), 7.86–7.84 (m, 1H), 7.56–7.53 (m, 2H), 7.45–7.40 (m, 2H), 7.27–7.24 (m, 2H), 7.20–7.16 (m, 3H), 4.75 (d, <i>J</i> = 5.7 Hz, 2H), 4.50 (dt, <i>J</i> = 7.9, 6.0 Hz, 1H), 4.36–4.30 (m, 1H), 3.45–3.41 (m, 2H), 3.12 (s, 3H), 2.79 (t, <i>J</i> = 7.9 Hz, 2H), 2.47–2.44 (m, 2H), 1.26 (d, <i>J</i> = 7.1 Hz, 3H). LCMS calcd for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 462.2. Found: 462.3.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> PKS2154</h4><div class="NLM_p last">Synthesized following the general procedure of HATU-mediated coupling of <i>boc</i>-β-methoxyalanine dicyclohexylamine (100 mg, 0.25 mmol) and 3-methoxybenzyl amine (36 mL, 0.275 mmol). The product was isolated by ethyl acetate extraction and purified by silica gel column chromatography (yield 74 mg, 87%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.26–7.22 (m, 1H), 6.86–6.84 (m, 1H), 6.82–6.80 (m, 2H), 6.75 (t, <i>J</i> = 6.2 Hz, 1H), 5.42 (b, 1H), 4.47–4.46 (m, 2H), 4.28 (m, 1H), 3.85 (dd, <i>J</i> = 9.2, 3.8 Hz, 1H), 3.80 (s, 3H), 3.51 (dd, <i>J</i> = 9.2, 6.2 Hz, 1H), 3.38 (s, 3H), 1.44 (s, 9H).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> PKS2158</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2154</b> (74 mg, 0.219 mmol). The isolated crude was dried under vacuum to give the product (70 mg, 91%). <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 9.13 (b, 1H), 8.01 (b, 2H), 7.56 (t, <i>J</i> = 5.8 Hz, 1H), 7.22 (t, <i>J</i> = 7.9 Hz, 1H), 6.80 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 6.75 (d, <i>J</i> = 7.6 Hz, 1H), 6.73–6.72 (m, 1H), 4.41–4.35 (m, 2H), 4.29 (dd, <i>J</i> = 15.0, 5.5 Hz, 1H), 3.75 (s, 3H), 3.73 (dd, <i>J</i> = 10.4, 4.7 Hz, 1H), 3.67 (dd, <i>J</i> = 10.4, 5.3 Hz, 1H), 3.32 (s, 3H).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> PKS2160</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS21059</b> (15.8 mg, 0.047 mmol) and <b>PKS2158</b> (18.4 mg, 0.052 mmol). The product was purified by HPLC (yield 16.2 mg, 62%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.51 (t, <i>J</i> = 6.1 Hz, 1H), 8.20 (d, <i>J</i> = 7.9 Hz, 1H), 8.09 (d, <i>J</i> = 7.7 Hz, 1H), 7.27–7.25 (m, 2H), 7.21–7.15 (m, 4H), 6.82–6.81 (m, 2H), 6.77 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 4.67–4.63 (m, 1H), 4.40–4.37 (m, 1H), 4.30–4.21 (m, 2H), 3.72 (s, 3H), 3.61 (dd, <i>J</i> = 9.8, 5.9 Hz, 1H), 3.50 (dd, <i>J</i> = 9.8, 4.6 Hz, 1H), 3.25 (s, 3H), 2.80–2.76 (m, 2H), 2.53–2.48 (m, 1H), 2.43–2.39 (m, 2H), 2.34 (dd, <i>J</i> = 14.8, 7.6 Hz, 1H), 1.11 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.0, 171.4, 169.7, 168.1, 159.8, 141.7, 141.3, 129.7, 128.8, 128.6, 126.4, 119.6, 112.9, 112.6, 81.1, 72.3, 58.8, 55.4, 53.7, 50.1, 42.5, 37.3, 35.3, 31.5, 26.7. HRMS calcd for C<sub>29</sub>H<sub>40</sub>N<sub>4</sub>O<sub>7</sub>Na [M + Na]<sup>+</sup>: 579.2789. Found: 579.2774.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> PKS2184</h4><div class="NLM_p last">Synthesized following the general procedure of HATU-mediated coupling of <i>boc</i>-β-methoxyalanine dicyclohexylamine (200 mg, 0.5 mmol) and 2,3-dimethoxybenzyl amine (83 μL, 0.55 mmol). The product was isolated by ethyl acetate extraction and purified by silica gel column chromatography (yield = 184 mg, quant.). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (t, <i>J</i> = 5.9 Hz, 1H), 7.00–6.97 (m, 1H), 6.93 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 6.81 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.31–4.23 (m, 2H), 4.20–4.15 (m, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 3.48–3.46 (m, 2H), 3.24 (s, 3H), 1.38 (s, 9H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> PKS2190</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2184</b> (180 mg, 0.49 mmol). The crude product was dried under vacuum to give a viscous paste, which upon standing turned solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78 (t, <i>J</i> = 5.7 Hz, 1H), 8.21 (b, 3H), 7.05–7.02 (m, 1H), 6.97 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 6.83 (dd, <i>J</i> = 7.6, 1.6 Hz, 1H), 4.36 (dd, <i>J</i> = 15.1, 5.7 Hz, 1H), 4.31 (dd, <i>J</i> = 15.1, 5.6 Hz, 1H), 4.04–4.01 (m, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 3.66 (d, <i>J</i> = 5.1 Hz, 2H), 3.30 (s, 3H).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> PKS2191</h4><div class="NLM_p last">Synthesized following the general procedure of HATU-mediated coupling of <i><b>N</b></i><b>-(</b><i><b>tert</b></i><b>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-aspartic acid 4-benzyl ester</b> (159 mg, 0.49 mmol) and <b>PKS2190</b> (0.49 mmol, from previous step). The product was isolated by ethyl acetate extraction and recrystallized with ethanol-water (yield = 245 mg, 87% for two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (t, <i>J</i> = 5.8 Hz, 1H), 7.86 (d, <i>J</i> = 7.9 Hz, 1H), 7.38–7.31 (m, 5H), 7.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.00–6.97 (m, 1H), 6.92 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 6.78 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 5.08 (d, <i>J</i> = 12.6 Hz, 1H), 5.05 (d, <i>J</i> = 12.6 Hz, 1H), 4.45–4.37 (m, 2H), 4.31–4.23 (m, 2H), 3.78 (s, 3H), 3.71 (s, 3H), 3.56 (dd, <i>J</i> = 9.7, 5.6 Hz, 1H), 3.46 (dd, <i>J</i> = 9.7, 5.1 Hz, 1H), 3.24 (s, 3H), 2.82–2.78 (m, 1H), 2.61 (dd, <i>J</i> = 16.3, 8.9 Hz, 1H), 1.37 (s, 9H).</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> PKS2197</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2191</b> (115 mg, 0.2 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81 (d, <i>J</i> = 7.8 Hz, 1H), 8.37 (t, <i>J</i> = 5.9 Hz, 1H), 8.26 (b, 3H), 7.39–7.34 (m, 5H), 6.99 (t, <i>J</i> = 7.9 Hz, 1H), 6.93 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 6.78 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 5.14 (d, <i>J</i> = 12.4 Hz, 1H), 5.11 (d, <i>J</i> = 12.4 Hz, 1H), 4.55–4.51 (m, 1H), 4.33–4.23 (m, 3H), 3.78 (s, 3H), 3.71 (s, 3H), 3.59 (dd, <i>J</i> = 9.9, 6.2 Hz, 1H), 3.52 (dd, <i>J</i> = 9.9, 4.8 Hz, 1H), 3.27 (s, 3H), 3.02 (dd, <i>J</i> = 17.5, 4.1 Hz, 1H), 2.82 (dd, <i>J</i> = 17.5, 8.8 Hz, 1H).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> PKS2200</h4><div class="NLM_p last">Synthesized following the general procedure of HATU-mediated coupling of 3-phenylpropanoic acid (33 mg, 0.22 mmol) and <b>PKS2197</b> (0.2 mmol, from previous step). The reaction mixture was precipitated with water, and the precipitate was filtered and dried to give the product (110 mg, 91% for two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 7.9 Hz, 1H), 8.24 (t, <i>J</i> = 5.9 Hz, 1H), 8.04 (d, <i>J</i> = 7.9 Hz, 1H), 7.38–7.32 (m, 5H), 7.28–7.25 (m, 2H), 7.18–7.15 (m, 3H), 6.99 (t, <i>J</i> = 7.9 Hz, 1H), 6.92 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 6.79 (dd, <i>J</i> = 7.5, 1.6 Hz, 1H), 5.04 (s, 2H), 4.74 (td, <i>J</i> = 8.1, 5.7 Hz, 1H), 4.42 (dt, <i>J</i> = 7.8, 5.4 Hz, 1H), 4.31–4.24 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.56 (dd, <i>J</i> = 9.8, 5.8 Hz, 1H), 3.47 (dd, <i>J</i> = 9.8, 5.0 Hz, 1H), 3.24 (s, 3H), 2.85–2.77 (m, 3H), 2.59 (dd, <i>J</i> = 16.2, 8.3 Hz, 1H), 2.41–2.38 (m, 2H).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> PKS2204</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation. The reaction was not complete, and the isolated crude was purified by HPLC to give 40 mg product (50% brsm; 16.0 mg starting material was recovered). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H), 8.27–8.24 (m, 2H), 7.95 (d, <i>J</i> = 7.9 Hz, 1H), 7.28–7.25 (m, 2H), 7.20–7.15 (m, 3H), 6.99 (t, <i>J</i> = 7.9 Hz, 1H), 6.93 (dd, <i>J</i> = 8.2, 1.5 Hz, 1H), 6.80 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 4.66–4.60 (m, 1H), 4.43–4. 38 (m, 1H), 4.28 (d, <i>J</i> = 5.9 Hz, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.56 (dd, <i>J</i> = 9.7, 5.8 Hz, 1H), 3.47 (dd, <i>J</i> = 9.7, 5.0 Hz, 1H), 3.24 (s, 3H), 2.79 (t, <i>J</i> = 7.9 Hz, 2H), 2.68 (dd, <i>J</i> = 16.6, 5.9 Hz, 1H), 2.48–2.39 (m, 3H).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> PKS2211</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <i>O</i>-<i>tert</i>-butyl hydroxylamine hydrochloride (6.6 mg, 0.0525 mmol) and <b>PKS2204</b> (18.0 mg, 0.035 mmol). After completion of reaction (1 h), the mixture was diluted with water and extracted with ethyl acetate. The organic layer was evaporated and purified by HPLC to give the product (11.0 mg, 54%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 8.37 (t, <i>J</i> = 6.0 Hz, 1H), 8.20 (d, <i>J</i> = 7.9 Hz, 1H), 8.05 (d, <i>J</i> = 7.7 Hz, 1H), 7.28–7.25 (m, 2H), 7.19–7.15 (m, 3H), 6.98 (t, <i>J</i> = 7.9 Hz, 1H), 6.92 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 6.82 (d, <i>J</i> = 7.7 Hz, 1H), 4.67–4.63 (m, 1H), 4.40 (dt, <i>J</i> = 7.6, 5.3 Hz, 1H), 4.31–4.24 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.59 (dd, <i>J</i> = 9.8, 6.0 Hz, 1H), 3.49 (dd, <i>J</i> = 9.8, 4.6 Hz, 1H), 3.24 (s, 3H), 2.80–2.76 (m, 2H), 2.52–2.48 (m, 1H), 2.43–2.39 (m, 2H), 2.33 (dd, <i>J</i> = 14.9, 7.8 Hz, 1H), 1.11 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.0, 171.3, 169.7, 168.0, 152.6, 146.5, 141.7, 132.8, 128.8, 128.6, 126.3, 124.1, 120.3, 112.0, 81.0, 72.3, 60.4, 58.7, 56.1, 53.6, 50.1, 37.4, 37.2, 35.3, 31.4, 26.7. HRMS calcd for C<sub>30</sub>H<sub>42</sub>N<sub>4</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup>: 609.2895. Found: 609.2897.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> PKS2175</h4><div class="NLM_p last">Synthesized following the general procedure for HATU coupling of boc-β-methoxyalanine dicyclohexylamine (80 mg, 0.02 mmol) and quinolin-8-ylmethylamine dihydrochloride (46 mg, 0.2 mmol) in 2 mL dimethylformamide. (<i>Note: the reaction mixture was not soluble in dimethylformamide</i>.) After completion of reaction (3 h), water was added to the reaction mixture (reaction mixture turned transparent) and extracted twice with chloroform. The combined organic layer was washed with water followed by brine, dried over anhydrous sodium sulfate, and evaporated. The crude product was purified by HPLC to give 68.5 mg (95%) of pure product. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96–8.94 (m, 1H), 8.46 (t, <i>J</i> = 6.2 Hz, 1H), 8.39 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.88 (d, <i>J</i> = 8.1 Hz, 1H), 7.64 (d, <i>J</i> = 7.1 Hz, 1H), 7.58 (dd, <i>J</i> = 8.3, 4.2 Hz, 1H), 7.54 (t, <i>J</i> = 7.6 Hz, 1H), 6.96 (d, <i>J</i> = 8.1 Hz, 1H), 4.96–4.87 (m, 2H), 4.26–4.22 (m, 1H), 3.54–3.53 (m, 2H), 3.27 (s, 3H), 1.39 (s, 9H).</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> PKS2181</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS2175</b> (68.5 mg, 0.19 mmol). The crude was used in the next step. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (dd, <i>J</i> = 4.2, 1.8 Hz, 1H), 8.95 (t, <i>J</i> = 5.9 Hz, 1H), 8.42 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 8.22 (b, 3H), 7.93 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.67 (dd, <i>J</i> = 7.1, 1.5 Hz, 1H), 7.62–7.58 (m, 2H), 5.02 (dd, <i>J</i> = 15.9, 5.9 Hz, 1H), 4.96 (dd, <i>J</i> = 15.9, 5.7 Hz, 1H), 4.13–4.10 (m, 1H), 3.75–3.69 (m, 2H), 3.32 (s, 3H).</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> PKS2188</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <i><b>N</b></i><b>-(</b><i><b>tert</b></i><b>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-aspartic acid 4-benzyl ester</b> (61.4 mg, 0.19 mmol) and <b>PKS2181</b> (0.19 mmol, from previous step). After completion of reaction (1 h), the reaction mixture was diluted with water and extracted twice with ethyl acetate. Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was dried under high vacuum and used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (dd, <i>J</i> = 4.3, 1.8 Hz, 1H), 8.49 (t, <i>J</i> = 5.9 Hz, 1H), 8.43 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 7.90 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.63 (dd, <i>J</i> = 7.1, 1.5 Hz, 1H), 7.61–7.55 (m, 2H), 7.37–7.30 (m, 6H), 5.09 (d, <i>J</i> = 12.7 Hz, 1H), 5.05 (d, <i>J</i> = 12.7 Hz, 1H), 4.96 (dd, <i>J</i> = 16.4, 6.0 Hz, 1H), 4.89 (dd, <i>J</i> = 16.4, 5.9 Hz, 1H), 4.51–4.48 (m, 1H), 4.43 (td, <i>J</i> = 8.5, 5.0 Hz, 1H), 3.63 (dd, <i>J</i> = 9.7, 5.5 Hz, 1H), 3.52 (dd, <i>J</i> = 9.7, 5.1 Hz, 1H), 3.28 (s, 3H), 2.85–2.81 (m, 1H), 2.62 (dd, <i>J</i> = 16.2, 8.9 Hz, 1H), 1.38 (s, 9H).</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> PKS2194</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS2188</b> (0.19 mmol, from previous step). After completion of reaction (3 h), excess trifluoroacetic acid and dichloromethane were evaporated. The crude paste was washed twice with diethyl ether to give the product as an off-white solid (yield = 111 mg, 84% for three steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (dd, <i>J</i> = 4.2, 1.8 Hz, 1H), 8.87 (d, <i>J</i> = 7.8 Hz, 1H), 8.53 (t, <i>J</i> = 6.0 Hz, 1H), 8.39 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 8.27 (b, 3H), 7.88 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.61 (dd, <i>J</i> = 7.2, 1.5 Hz, 1H), 7.58–7.54 (m, 2H), 7.40–7.31 (m, 5H), 5.13 (<i>J</i> = 12.5 Hz, 1H), 5.10 (d, <i>J</i> = 12.5 Hz, 1H), 4.97 (dd, <i>J</i> = 16.4, 6.1 Hz, 1H), 4.90 (dd, <i>J</i> = 16.4, 5.9 Hz, 1H), 4.62–4.58 (m, 1H), 4.27 (m, 1H), 3.66 (dd, <i>J</i> = 9.8, 6.0 Hz, 1H), 3.57 (dd, <i>J</i> = 9.8, 4.8 Hz, 1H), 3.30 (s, 3H), 3.04 (dd, <i>J</i> = 17.5, 3.9 Hz, 1H), 2.85–2.80 (m, 1H). LCMS calcd for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 464.2. Found: 464.3.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> PKS2198</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of 3-phenylpropanoic acid (26.4 mg, 0.176 mmol) and <b>PKS2194</b> (111 mg, 0.16 mmol). After completion of reaction (3 h), the mixture was precipitated with water. The precipitate was filtered and dried to give the product (77 mg, 81%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (dd, <i>J</i> = 4.2, 1.8 Hz, 1H), 8.43 (t, <i>J</i> = 6.1 Hz, 1H), 8.38 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 8.32 (d, <i>J</i> = 8.0 Hz, 1H), 8.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.87 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.61 (dd, <i>J</i> = 7.2, 1.5 Hz, 1H), 7.57–7.53 (m, 2H), 7.35–7.30 (m, 5H), 7.27–7.24 (m, 2H), 7.19–7.15 (m, 3H), 5.03 (s, 2H), 4.95 (dd, <i>J</i> = 16.4, 6.1 Hz, 1H), 4.90 (dd, <i>J</i> = 16.4, 5.9 Hz, 1H), 4.77 (td, <i>J</i> = 8.2, 5.7 Hz, 1H), 4.49 (dt, <i>J</i> = 7.8, 5.3 Hz, 1H), 3.62 (dd, <i>J</i> = 9.7, 5.8 Hz, 1H), 3.52 (dd, <i>J</i> = 9.7, 5.0 Hz, 1H), 3.28 (s, 3H), 2.85–2.77 (m, 3H), 2.59 (dd, <i>J</i> = 16.2, 8.4 Hz, 1H), 2.42–2.38 (m, 2H).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> PKS2202</h4><div class="NLM_p last">Synthesized by following the general procedure for O-debenzylation of <b>PKS2198</b> (73 mg, 0.122 mmol). The mixture was filtered through celite, evaporated, and purified by HPLC to give the product (19 mg, 30%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H), 8.26–8.23 (m, 2H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.28–7.25 (m, 2H), 7.21–7.15 (m, 3H), 6.81 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 6.76 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 6.40 (t, <i>J</i> = 7.4 Hz, 1H), 4.63 (td, <i>J</i> = 7.8, 5.8 Hz, 1H), 4.40 (dt, <i>J</i> = 7.7, 5.4 Hz, 1H), 4.08 (dd, <i>J</i> = 15.3, 6.1 Hz, 1H), 4.03 (dd, <i>J</i> = 15.3, 5.9 Hz, 1H), 3.56 (dd, <i>J</i> = 9.8, 5.8 Hz, 1H), 3.47 (dd, <i>J</i> = 9.8, 5.0 Hz, 1H), 3.24 (s, 3H), 3.22 (t, <i>J</i> = 5.5 Hz, 2H), 2.80 (t, <i>J</i> = 7.9 Hz, 2H), 2.70–2.65 (m, 3H), 2.48–2.39 (m, 3H), 1.79–1.74 (m, 2H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> PKS2226</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS2202</b> (19.0 mg, 0.037 mmol) and <i>O</i>-<i>tert</i>-butyl hydroxylamine hydrochloride (5.1 mg, 0.041 mmol). The product was purified by HPLC (17.9 mg, 83%) <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.41 (t, <i>J</i> = 6.1 Hz, 1H), 8.18 (d, <i>J</i> = 7.9 Hz, 1H), 8.10 (d, <i>J</i> = 7.8 Hz, 1H), 7.28–7.25 (m, 2H), 7.20–7.15 (m, 3H), 6.84 (d, <i>J</i> = 7.5 Hz, 1H), 6.75 (d, <i>J</i> = 7.5 Hz, 1H), 6.38 (t, <i>J</i> = 7.4 Hz, 1H), 5.24–5.20 (m, 1H), 4.67–4.62 (m, 1H), 4.40–4.37 (m, 1H), 4.10 (dd, <i>J</i> = 15.1, 6.3 Hz, 1H), 4.00 (dd, <i>J</i> = 15.1, 5.8 Hz, 1H), 3.60 (dd, <i>J</i> = 9.8, 5.9 Hz, 1H), 3.49 (dd, <i>J</i> = 9.8, 4.5 Hz, 1H), 3.24 (s, 3H), 3.22–3.21 (m, 2H), 2.80–2.76 (m, 2H), 2.66 (t, <i>J</i> = 6.4 Hz, 2H), 2.52–2.48 (m, 1H), 2.42–2.39 (m, 2H), 2.35 (dd, <i>J</i> = 14.8, 7.5 Hz, 1H), 1.79–1.74 (m, 2H), 1.14 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.5, 170.9, 169.5, 167.6, 142.5, 141.2, 128.3, 128.1, 128.0, 126.5, 125.8, 121.3, 120.0, 114.6, 80.6, 71.7, 58.3, 53.1, 49.6, 41.3, 36.8, 34.8, 31.00, 27.2, 26.3, 21.3. HRMS calcd for C<sub>31</sub>H<sub>43</sub>N<sub>5</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 604.3106. Found: 604.3105.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> PKS2220</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS21059</b> (20.2 mg, 0.06 mmol) and <b>PKS2181</b> (32.2 mg, 0.066 mmol). The product was purified be HPLC (yield = 21.6 mg, 62%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.95 (dd, <i>J</i> = 4.2, 1.8 Hz, 1H), 8.57 (t, <i>J</i> = 6.1 Hz, 1H), 8.38 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 8.15 (d, <i>J</i> = 7.8 Hz, 1H), 7.87 (dd, <i>J</i> = 8.3, 1.5 Hz 1H), 7.63 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.59–7.54 (m, 2H), 7.28–7.25 (m, 2H), 7.20–7.17 (m, 3H), 4.98–4.89 (m, 2H), 4.71–4.67 (m, 1H), 4.50–4.46 (m, 1H), 3.66 (dd, <i>J</i> = 9.7, 5.8 Hz, 1H), 3.55 (dd, <i>J</i> = 9.7, 4.7 Hz, 1H), 3.29 (s, 3H), 2.80–2.77 (m, 2H), 2.55–2.51 (m, 1H), 2.43–2.40 (m, 2H), 2.35 (dd, <i>J</i> = 14.7, 7.7 Hz, 1H), 1.06 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.0, 171.5, 170.0, 168.0, 150.1, 145.8, 141.7, 136.9, 136.8, 128.8, 128.6, 128.1, 127.1, 126.9, 126.7, 126.3, 121.9, 81.0, 72.3, 58.8, 53.7, 50.1, 39.2, 37.2, 35.3, 31.5, 26.7. HRMS calcd for C<sub>31</sub>H<sub>39</sub>N<sub>5</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 600.2793. Found: 600.2783.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> PKS2130</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS2124</b> (12.4 mg, 0.026 mmol) and 3-aminooxetane (2.2 μL, 0.031 mmol). The mixture was purified by HPLC to give the product (12.0 mg, 87%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (d, <i>J</i> = 6.4 Hz, 1H), 8.44 (t, <i>J</i> = 5.8 Hz, 1H), 8.21 (d, <i>J</i> = 7.3 Hz, 1H), 8.15 (d, <i>J</i> = 7.9 Hz, 1H), 8.07–8.05 (m, 1H), 7.95–7.94 (m, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 1H), 7.57–7.52 (m, 2H), 7.47–7.42 (m, 2H), 7.27–7.24 (m, 2H), 7.19–7.15 (m, 3H), 4.76 (dd, <i>J</i> = 15.4, 5.9 Hz, 1H), 4.70 (dd, <i>J</i> = 15.4, 5.8 Hz, 1H), 4.64–4.51 (m, 4H), 4.34–4.22 (m, 3H), 2.78 (t, <i>J</i> = 7.8 Hz, 2H), 2.58 (dd, <i>J</i> = 15.2, 7.5 Hz, 1H), 2.44–2.40 (m, 3H), 1.25 (d, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 172.0, 171.0, 169.8, 141.7, 134.8, 133.7, 131.2, 128.9, 128.7, 128.6, 127.9, 126.6, 126.3, 126.2, 125.8, 125.6, 123.8, 77.4, 77.3, 50.0, 49.1, 44.3, 40.6, 37.8, 37.1, 31.4, 18.3. LCMS calcd for C<sub>30</sub>H<sub>35</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 531.3. Found: 531.3.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> PKS2209</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS2201</b> (15.2 mg, 0.03 mmol) and azetidine hydrochloride (4.2 mg, 0.045 mmol). The mixture was purified by HPLC to give a pure product (10.5 mg, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (t, <i>J</i> = 5.9 Hz, 1H), 8.29 (d, <i>J</i> = 7.7 Hz, 1H), 8.16 (d, <i>J</i> = 7.9 Hz, 1H), 8.08–8.06 (m, 1H), 7.95–7.93 (m, 1H), 7.84–7.82 (m, 1H), 7.55–7.52 (m, 2H), 7.46–7.41 (m, 2H), 7.28–7.25 (m, 2H), 7.20–7.15 (m, 3H), 4.80–4.62 (m, 3H), 4.43–4.39 (m, 1H), 4.07 (td, <i>J</i> = 8.7, 6.3 Hz, 1H), 4.00 (td, <i>J</i> = 8.7, 6.3 Hz, 1H), 3.72–3.56 (m, 3H), 3.53 (dd, <i>J</i> = 9.8, 4.3 Hz, 1H), 3.24 (s, 3H), 2.79 (t, <i>J</i> = 7.8 Hz, 2H), 2.47–2.36 (m, 3H), 2.29 (dd, <i>J</i> = 15.4, 5.8 Hz, 1H), 2.12–2.03 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 171.0, 169.3, 169.2, 141.2, 134.2, 133.2, 130.7, 128.4, 128.2, 127.3, 126.1, 125.8, 125.7, 125.3, 124.9, 124.8, 123.4, 71.7, 58.2, 53.5, 49.6, 49.1, 47.3, 40.2, 36.6, 33.1, 31.0, 14.5. LCMS calcd for C<sub>31</sub>H<sub>37</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 545.3. Found: 545.2.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> PKS2230</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of <b>PKS2201</b> (15.2 mg, 0.03 mmol) and <i>tert</i>-butylamine (9.5 μL, 0.09 mmol). The product was purified by HPLC to give a pure product (8.7 mg, 52%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (t, <i>J</i> = 5.9 Hz, 1H), 8.19 (d, <i>J</i> = 7.7 Hz, 1H), 8.12 (d, <i>J</i> = 8.0 Hz, 1H), 8.07–8.05 (m, 1H), 7.94–7.92 (m, 1H), 7.83–7.81 (m, 1H), 7.55–7.50 (m, 3H), 7.46–7.40 (m, 2H), 7.28–7.25 (m, 2H), 7.20–7.15 (m, 3H), 4.79 (dd, <i>J</i> = 15.6, 6.0 Hz, 1H), 4.70 (dd, <i>J</i> = 15.6, 5.8 Hz, 1H), 4.63–4.59 (m, 1H), 4.45–4.41 (m, 1H), 3.63 (dd, <i>J</i> = 9.8, 6.1 Hz, 1H), 3.54 (dd, <i>J</i> = 9.8, 4.4 Hz, 1H), 3.24 (s, 3H), 2.78 (t, <i>J</i> = 7.9 Hz, 2H), 2.55–2.51 (m, 1H), 2.43–2.34 (m, 3H), 1.14 (s, 9H).<sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 171.2, 169.3, 169.1, 141.3, 134.2, 133.2, 130.7, 128.4, 128.3, 128.1, 127.3, 126.1, 125.8, 125.7, 125.3, 124.9, 123.3, 71.8, 58.2, 53.3, 50.1, 49.7, 40.2, 38.5, 36.7, 31.0, 28.4. HRMS calcd for C<sub>32</sub>H<sub>40</sub>N<sub>4</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 583.2891. Found: 583.2877.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> PKS2230BP</h4><div class="NLM_p last">Isolated as a byproduct in the above reaction. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (t, <i>J</i> = 6.0 Hz, 1H), 8.32 (d, <i>J</i> = 7.7 Hz, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 8.09–8.04 (m, 1H), 7.96–7.91 (m, 1H), 7.84–7.80 (m, 1H), 7.55–7.50 (m, 2H), 7.45–7.39 (m, 2H), 7.28–7.23 (m, 2H), 7.20–7.15 (m, 3H), 4.77 (dd, <i>J</i> = 15.6, 5.8 Hz, 1H), 4.74–4.64 (m, 2H), 4.42–4.37 (m, 1H), 3.66 (dd, <i>J</i> = 9.7, 6.3 Hz, 1H), 3.55 (dd, <i>J</i> = 9.7, 4.1 Hz, 1H), 3.24 (s, 3H), 2.87 (s, 3H), 2.79 (t, <i>J</i> = 7.8 Hz, 2H), 2.67 (dd, <i>J</i> = 16.2, 8.4 Hz, 1H), 2.54–2.60 (m, 1H), 2.57 (s, 3H), 2.46–2.37 (m, 2H). LCMS calcd for C<sub>30</sub>H<sub>37</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 533.3. Found: 533.5.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> PKS2237</h4><div class="NLM_p last">The title compound was prepared following the general procedure for HATU-mediated coupling of <b>PKS2131</b> (118 mg, 0.25 mmol) and <i>tert</i>-butylamine (32 mL, 0.3 mmol). The product was isolated by ethyl acetate extraction and purified by HPLC (yield = 37.0 mg). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (t, <i>J</i> = 5.8 Hz, 1H), 8.05–8.03 (m, 1H), 7.98–7.93 (m, 2H), 7.84–7.82 (m, 1H), 7.55–7.51 (m, 2H), 7.46–7.43 (m, 3H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 4.79–4.70 (m, 2H), 4.47–4.43 (m, 1H), 4.31–4.26 (m, 1H), 3.61 (dd, <i>J</i> = 9.7, 5.7 Hz, 1H), 3.51 (dd, <i>J</i> = 9.7, 4.8 Hz, 1H), 3.24 (s, 3H), 2.50–2.45 (m, 1H), 2.33 (dd, <i>J</i> = 14.9, 7.8 Hz, 1H), 1.36 (s, 9H), 1.18 (s, 9H).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> PKS2242</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>boc</i>-deprotection of <b>PKS2237</b> (34.4 mg, 0.065 mmol). Yield = 32 mg, 91%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.76 (d, <i>J</i> = 7.7 Hz, 1H), 8.67 (t, <i>J</i> = 5.8 Hz, 1H), 8.14 (b, 3H), 8.04–8.02 (m, 1H), 7.95–7.93 (m, 1H), 7.88 (s, 1H), 7.85–7.83 (m, 1H), 7.56–7.52 (m, 2H), 7.47–7.43 (m, 2H), 4.80–4.72 (m, 2H), 4.53 (ddd, <i>J</i> = 7.7, 5.9, 4.6 Hz, 1H), 4.16–4.13 (m, 1H), 3.63 (dd, <i>J</i> = 9.8, 5.9 Hz, 1H), 3.53 (dd, <i>J</i> = 9.8, 4.6 Hz, 1H), 3.26 (s, 3H), 2.73 (dd, <i>J</i> = 16.7, 5.2 Hz, 1H), 2.60–2.55 (m, 1H), 1.21 (s, 9H). LCMS calcd for C<sub>23</sub>H<sub>33</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 429.2. Found 429.5.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> PKS2244</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated coupling of 5-methylisoxazole-3-carboxylic acid (5.6 mg, 0.044 mmol) and <b>PKS2242</b> (21.7 mg, 0.04 mmol). The isolated crude was purified by HPLC to give a pure product (18.6 mg, 87%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (t, <i>J</i> = 5.8 Hz, 1H), 8.56 (d, <i>J</i> = 8.0 Hz, 1H), 8.25 (d, <i>J</i> = 7.8 Hz, 1H), 8.05–8.03 (m, 1H), 7.95–7.93 (m, 1H), 7.85–7.82 (m, 1H), 7.54–7.51 (m, 3H), 7.45–7.43 (m, 2H), 6.54 (s, 1H), 4.80–4.74 (m, 3H), 4.50–4.46 (m, 1H), 3.60 (dd, <i>J</i> = 9.8, 5.9 Hz, 1H), 3.53 (dd, <i>J</i> = 9.8, 4.9 Hz, 1H), 3.23 (s, 3H), 2.58 (d, <i>J</i> = 6.7 Hz, 2H), 2.47 (s, 3H), 1.16 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 170.4, 169.2, 168.9, 158.5, 158.3, 134.2, 133.2, 130.7, 128.4, 127.4, 126.1, 125.7, 125.4, 125.0, 123.3, 101.3, 71.8, 58.2, 53.1, 50.2, 50.1, 40.3, 38.1, 28.3, 11.8. HRMS calcd for C<sub>28</sub>H<sub>35</sub>N<sub>5</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 560.2480. Found: 560.2478.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> PKS2231</h4><div class="NLM_p last">Synthesized by following the general procedure of EDC-mediated coupling of Boc-Glu-OBn (5.06 g, 15.0 mmol) with <i>tert</i>-butylamine (2.37 mL, 22.5 mmol). After completion of reaction, water was added to the mixture. The mixture was extracted twice with ethyl acetate. The combined organic layer was washed with aq. NaHCO<sub>3</sub>, water, 1 N HCl, water followed by saturated brine solution. Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to give the product (5.78 g, 98%) as a white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.43–7.29 (m, 5H), 5.58 (s, 1H), 5.27 (d, <i>J</i> = 8.3 Hz, 1H), 5.20 (d, <i>J</i> = 12.3 Hz, 1H), 5.13 (d, <i>J</i> = 12.3 Hz, 1H), 4.36–4.23 (m, 1H), 2.22–2.06 (m, 3H), 2.02–1.87 (m, 1H), 1.42 (s, 9H), 1.32 (s, 9H).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> PKS2233</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS2231</b> (3.68 g, 9.38 mmol). The crude was dried under high vacuum to give the product (3.81 g, quant.) as a colorless paste. The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.44 (s, 3H), 7.42–7.29 (m, 5H), 6.07 (b, 1H), 5.27 (d, <i>J</i> = 11.9 Hz, 1H), 5.20 (d, <i>J</i> = 11.9 Hz, 1H), 4.24–4.16 (m, 1H), 2.53–2.44 (m, 1H), 2.43–2.34 (m, 1H), 2.34–2.24 (m, 1H), 2.24–2.13 (m, 1H), 1.30 (d, <i>J</i> = 2.1 Hz, 9H).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> PKS2234</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of 3-phenylpropanoic acid (82.6 mg, 0.55 mmol) and <b>PKS2233</b> (203.2 mg, 0.5 mmol). The crude was purified by column chromatography to give the product (193 mg, 91%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.28 (d, <i>J</i> = 7.4 Hz, 1H), 7.41–7.30 (m, 5H), 7.30–7.21 (m, 3H), 7.21–7.13 (m, 3H), 5.13 (d, <i>J</i> = 12.6 Hz, 1H), 5.10 (d, <i>J</i> = 12.6 Hz,1H), 4.31–4.20 (m, 1H), 2.80–2.76 (m, 2H), 2.45–2.38 (m, 2H), 2.07 (t, <i>J</i> = 7.7 Hz, 2H), 1.97–1.84 (m, 1H), 1.79–1.67 (m, 1H), 1.22 (s, 9H).</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> PKS2239</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS2234</b> (180 mg, 0.34 mmol). The product was isolated as a white solid (140 mg, 99%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.58 (s, 1H), 8.10 (d, <i>J</i> = 7.7 Hz, 1H), 7.37 (s, 1H), 7.27–7.13 (m, 5H), 4.19–4.11 (m, 1H), 2.81 (t, <i>J</i> = 7.9 Hz, 2H), 2.49–2.36 (m, 2H), 2.10–1.98 (m, 2H), 1.96–1.85 (m, 1H), 1.76–1.63 (m, 1H), 1.23 (s, 9H). LCMS calcd for C<sub>18</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub> [M – H]<sup>+</sup>: 333.2. Found: 333.4.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> PKS2243</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2239</b> (20.1 mg, 0.06 mmol) and <b>PKS2082</b> (22.3 mg, 0.06 mmol). The crude was purified by HPLC to give the product (18.8 mg, 54%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (t, <i>J</i> = 5.8 Hz, 1H), 8.10–8.00 (m, 3H), 7.96–7.92 (m, 1H), 7.83 (dd, <i>J</i> = 6.1, 3.4 Hz, 1H), 7.56–7.50 (m, 2H), 7.47–7.43 (m, 2H), 7.35 (s, 1H), 7.28–7.23 (m, 2H), 7.21–7.13 (m, 3H), 4.75 (d, <i>J</i> = 5.7 Hz, 2H), 4.51 (dt, <i>J</i> = 7.7, 5.6 Hz, 1H), 4.27 (td, <i>J</i> = 8.3, 5.3 Hz, 1H), 3.55 (dd, <i>J</i> = 9.7, 6.0 Hz, 1H), 3.50 (dd, <i>J</i> = 9.7, 5.4 Hz, 1H), 3.24 (s, 3H), 2.79 (t, <i>J</i> = 7.9 Hz, 2H), 2.48–2.37 (m, 2H), 2.03 (t, <i>J</i> = 8.0 Hz, 2H), 1.92–1.78 (m, 1H), 1.77–1.60 (m, 1H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.6, 171.5, 171.2, 169.4, 141.3, 134.1, 133.2, 130.7, 128.4, 128.2, 128.1, 127.4, 126.1, 125.8, 125.7, 125.4, 124.9, 123.4, 71.9, 58.2, 52.6, 52.3, 49.8, 40.3, 36.8, 32.6, 31.0, 28.5, 28.3. HRMS calcd for C<sub>33</sub>H<sub>42</sub>N<sub>4</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 597.3047. Found: 597.3027.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> PKS2255</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2239</b> (18.4 mg, 0.055 mmol) and <b>PKS2026</b> (17.1 mg, 0.05 mmol). The crude was purified by HPLC to give the product (20.2 mg, 74%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (t, <i>J</i> = 5.7 Hz, 1H), 8.10–8.01 (m, 3H), 7.98–7.90 (m, 1H), 7.84 (dd, <i>J</i> = 7.5, 1.9 Hz, 1H), 7.58–7.50 (m, 2H), 7.50–7.41 (m, 2H), 7.35 (s, 1H), 7.29–7.22 (m, 2H), 7.22–7.11 (m, 3H), 4.76 (dd, <i>J</i> = 14.2, 4.6 Hz, 1H), 4.73 (dd, <i>J</i> = 14.2, 4.5 Hz, 1H), 4.37–4.27 (m, 1H), 4.27–4.18 (m, 1H), 2.79 (t, <i>J</i> = 7.9 Hz, 2H), 2.47–2.36 (m, 2H), 2.09–2.00 (m, 2H), 1.90–1.79 (m, 1H), 1.75–1.63 (m, 1H), 1.24 (d, <i>J</i> = 7.1 Hz, 3H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO<i>-d</i><sub>6</sub>) δ 172.1, 171.6, 171.2, 171.2, 141.3, 134.4, 133.2, 130.8, 128.5, 128.2, 128.2, 127.5, 126.2, 125.8, 125.8, 125.4, 125.1, 123.4, 52.3, 49.8, 48.3, 40.2, 36.7, 32.6, 31.0, 28.5, 28.3, 18.2. HRMS calcd for C<sub>32</sub>H<sub>40</sub>N<sub>4</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup>: 567.2942. Found: 567.2937.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> PKS21201</h4><div class="NLM_p last">Boc-Ala-OSu (143 mg, 0.5 mmol) was dissolved in dichloromethane (5 mL), and (4-fluoro-1-naphthyl)methanamine (88 mg, 0.5 mmol) was added. The solution was cooled to 0 °C, and triethylamine (51 mg, 0.5 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 2 h. After completion of reaction, dichloromethane was evaporated and water was added. The mixture was extracted with ethyl acetate twice. The combined organic layer was washed with 1 N HCl followed by brine and dried over anhydrous sodium sulfate. The organic layer was evaporated to give the product (170 mg, 98%) as a white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.16–8.09 (m, 1H), 7.96 (d, <i>J =</i> 7.8 Hz, 1H), 7.62–7.52 (m, 2H), 7.35 (dd, <i>J =</i> 7.8, 5.4 Hz, 1H), 7.07 (dd, <i>J =</i> 10.2, 7.9 Hz, 1H), 6.48 (b, 1H), 4.95 (b, 1H), 4.88–4.76 (m, 2H), 4.21–4.06 (m, 1H), 1.36 (d, <i>J =</i> 7.0 Hz, 3H), 1.33 (s, 9H). LCMS calcd for C<sub>19</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 347.2. Found 347.1.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> PKS21202</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS21201</b>. The crude was dried under vacuum to give a colorless paste (which turned off-white solid upon standing overnight at 0 °C). The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (t, <i>J =</i> 5.6 Hz, 1H), 8.16–8.06 (m, 5H), 7.72–7.64 (m, 2H), 7.47 (dd, <i>J =</i> 7.9, 5.5 Hz, 1H), 7.32 (dd, <i>J =</i> 10.6, 7.9 Hz, 1H), 4.80 (dd, <i>J =</i> 15.1, 5.6 Hz, 1H), 4.75 (dd, <i>J =</i> 15.1, 5.5 Hz, 1H), 3.92–3.80 (m, 1H), 1.35 (d, <i>J =</i> 6.9 Hz, 3H). LCMS calcd for C<sub>14</sub>H<sub>16</sub>FN<sub>2</sub>O [M + H]<sup>+</sup>: 247.1. Found 247.2.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> PKS21210</h4><div class="NLM_p last">Synthesized by following the general procedure for the HATU-mediated coupling of <b>PKS2239</b> (16.7 mg, 0.05 mmol) and <b>PKS21202</b> (18.0 mg, 0.05 mmol). The isolated mixture was purified by HPLC to give the product (19.6 mg, 70%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (t, <i>J =</i> 5.6 Hz, 1H), 8.12–8.05 (m, 3H), 8.03 (d, <i>J =</i> 7.7 Hz, 1H), 7.68–7.62 (m, 2H), 7.42 (dd, <i>J =</i> 7.8, 5.6 Hz, 1H), 7.35 (s, 1H), 7.30–7.23 (m, 3H), 7.21–7.13 (m, 3H), 4.71 (d, <i>J =</i> 5.6 Hz, 2H), 4.34–4.26 (m, 1H), 4.25–4.17 (m, 1H), 2.78 (t, <i>J =</i> 7.8 Hz, 2H), 2.48–2.36 (m, 2H), 2.03 (t, <i>J</i> = 8.0 Hz, 2H), 1.89–1.78 (m, 1H), 1.74–1.62 (m, 1H), 1.28–1.20 (m, 12H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.2, 171.6, 171.2, 171.2, 157.4 (d, <i>J</i> = 248.8 Hz), 141.3, 132.0 (d, <i>J</i> = 3.7 Hz), 130.8 (d, <i>J</i> = 3.2 Hz), 128.2, 128.1, 127.3, 126.6, 125.8, 125.2 (d, <i>J</i> = 8.9 Hz), 123.8, 122.9 (d, <i>J</i> = 16.3 Hz), 120.4 (d, <i>J</i> = 5.3 Hz), 108.9 (d, <i>J</i> = 19.8 Hz), 52.3, 49.8, 48.3, 39.8, 36.7, 32.6, 31.0, 28.5, 28.3, 18.2. HRMS calcd for C<sub>32</sub>H<sub>39</sub>FN<sub>4</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup>: 585.2848. Found: 585.2843.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> PKS3053</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS3052</b> (7.2 mg, 0.02 mmol) and <b>PKS2026</b> (7.5 mg, 0.022 mmol). The mixture was purified by HPLC to give the product (6.4 mg, 56%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.26 (d, <i>J</i> = 3.4 Hz, 1H), 8.77 (d, <i>J</i> = 3.2 Hz, 1H), 8.71 (d, <i>J</i> = 8.1 Hz, 1H), 8.52 (t, <i>J</i> = 5.8 Hz, 1H), 8.30–8.21 (m, 2H), 8.08–8.02 (m, 1H), 7.97–7.91 (m, 1H), 7.86–7.80 (m, 1H), 7.57 (s, 1H), 7.56–7.49 (m, 3H), 7.47–7.41 (m, 2H), 7.31–7.24 (m, 2H), 4.75 (d, <i>J</i> = 5.8 Hz, 2H), 4.70–4.60 (m, 1H), 4.38–4.25 (m, 1H), 2.66–2.54 (m, 2H), 1.27 (d, <i>J</i> = 7.1 Hz, 3H), 1.17 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO<i>-d</i><sub>6</sub>) δ 181.1, 171.9, 170.0, 169.0, 162.8, 138.6, 136.2, 134.4, 133.2, 130.8, 128.5, 127.5, 126.1, 125.7, 125.4, 125.1, 123.5, 123.3, 122.6, 121.3, 112.6, 112.1, 50.2, 50.1, 48.7, 40.2, 38.1, 28.4, 18.1. HRMS calcd for C<sub>32</sub>H<sub>35</sub>N<sub>5</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 592.2530. Found: 592.2508.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> PKS21271</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS21013</b> (16.0 mg, 0.05 mmol) and <b>PKS21202</b> (18.0 mg, 0.05 mmol). The isolated mixture was purified by HPLC to give the product (21.6 mg, 79%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (t, <i>J =</i> 6.1 Hz, 1H), 8.26 (d, <i>J =</i> 7.4 Hz, 1H), 8.16–8.04 (m, 3H), 7.69–7.61 (m, 2H), 7.53 (s, 1H), 7.46–7.39 (m, 1H), 7.29–7.22 (m, 3H), 7.21–7.12 (m, 3H), 4.76 (dd, <i>J =</i> 15.6, 5.9 Hz, 1H), 4.64 (dd, <i>J =</i> 15.6, 5.5 Hz, 1H), 4.55–4.47 (m, 1H), 4.29–4.18 (m, 1H), 2.78 (t, <i>J =</i> 8.0 Hz, 2H), 2.56–2.50 (m, 1H), 2.41 (t, <i>J =</i> 8.0 Hz, 2H), 2.35 (dd, <i>J =</i> 15.3, 6.1 Hz, 1H), 1.25 (d, <i>J =</i> 6.7 Hz, 3H), 1.12 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.0, 171.3, 170.8, 169.3, 157.3 (d, <i>J =</i> 249.2 Hz), 141.3, 132.0 (d, <i>J =</i> 5.0 Hz), 130.8 (d, <i>J =</i> 5.3 Hz), 128.3, 128.2, 127.3, 126.5, 125.9, 125.1 (d, <i>J =</i> 8.7 Hz), 123.8, 122.9 (d, <i>J =</i> 16.3 Hz), 120.4 (d, <i>J =</i> 5.4 Hz), 108.8 (d, <i>J =</i> 19.2 Hz), 50.1, 49.8, 48.7, 39.8, 38.4, 36.7, 31.0, 28.3, 17.8. HRMS calcd for C<sub>31</sub>H<sub>37</sub>FN<sub>4</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup>: 571.2691. Found: 571.2689.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> PKS21237</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated amide bond formation of <i>boc</i>-β-methoxyalanine dicyclohexylamine (401 mg, 1 mmol) with (4-fluoro-1-naphthyl)methanamine (175 mg, 1 mmol). The crude was isolated by ethyl acetate extraction and purified by combi-flash to give the product (337 mg, 90%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.16–8.08 (m, 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 7.61–7.51 (m, 2H), 7.35 (dd, <i>J</i> = 7.9, 5.3 Hz, 1H), 7.11–7.01 (m, 1H), 6.71 (t, <i>J</i> = 5.6 Hz, 1H), 5.47–5.25 (m, 1H), 4.94–4.76 (m, 2H), 4.34–4.18 (m, 1H), 3.81 (dd, <i>J</i> = 9.3, 3.8 Hz, 1H), 3.51–3.43 (m, 1H), 3.27 (s, 3H), 1.37 (s, 9H).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> PKS21238</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS21237</b> (335 mg, 0.9 mmol). The isolated crude was dried under vacuum to give the product (347 mg, quant.) as an off-white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (b, 1H), 8.23 (b, 3H), 8.14–8.06 (m, 2H), 7.72–7.64 (m, 2H), 7.51–7.44 (m, 1H), 7.32 (dd, <i>J</i> = 10.3, 8.2 Hz, 1H), 4.82 (dd, <i>J</i> = 15.2, 5.7 Hz, 1H), 4.75 (dd, <i>J</i> = 15.2, 5.4 Hz, 1H), 4.09–3.98 (m, 1H), 3.72–3.59 (m, 2H), 3.27 (s, 3H). LCMS calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 277.1. Found 277.7.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> PKS21218</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of 5-methylisoxazole-3-carboxylic acid (720 mg, 3.00 mmol) and <b>PKS2233</b> (880 mg, 3.00 mmol). After completion of reaction (2 h), water was added and the mixture was stirred for 30 min. A white precipitate appeared. The precipitate was filtered, washed with water, and dried in air to give the product (1.03 g, 86%) as a white solid.<sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.58 (d, <i>J</i> = 7.9 Hz, 1H), 7.39–7.30 (m, 5H), 6.41 (s, 1H), 5.47 (s, 1H), 5.20 (s, 2H), 4.80–4.72 (m, 1H), 2.47 (s, 3H), 2.35–2.25 (m, 1H), 2.23–2.04 (m, 3H), 1.31 (s, 9H). LCMS calcd for C<sub>21</sub>H<sub>28</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 402.2. Found 402.3.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> PKS21233</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS21218</b> (1.02 g, 2.54 mmol). The product (780 mg, 99%) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.71 (s, 1H), 8.78 (d, <i>J</i> = 7.6 Hz, 1H), 7.41 (s, 1H), 6.55 (s, 1H), 4.35–4.27 (m, 1H), 2.47 (s, 3H), 2.16–2.10 (m, 2H), 2.10–2.00 (m, 1H), 1.97–1.86 (m, 1H), 1.21 (s, 9H). LCMS calcd for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub> [M – H]<sup>+</sup>: 310.1. Found: 310.4.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> PKS21213</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21178</b> (14.9 mg, 0.05 mmol) with <b>PKS21202</b> (18.0 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (18.6 mg, 71%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54 (d, <i>J</i> = 7.9 Hz, 1H), 8.50 (t, <i>J</i> = 5.8 Hz, 1H), 8.27 (d, <i>J</i> = 7.3 Hz, 1H), 8.16–8.05 (m, 2H), 7.69–7.59 (m, 2H), 7.54 (s, 1H), 7.42 (dd, <i>J</i> = 7.8, 5.7 Hz, 1H), 7.27 (dd, <i>J</i> = 10.5, 8.0 Hz, 1H), 6.53 (s, 1H), 4.75–4.63 (m, 3H), 4.34–4.23 (m, 1H), 2.57 (d, <i>J</i> = 6.7 Hz, 2H), 2.47 (s, 3H), 1.25 (d, <i>J</i> = 7.1 Hz, 3H), 1.15 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.9, 171.3, 170.0, 169.0, 158.5, 158.3, 157.3 (d, <i>J</i> = 249.3 Hz), 132.0 (d, <i>J</i> = 5.0 Hz), 130.8 (d, <i>J</i> = 5.2 Hz), 127.3, 126.5, 125.2 (d, <i>J</i> = 8.8 Hz), 123.8, 122.9 (d, <i>J</i> = 16.0 Hz), 120.4 (d, <i>J</i> = 5.9 Hz), 108.9 (d, <i>J</i> = 19.9 Hz), 101.3,50.2, 50.1, 48.7, 39.8, 38.0, 28.3, 18.0, 11.8. HRMS calcd for C<sub>27</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 548.2280. Found: 548.2267.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> PKS21272</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21233</b> (15.6 mg, 0.05 mmol) with <b>PKS21202</b> (18.0 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (20.7 mg, 77%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54 (d, <i>J</i> = 7.7 Hz, 1H), 8.50 (t, <i>J</i> = 6.0 Hz, 1H), 8.26 (d, <i>J</i> = 7.3 Hz, 1H), 8.12–8.04 (m, 2H), 7.69–7.60 (m, 2H), 7.45–7.37 (m, 2H), 7.32–7.24 (m, 1H), 6.54 (s, 1H), 4.76–4.65 (m, 2H), 4.45–4.38 (m, 1H), 4.38–4.29 (m, 1H), 2.46 (s, 3H), 2.18–2.05 (m, 2H), 2.03–1.93 (m, 1H), 1.92–1.81 (m, 1H), 1.24 (d, <i>J</i> = 7.1 Hz, 3H), 1.21 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.0, 171.2, 171.2, 170.4, 158.5, 158.5, 157.4 (d, <i>J</i> = 248.8 Hz), 132.0 (d, <i>J</i> = 5.3 Hz), 130.8 (d, <i>J</i> = 5.3 Hz), 127.4, 126.6, 125.2 (d, <i>J</i> = 10.2 Hz), 123.8, 122.9 (d, <i>J</i> = 16.3 Hz), 120.4 (d, <i>J</i> = 5.4 Hz), 108.9 (d, <i>J</i> = 19.5 Hz), 101.3, 52.7, 49.9, 48.3, 39.8, 32.6, 28.5, 27.9, 18.3, 11.8. HRMS calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>5</sub>O<sub>5</sub>Na [M + Na]<sup>+</sup>: 562.2436. Found: 562.2433.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> PKS21244</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21178</b> (14.9 mg, 0.05 mmol) with <b>PKS21238</b> (19.5 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by preparative LCMS to give the product (19.7 mg, 71%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (t, <i>J</i> = 5.9 Hz, 1H), 8.55 (d, <i>J</i> = 7.9 Hz, 1H), 8.25 (d, <i>J</i> = 7.7 Hz, 1H), 8.13–8.04 (m, 2H), 7.68–7.60 (m, 2H), 7.53 (s, 1H), 7.46–7.38 (m, 1H), 7.31–7.22 (m, 1H), 6.53 (s, 1H), 4.81–4.74 (m, 1H), 4.74–4.66 (m, 2H), 4.50–4.41 (m, 1H), 3.63–3.55 (m, 1H), 3.52 (dd, <i>J</i> = 10.2, 4.7 Hz, 1H), 3.22 (s, 3H), 2.57 (d, <i>J</i> = 6.7 Hz, 2H), 2.47 (s, 3H), 1.15 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.4, 170.4, 169.2, 168.9, 158.5, 158.3, 157.3 (d, <i>J</i> = 249.3 Hz), 131.9 (d, <i>J</i> = 4.4 Hz), 130.6 (d, <i>J</i> = 3.1 Hz), 127.3, 126.5, 125.1 (d, <i>J</i> = 8.6 Hz), 123.8, 122.9 (d, <i>J</i> = 16.4 Hz), 120.4 (d, <i>J</i> = 5.4 Hz), 108.8 (d, <i>J</i> = 19.7 Hz), 101.3, 71.8, 58.3, 53.2, 50.2, 50.1, 40.0, 38.1, 28.3, 11.8. HRMS calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>5</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 578.2385. Found: 578.2377.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> PKS21245</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21233</b> (15.6 mg, 0.05 mmol) with <b>PKS21238</b> (19.5 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by preparative LCMS to give the product (22.5 g, 79%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63–8.57 (m, 1H), 8.56 (d, <i>J</i> = 7.8 Hz, 1H), 8.25 (d, <i>J</i> = 7.8 Hz, 1H), 8.11–8.03 (m, 2H), 7.69–7.60 (m, 2H), 7.45–7.34 (m, 2H), 7.28 (dd, <i>J</i> = 10.6, 8.1 Hz, 1H), 6.54 (s, 1H), 4.72 (d, <i>J</i> = 5.6 Hz, 2H), 4.56–4.49 (m, 1H), 4.49–4.40 (m, 1H), 3.57–3.45 (m, 2H), 3.23 (s, 3H), 2.46 (s, 3H), 2.17–2.03 (m, 2H), 2.02–1.91 (m, 1H), 1.91–1.77 (m, 1H), 1.21 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.2, 171.1, 170.8, 169.3, 158.5, 158.5, 157.4 (d, <i>J</i> = 248.9 Hz), 131.9, 130.5, 127.3, 126.5, 125.1 (d, <i>J</i> = 8.6 Hz), 123.8, 122.9 (d, <i>J</i> = 16.1 Hz), 120.4, 108.9 (d, <i>J</i> = 19.1 Hz), 101.3, 71.9, 58.2, 52.8, 52.6, 49.9, 39.9, 32.6, 28.5, 27.9, 11.8. HRMS calcd for C<sub>29</sub>H<sub>36</sub>FN<sub>5</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup>: 592.2542. Found: 592.2537.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> PKS2238</h4><div class="NLM_p last"><b>PKS2233</b> (203.0 mg, 0.5 mmol) was dissolved in dichloromethane (6 mL), and triethylamine (140 μL, 1.0 mmol) was added. After stirring the mixture for 10 min at room temperature, 4-toluenesulfonyl chloride (143.0 mg, 0.75 mmol) was added. The reaction mixture was stirred for 2 h at room temperature. Dichloromethane was evaporated, and the crude was dissolved in ethyl acetate. The solution was washed with water, 1 N HCl followed by brine. The product was purified by column chromatography to give the product (177.0 mg, 79%) as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.66 (d, <i>J</i> = 8.5 Hz, 2H), 7.35–7.29 (m, 3H), 7.20 (d, <i>J</i> = 8.0 Hz, 2H), 7.18–7.13 (m, 2H), 5.52 (s, 1H), 5.47 (d, <i>J</i> = 9.1 Hz, 1H), 4.91 (d, <i>J</i> = 12.2 Hz, 1H), 4.87 (d, <i>J</i> = 12.2 Hz, 1H), 3.93–3.84 (m, 1H), 2.38 (s, 3H), 2.33–2.11 (m, 3H), 1.88–1.77 (m, 1H), 1.35 (s, 9H). LCMS calcd for C<sub>23</sub>H<sub>32</sub>N<sub>2</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: 447.2. Found 447.3.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> PKS2254</h4><div class="NLM_p last">Synthesized by following the general procedure for <i>O</i>-debenzylation of <b>PKS2238</b> (170 mg, 0.38 mmol). The product (135 mg, quant.) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.69 (d, <i>J</i> = 7.9 Hz, 2H), 7.26 (d, <i>J</i> = 7.9 Hz, 2H), 6.15–5.91 (m, 2H), 3.82–3.69 (m, 1H), 2.39 (s, 3H), 2.35–2.27 (m, 1H), 2.21–2.12 (m, 1H), 2.11–2.02 (m, 1H), 1.99–1.88 (m, 1H), 1.31 (s, 9H). LCMS calcd for C<sub>16</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>S [M – H]<sup>+</sup>: 355.1. Found: 355.0.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> PKS2256</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated coupling of <b>PKS2254</b> (29.0 mg, 0.08 mmol) and <b>PKS2026</b> (27.4 mg, 0.08 mmol). The crude was purified by HPLC to give the product (32.8 mg, 74%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.43 (t, <i>J</i> = 5.7 Hz, 1H), 8.09 (d, <i>J</i> = 7.3 Hz, 1H), 8.04–7.98 (m, 1H), 7.97–7.90 (m, 1H), 7.86 (b, 1H), 7.84 (d, <i>J</i> = 8.1 Hz, 1H), 7.63 (d, <i>J</i> = 8.3 Hz, 2H), 7.58–7.49 (m, 2H), 7.49–7.42 (m, 1H), 7.42–7.39 (m, 1H), 7.38 (s, 1H), 7.30 (d, <i>J</i> = 7.9 Hz, 2H), 4.75 (dd, <i>J</i> = 15.4, 5.8 Hz, 1H), 4.69 (dd, <i>J</i> = 15.4, 5.6 Hz, 1H), 4.11–4.01 (m, 1H), 3.74–3.67 (m, 1H), 2.34 (s, 3H), 2.11–1.93 (m, 2H), 1.77–1.66 (m, 1H), 1.66–1.56 (m, 1H), 1.21 (s, 9H), 1.07 (d, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.8, 171.0, 169.9, 142.4, 138.0, 134.3, 133.2, 130.8, 129.2, 128.5, 127.5, 126.7, 126.2, 125.8, 125.4, 125.1, 123.4, 55.8, 49.8, 48.1, 40.1, 32.3, 29.2, 28.5, 20.9, 18.1. LCMS calcd for C<sub>30</sub>H<sub>39</sub>N<sub>4</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: 567.3. Found: 567.1.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> PKS21206</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21241</b> (17.1 mg, 0.05 mmol) with <b>PKS21202</b> (18.0 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (24.0 mg, 84%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.46 (t, <i>J</i> = 6.0 Hz, 1H), 8.21 (d, <i>J</i> = 7.2 Hz, 1H), 8.12–8.03 (m, 2H), 8.03–7.93 (m, 1H), 7.68–7.60 (m, 4H), 7.54 (s, 1H), 7.36 (dd, <i>J</i> = 7.9, 5.6 Hz, 1H), 7.32 (d, <i>J</i> = 7.9 Hz, 2H), 7.23 (dd, <i>J</i> = 10.6, 7.9 Hz, 1H), 4.72 (dd, <i>J</i> = 15.5, 6.1 Hz, 1H), 4.59 (dd, <i>J</i> = 15.5, 5.6 Hz, 1H), 4.05–3.95 (m, 1H), 3.91–3.81 (m, 1H), 2.49–2.45 (m, 1H), 2.35 (s, 3H), 2.29 (dd, <i>J</i> = 15.2, 5.5 Hz, 1H), 1.11–1.01 (m, 12H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.8, 169.7, 168.7, 157.3 (d, <i>J</i> = 249.5 Hz), 142.4, 138.3, 131.9 (d, <i>J</i> = 5.2 Hz), 130.7 (d, <i>J</i> = 3.3 Hz), 129.2, 127.3, 126.6, 126.5, 125.0 (d, <i>J</i> = 8.0 Hz), 123.7, 122.9 (d, <i>J</i> = 16.4 Hz), 120.4 (d, <i>J</i> = 6.7 Hz), 108.8 (d, <i>J</i> = 18.4 Hz), 53.0, 50.1, 48.6, 39.7, 39.2, 28.2, 20.9, 17.4. HRMS calcd for C<sub>29</sub>H<sub>35</sub>FN<sub>4</sub>O<sub>5</sub>SNa [M + Na]<sup>+</sup>: 593.2204. Found: 593.2206.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> PKS21209</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS2254</b> (17.8 mg, 0.05 mmol) with <b>PKS21202</b> (18.0 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (17.0 mg, 58%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (t, <i>J</i> = 5.7 Hz, 1H), 8.12–8.02 (m, 3H), 7.90–7.78 (m, 1H), 7.70–7.57 (m, 4H), 7.42–7.33 (m, 2H), 7.32–7.21 (m, 3H), 4.74–4.62 (m, 2H), 4.08–3.97 (m, 1H), 3.74–3.63 (m, 1H), 2.34 (s, 3H), 2.09–1.91 (m, 2H), 1.76–1.65 (m, 1H), 1.65–1.51 (m, 1H), 1.20 (s, 9H), 1.05 (d, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.9, 171.1, 170.0, 157.4 (d, <i>J</i> = 248.9 Hz), 142.4, 138.0, 132.0 (d, <i>J</i> = 5.2 Hz), 130.7 (d, <i>J</i> = 5.1 Hz), 129.2, 127.4, 126.7, 126.5, 125.2 (d, <i>J</i> = 9.0 Hz), 123.8, 122.9 (d, <i>J</i> = 16.3 Hz), 120.4 (d, <i>J</i> = 5.4 Hz), 108.9 (d, <i>J</i> = 18.4 Hz), 55.8, 49.8, 48.1, 39.8, 32.3, 29.2, 28.5, 20.9, 18.1. HRMS calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>4</sub>O<sub>5</sub>SNa [M + Na]<sup>+</sup>: 607.2361. Found: 607.2349.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> PKS21265</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS2254</b> (17.8 mg, 0.05 mmol) with <b>PKS21238</b> (19.5 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by preparative LCMS to give the product (24.5 g, 80%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59–8.48 (m, 1H), 8.11 (d, <i>J</i> = 7.8 Hz, 1H), 8.09–8.02 (m, 2H), 7.89 (s, 1H), 7.69–7.59 (m, 4H), 7.43–7.35 (m, 2H), 7.32 (d, <i>J</i> = 7.9 Hz, 2H), 7.30–7.22 (m, 1H), 4.75–4.64 (m, 2H), 4.31–4.21 (m, 1H), 3.81–3.70 (m, 1H), 3.31–3.23 (m, 2H), 3.19 (s, 3H), 2.35 (s, 3H), 2.10–2.00 (m, 1H), 2.00–1.90 (m, 1H), 1.75–1.64 (m, 1H), 1.64–1.50 (m, 1H), 1.20 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.1, 170.5, 169.2, 157.4 (d, <i>J</i> = 248.9 Hz), 142.4, 138.0, 131.9 (d, <i>J</i> = 5.2 Hz), 130.5 (d, <i>J</i> = 4.7 Hz), 129.3, 127.4, 126.7, 126.6, 125.1 (d, <i>J</i> = 8.8 Hz), 123.8, 122.9 (d, <i>J</i> = 16.3 Hz), 120.4 (d, <i>J</i> = 6.8 Hz), 108.9 (d, <i>J</i> = 20.0 Hz), 71.7, 58.3, 55.8, 52.3, 49.9, 39.9, 32.4, 29.3, 28.5, 21.0. HRMS calcd for C<sub>31</sub>H<sub>39</sub>FN<sub>4</sub>O<sub>6</sub>SNa [M + Na]<sup>+</sup>: 637.2467. Found: 637.2464.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> PKS21266</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS21241</b> (17.1 mg, 0.05 mmol) with <b>PKS21238</b> (19.5 mg, 0.05 mmol). After completion of reaction (1 h), the mixture was purified by preparative LCMS to give the product (26.8 mg, 89%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (t, <i>J</i> = 6.0 Hz, 1H), 8.20 (d, <i>J</i> = 7.6 Hz, 1H), 8.12–8.03 (m, 2H), 7.93 (d, <i>J</i> = 8.6 Hz, 1H), 7.68–7.59 (m, 4H), 7.48 (s, 1H), 7.41–7.36 (m, 1H), 7.32 (d, <i>J</i> = 7.9 Hz, 2H), 7.23 (dd, <i>J</i> = 10.8, 8.2 Hz, 1H), 4.73 (dd, <i>J</i> = 15.7, 5.9 Hz, 1H), 4.63 (dd, <i>J</i> = 15.7, 5.5 Hz, 1H), 4.20–4.07 (m, 2H), 3.53–3.46 (m, 1H), 3.29–3.23 (m, 1H), 3.20 (s, 3H), 2.44 (dd, <i>J</i> = 15.6, 8.2 Hz, 1H), 2.36 (s, 3H), 2.26 (dd, <i>J</i> = 15.6, 6.2 Hz, 1H), 1.08 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.3, 169.2, 168.5, 157.3 (d, <i>J</i> = 248.8 Hz), 142.4, 138.3, 131.9 (d, <i>J</i> = 3.8 Hz), 130.6 (d, <i>J</i> = 3.3 Hz), 129.3, 127.2, 126.6, 126.5, 125.0 (d, <i>J</i> = 7.5 Hz), 123.8, 122.8 (d, <i>J</i> = 16.2 Hz), 120.3 (d, <i>J</i> = 5.3 Hz), 108.8 (d, <i>J</i> = 19.5 Hz), 71.5, 58.3, 53.3, 52.9, 50.1, 39.9, 39.4, 28.3, 21.0. HRMS calcd for C<sub>30</sub>H<sub>37</sub>FN<sub>4</sub>O<sub>6</sub>SNa [M + Na]<sup>+</sup>: 623.2310. Found: 623.2307.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> PKS21066</h4><div class="NLM_p last">Synthesized following the general procedure for HATU-mediated amide bond formation of <b>PKS2141</b> (22.8 mg, 0.04 mmol) with <i>neo</i>-pentylamine (9.4 μL, 0.08 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (17.8 mg, 70%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (t, <i>J</i> = 5.9 Hz, 1H), 8.21 (d, <i>J</i> = 8.2 Hz, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 8.07 (d, <i>J</i> = 7.9 Hz, 1H), 7.94 (d, <i>J</i> = 7.4 Hz, 1H), 7.89–7.81 (m, 2H), 7.57–7.51 (m, 2H), 7.42 (t, <i>J</i> = 7.6 Hz, 1H), 7.36 (d, <i>J</i> = 6.9 Hz, 1H), 7.30–7.13 (m, 7H), 7.04–6.95 (m, 2H), 4.78 (dd, <i>J</i> = 15.3, 5.9 Hz, 1H), 4.68 (dd, <i>J</i> = 15.3, 5.6 Hz, 1H), 4.59–4.52 (m, 1H), 4.50–4.42 (m, 1H), 3.09 (dd, <i>J</i> = 13.9, 4.7 Hz, 1H), 2.87–2.79 (m, 2H), 2.77–2.70 (m, 3H), 2.55 (dd, <i>J</i> = 15.0, 7.1 Hz, 1H), 2.41 (dd, <i>J</i> = 15.0, 7.2 Hz, 1H), 2.35 (t, <i>J</i> = 8.0 Hz, 2H), 0.76 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 171.0, 170.5, 169.7, 160.9 (d, <i>J</i> = 240.3 Hz), 141.3, 134.2, 134.0, 133.2, 131.0 (d, <i>J</i> = 7.7 Hz), 130.8, 128.5, 128.3, 128.1, 127.5, 126.2, 125.8, 125.7, 125.4, 125.3, 123.4, 114.7 (d, <i>J</i> = 20.2 Hz), 54.3, 49.9, 49.7, 40.3, 37.5, 36.8, 36.2, 31.8, 31.0, 27.2. HRMS calcd for C<sub>38</sub>H<sub>43</sub>FN<sub>4</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup>: 661.3161. Found: 661.3154.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> PKS21076</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU coupling of Boc-Asn-OH (130 mg, 0.56 mmol) and <b>PKS2123</b> (245 mg, 0.56 mmol). After completion of reaction (1 h), water was added. A white precipitate was formed. The precipitate was filtered, washed with water, and dried to give the product (298 mg, 99%) as a white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (d, <i>J</i> = 5.9 Hz, 1H), 8.08–7.98 (m, 2H), 7.98–7.92 (m, 1H), 7.84 (d, <i>J</i> = 8.1 Hz, 1H), 7.60–7.49 (m, 2H), 7.47–7.40 (m, 1H), 7.40–7.28 (m, 2H), 7.28–7.15 (m, 2H), 7.11–6.97 (m, 2H), 6.97–6.87 (m, 2H), 4.72 (d, <i>J</i> = 5.6 Hz, 2H), 4.58–4.43 (m, 1H), 4.27–4.10 (m, 1H), 3.02 (dd, <i>J</i> = 13.9, 5.0 Hz, 1H), 2.85 (dd, <i>J</i> = 13.9, 8.9 Hz, 1H), 2.43 (dd, <i>J</i> = 15.3, 5.9 Hz, 1H), 2.32 (dd, <i>J</i> = 15.3, 7.9 Hz, 1H), 1.35 (s, 9H). LCMS calcd for C<sub>29</sub>H<sub>34</sub>FN<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 537.2. Found: 537.4.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> PKS21078</h4><div class="NLM_p last">Synthesized by following the general procedure for boc-deprotection of <b>PKS21076</b> (298 mg, 0.56 mmol). The isolated crude was triturated with diethyl ether to give a white solid. Diethyl ether was decanted, and white solid was dried under high vacuum to give the product (300 mg, 98%). The product was used in the next step without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (d, <i>J</i> = 8.0 Hz, 1H), 8.72–8.66 (m, 1H), 8.15–7.98 (m, 4H), 7.96 (d, <i>J</i> = 6.7 Hz, 1H), 7.86 (d, <i>J</i> = 8.2 Hz, 1H), 7.72 (s, 1H), 7.59–7.52 (m, 2H), 7.47–7.41 (m, 1H), 7.33–7.28 (m, 2H), 7.28–7.22 (m, 2H), 7.09–7.02 (m, 2H), 4.77 (dd, <i>J</i> = 15.5, 5.7 Hz, 1H), 4.69 (dd, <i>J</i> = 15.5, 5.4 Hz, 1H), 4.60–4.52 (m, 1H), 4.09–3.98 (m, 1H), 3.00 (dd, <i>J</i> = 14.1, 5.1 Hz, 1H), 2.85–2.72 (m, 2H), 2.58 (dd, <i>J</i> = 17.3, 9.0 Hz, 1H). LCMS calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 437.2. Found: 437.4.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> PKS21083</h4><div class="NLM_p last">Synthesized by following the general procedure for HATU-mediated amide bond formation of 3-phenylpropanoic acid (8.3 mg, 0.055 mmol) and <b>PKS21078</b> (27.5 mg. 0.05 mmol). After completion of reaction (1 h), the mixture was purified by HPLC to give the product (21.6 mg, 76%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61–8.49 (m, 1H), 8.16 (d, <i>J</i> = 8.2 Hz, 1H), 8.07 (d, <i>J</i> = 7.9 Hz, 2H), 7.94 (d, <i>J</i> = 7.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.2 Hz, 1H), 7.61–7.50 (m, 2H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.40 (s, 1H), 7.36 (d, <i>J</i> = 7.2 Hz, 1H), 7.29–7.22 (m, 2H), 7.24–7.13 (m, 5H), 7.03–6.95 (m, 2H), 6.94 (s, 1H), 4.76 (dd, <i>J</i> = 15.6, 5.7 Hz, 1H), 4.70 (dd, <i>J</i> = 15.6, 5.7 Hz, 1H), 4.61–4.51 (m, 1H), 4.50–4.41 (m, 1H), 3.08 (dd, <i>J</i> = 14.3, 4.5 Hz, 1H), 2.83 (dd, <i>J</i> = 13.9, 9.7 Hz, 1H), 2.78–2.70 (m, 2H), 2.57–2.49 (m, 1H), 2.42–2.29 (m, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.8, 171.3, 170.9, 170.5, 160.9 (d, <i>J</i> = 240.0 Hz), 141.3, 134.2, 134.0, 133.2, 130.9 (d, <i>J</i> = 6.3 Hz), 130.7, 128.5, 128.3, 128.1, 127.4, 126.2, 125.8, 125.7, 125.4, 125.0, 123.4, 114.7 (d, <i>J</i> = 21.6 Hz), 54.3, 49.5, 40.2, 37.0, 36.7, 36.2, 31.0. <sup>19</sup>F NMR (471 MHz, DMSO-<i>d</i><sub>6</sub>) δ −119.31 (m). HRMS calcd for C<sub>33</sub>H<sub>33</sub>FN<sub>4</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup>: 591.2378. Found: 591.2374.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> IC<sub>50</sub> Determination</h4><div class="NLM_p last">IC<sub>50</sub> values of all compounds against hu i-20S and c-20S were performed using a 96-well format assay, as described.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Cell-Based Proteasome β5 Activity Assay</h4><div class="NLM_p last">Karpas-1106P (22 000 cells per well) or Hela (3000 cells per well) were plated in a 384-well plate and incubated with the compound at indicated concentrations for 2 h at 37 °C. The activity of the overall β5 activity including β5i and β5c in each was measured in situ after compound removal with the Proteasome-Glo assay kit according to the manufacturer’s instructions. Luminescence was recorded on a SpectraMax M5 plate reader. The relative percentage of RLU was used to calculate the IC<sub>50</sub> values.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Human PBMC Proliferation Assay</h4><div class="NLM_p last">IC<sub>50</sub> values of select compounds against T cell proliferation in PBMCs were determined as reported.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Kinetic Assay of PKS21265 vs hu i-20S</h4><div class="NLM_p last">The assay was performed on a SpectraMax Gemini plate reader from Molecular Devices (Sunnyvale, CA). One microliter of PKS21265 at 100× indicated concentrations in DMSO was spotted at the bottom of the wells of a black wall/clear-bottom 96-well plate. Ninety-nine microliter of assay mixture containing 0.4 nM human i-20S and the indicated concentration of Suc-LLVY-AMC in HEPES buffer (25 mM HEPES, 0.5 mM EDTA, 0.02% sodium dodecyl sulfate, pH 7.4) were dispensed into the designated wells. The reaction progress of each well was immediately recorded by monitoring the fluorescence at Ex 360 nm and Em 460 nm for 1.2 h at 37 °C. The <i>K<sub>i</sub></i> value for PKS21225 was derived by fitting data to the equation <i>V</i> = (<i>V</i><sub>max</sub>/(1 + <i>I</i>/(α × <i>K<sub>i</sub></i>))) × S/(<i>K</i><sub>M</sub> * (1 + <i>I</i>/<i>K</i><sub>i</sub>)/(1 + <i>I</i>/(α × <i>K<sub>i</sub></i>)) + <i>S</i>) in Prism (GraphPad Software, Inc., La Jolla, CA).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01520" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01520?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01520</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis and compound characterization of all new compounds, and tables (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf">jm0c01520_si_001.pdf (10.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_002.csv">jm0c01520_si_002.csv (5.02 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01520" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Lin</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4797-7073" title="Orcid link">http://orcid.org/0000-0003-4797-7073</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2047414c12101015604d45440e434f524e454c4c0e454455"><span class="__cf_email__" data-cfemail="0d6a6c613f3d3d384d606869236e627f6368616123686978">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhu Zhan</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7095-7081" title="Orcid link">http://orcid.org/0000-0002-7095-7081</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pradeep K. Singh</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Milstein Chemistry Core Facility, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span>; 
    <span>Present Address:
                        Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois–60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Ban</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoping Qing</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity
and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie Dominique Ah Kioon</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity
and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Fan</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Quanju Zhao</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Wang</span> - <span class="hlFld-Affiliation affiliation">NMR
Analytical Core Facility, Memorial Sloan
Kettering Cancer Center, 417 East 68th Street, Room 1735, New York, New York 10065-6007, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Sukenick</span> - <span class="hlFld-Affiliation affiliation">NMR
Analytical Core Facility, Memorial Sloan
Kettering Cancer Center, 417 East 68th Street, Room 1735, New York, New York 10065-6007, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane Salmon</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity
and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. David Warren</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Milstein Chemistry Core Facility, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojing Ma</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Franck J. Barrat</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">Autoimmunity
and Inflammation Program, HSS Research Institute, Hospital for Special Surgery, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl F. Nathan</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology & Immunology, Weill
Cornell Medicine, 1300 York Ave, New York, New York 10065, United
States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.Z. and P.K.S. contributed equally to this work. The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by NIH R21AI101393 (G.L.), R01AI143714 (G.L.), R01AI134842 (Jamil Azzi at Brigham and Women's Hospital, G.L. subaward), Alliance for Lupus Research (Award 255848, G.L.), the Daedalus Fund for Innovation (G.L.) of Weill Cornell Medicine, and the Milstein Program in Translational Medicine and Chemical Biology (C.F.N.). The Department of Microbiology and Immunology is supported by the William Randolph Hearst Foundation. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Cornell University has obtained a United States patent on these immunoproteasome inhibitors, patent number 9,988,421, as well as corresponding foreign patents. G. Lin, C. Nathan and X. Ma are listed as inventors on these patents.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">i-20S</td><td class="NLM_def"><p class="first last">immunoproteasome</p></td></tr><tr><td class="NLM_term">c-20S</td><td class="NLM_def"><p class="first last">constitutive proteasome</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i108">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemuller, E.</span></span> <span> </span><span class="NLM_article-title">The proteasome: paradigm of a self-compartmentalizing protease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80929-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0092-8674%2800%2980929-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=9476896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK1cXhtFGisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=367-380&author=W.+Baumeisterauthor=J.+Walzauthor=F.+Zuhlauthor=E.+Seemuller&title=The+proteasome%3A+paradigm+of+a+self-compartmentalizing+protease&doi=10.1016%2FS0092-8674%2800%2980929-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: paradigm of a self-compartmentalizing protease</span></div><div class="casAuthors">Baumeister, Wolfgang; Walz, Jochen; Zuhl, Frank; Seemuller, Erika</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-380</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with ∼100 refs. on advances in understanding the structure of the proteasome and its mechanism of action which shaped the concept of self-compartmentalization and the proteasome became the paradigm of this form of regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tVahAhrt17Vg90H21EOLACvtfcHk0lgvnJNyI-LgOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtFGisLY%253D&md5=0a865caef4357214337a03025ba611d6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980929-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980929-0%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DW.%26aulast%3DWalz%26aufirst%3DJ.%26aulast%3DZuhl%26aufirst%3DF.%26aulast%3DSeemuller%26aufirst%3DE.%26atitle%3DThe%2520proteasome%253A%2520paradigm%2520of%2520a%2520self-compartmentalizing%2520protease%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D367%26epage%3D380%26doi%3D10.1016%2FS0092-8674%2800%2980929-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1042/BST0350012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1042%2FBST0350012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=17212580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=12-17&author=A.+L.+Goldberg&title=Functions+of+the+proteasome%3A+from+protein+degradation+and+immune+surveillance+to+cancer+therapy&doi=10.1042%2FBST0350012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy</span></div><div class="casAuthors">Goldberg, A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-17</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Here, the author focuses on recent insights into the mechanisms and the biol. functions of the proteasome.  This large ATP-dependent proteolytic complex is the main site for protein degrdn. in mammalian cells and catalyzes the rapid degrdn. of ubiquitinated proteins, and is the source of most antigenic peptides used by the immune system to screen for viruses and cancer.  ATP is required to unfold globular proteins to open the gated channel into the 20S proteasome and to facilitate protein translation into it.  Inhibitors of its proteolytic activity are widely used as research tools and have proven effective in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopbyyvkotcZbVg90H21EOLACvtfcHk0lgvnJNyI-LgOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Ohtrg%253D&md5=5d5ad04a404f4d7e39f2bee7943afe17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1042%2FBST0350012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350012%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DFunctions%2520of%2520the%2520proteasome%253A%2520from%2520protein%2520degradation%2520and%2520immune%2520surveillance%2520to%2520cancer%2520therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D12%26epage%3D17%26doi%3D10.1042%2FBST0350012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(94)90462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0092-8674%2894%2990462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=8087844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=761-771&author=K.+L.+Rockauthor=C.+Grammauthor=L.+Rothsteinauthor=K.+Clarkauthor=R.+Steinauthor=L.+Dickauthor=D.+Hwangauthor=A.+L.+Goldberg&title=Inhibitors+of+the+proteasome+block+the+degradation+of+most+cell+proteins+and+the+generation+of+peptides+presented+on+MHC+class+I+molecules&doi=10.1016%2FS0092-8674%2894%2990462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span></div><div class="casAuthors">Rock, Kenneth L.; Gramm, Colette; Rothstein, Lisa; Clark, Karen; Stein, Ross; Dick, Lawrence; Hwang, Daniel; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">761-71</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells have not been available.  Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degrdn. of protein and ubiquitinated protein substrates by 26S particles.  Unlike inhibitors of lysosomal proteolysis, these compds. inhibit the degrdn. of not only abnormal and short-lived polypeptides but also long-lived proteins in intact cells.  The authors used these agents to test the importance of the proteasome in antigen presentation.  When ovalbumin is introduced into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I mols. of an ovalbumin-derived peptide by preventing its proteolytic generation.  By preventing peptide prodn. from cell proteins, these inhibitors block the assembly of class I mols.  Therefore, the proteasome catalyzes the degrdn. of the vast majority of cell proteins and generates most peptides presented on MHC class I mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVw5InxABShLVg90H21EOLACvtfcHk0lh_txkia5X4rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D&md5=2960e350aedb5a0d9e04d672f96f9c4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990462-6%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGramm%26aufirst%3DC.%26aulast%3DRothstein%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520proteasome%2520block%2520the%2520degradation%2520of%2520most%2520cell%2520proteins%2520and%2520the%2520generation%2520of%2520peptides%2520presented%2520on%2520MHC%2520class%2520I%2520molecules%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D761%26epage%3D771%26doi%3D10.1016%2FS0092-8674%2894%2990462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liepe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span> <span> </span><span class="NLM_article-title">A large fraction of HLA class I ligands are proteasome-generated spliced peptides</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1126/science.aaf4384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1126%2Fscience.aaf4384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27846572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yltLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2016&pages=354-358&author=J.+Liepeauthor=F.+Marinoauthor=J.+Sidneyauthor=A.+Jekoauthor=D.+E.+Buntingauthor=A.+Setteauthor=P.+M.+Kloetzelauthor=M.+P.+Stumpfauthor=A.+J.+Heckauthor=M.+Mishto&title=A+large+fraction+of+HLA+class+I+ligands+are+proteasome-generated+spliced+peptides&doi=10.1126%2Fscience.aaf4384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A large fraction of HLA class I ligands are proteasome-generated spliced peptides</span></div><div class="casAuthors">Liepe, Juliane; Marino, Fabio; Sidney, John; Jeko, Anita; Bunting, Daniel E.; Sette, Alessandro; Kloetzel, Peter M.; Stumpf, Michael P. H.; Heck, Albert J. R.; Mishto, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6310</span>),
    <span class="NLM_cas:pages">354-358</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I mols. that elicit CD8+ T cell responses.  Reports of proteasome-generated spliced epitopes exist, but they have been regarded as rare events.  Here, however, we show that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance.  This pool also represents a unique set of antigens, possessing particular and distinguishing features.  We validated this observation using a range of complementary exptl. and bioinformatics approaches, as well as multiple cell types.  The widespread appearance and abundance of proteasome-catalyzed peptide splicing events has implications for immunobiol. and autoimmunity theories and may provide a previously untapped source of epitopes for use in vaccines and cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUQ5L5VkfSvrVg90H21EOLACvtfcHk0lh_txkia5X4rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yltLbF&md5=7c8f7a4d50e43b853488223678bc46ed</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf4384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf4384%26sid%3Dliteratum%253Aachs%26aulast%3DLiepe%26aufirst%3DJ.%26aulast%3DMarino%26aufirst%3DF.%26aulast%3DSidney%26aufirst%3DJ.%26aulast%3DJeko%26aufirst%3DA.%26aulast%3DBunting%26aufirst%3DD.%2BE.%26aulast%3DSette%26aufirst%3DA.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DStumpf%26aufirst%3DM.%2BP.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DMishto%26aufirst%3DM.%26atitle%3DA%2520large%2520fraction%2520of%2520HLA%2520class%2520I%2520ligands%2520are%2520proteasome-generated%2520spliced%2520peptides%26jtitle%3DScience%26date%3D2016%26volume%3D354%26spage%3D354%26epage%3D358%26doi%3D10.1126%2Fscience.aaf4384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">York, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saric, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Protein degradation and the generation of MHC class I-presented peptides</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0065-2776(02)80012-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0065-2776%2802%2980012-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=12078479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD38Xoslehurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=1-70&author=K.+L.+Rockauthor=I.+A.+Yorkauthor=T.+Saricauthor=A.+L.+Goldberg&title=Protein+degradation+and+the+generation+of+MHC+class+I-presented+peptides&doi=10.1016%2FS0065-2776%2802%2980012-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation and the generation of MHC class I-presented peptides</span></div><div class="casAuthors">Rock, Kenneth L.; York, Ian A.; Saric, Tomo; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-70</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the past decade there has been considerable progress in understanding how MHC class I-presented peptides are generated.  The emerging theme is that the immune system has not evolved its own specialized proteolytic mechanisms but instead utilizes the phylogenetically ancient catabolic pathways that continually turnover proteins in all cells.  Three distinct proteolytic steps have now been defined in MHC class I antigen presentation.  The first step is the degrdn. of proteins by the ubiquitin-proteasome pathway into oligopeptides that either are of the correct size for presentation or are extended on their amino-termini.  In the second step, aminopeptidases trim N-extended precursors into peptides of the correct length to be presented on class I mols.  The third step involves the destruction of peptides by endo- and exopeptidases, which limits antigen presentation, but is important for preventing the accumulation of peptides and recycling them back to amino acids for protein synthesis or prodn. of energy.  The immune system has evolved several components that modify the activity of these ancient pathways in ways that enhance the generation of class I-presented peptides.  These include catalytically active subunits of the proteasome, the PA28 proteasome activator, and leucine aminopeptidase, all of which are upregulated by interferon-γ.  In addn. to these pathways that operate in all cells, dendritic cells and macrophages can also generate class I-presented peptides from proteins internalized from the extracellular fluids by degrading them in endocytic compartments or transferring them to the cytosol for degrdn. by proteasomes.  (c) 2002 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5a3DymenFa7Vg90H21EOLACvtfcHk0lh_txkia5X4rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xoslehurw%253D&md5=430e7b1e7fd6d4db80e51658895e0f7a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2802%2980012-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252802%252980012-8%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DYork%26aufirst%3DI.%2BA.%26aulast%3DSaric%26aufirst%3DT.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DProtein%2520degradation%2520and%2520the%2520generation%2520of%2520MHC%2520class%2520I-presented%2520peptides%26jtitle%3DAdv.%2520Immunol.%26date%3D2002%26volume%3D80%26spage%3D1%26epage%3D70%26doi%3D10.1016%2FS0065-2776%2802%2980012-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maseda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalden, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voll, R. E.</span></span> <span> </span><span class="NLM_article-title">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1038/nm1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnm1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=18542049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=748-755&author=K.+Neubertauthor=S.+Meisterauthor=K.+Moserauthor=F.+Weiselauthor=D.+Masedaauthor=K.+Amannauthor=C.+Wietheauthor=T.+H.+Winklerauthor=J.+R.+Kaldenauthor=R.+A.+Manzauthor=R.+E.+Voll&title=The+proteasome+inhibitor+bortezomib+depletes+plasma+cells+and+protects+mice+with+lupus-like+disease+from+nephritis&doi=10.1038%2Fnm1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span></div><div class="casAuthors">Neubert, Kirsten; Meister, Silke; Moser, Katrin; Weisel, Florian; Maseda, Damian; Amann, Kerstin; Wiethe, Carsten; Winkler, Thomas H.; Kalden, Joachim R.; Manz, Rudolf A.; Voll, Reinhard E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">748-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bortezomib, a drug useful for the treatment of multiple myeloma, reduces kidney damage in animal models of lupus.  Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge.  In particular, long-lived plasma cells producing autoantibodies resist current therapeutic and exptl. approaches.  Recently, we showed that the sensitivity of myeloma cells toward proteasome inhibitors directly correlates with their Ig synthesis rates.  Therefore, we hypothesized that normal plasma cells are also hypersensitive to proteasome inhibition owing to their extremely high amt. of protein biosynthesis.  Here we show that the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma, eliminates both short- and long-lived plasma cells by activation of the terminal unfolded protein response.  Treatment with bortezomib depleted plasma cells producing antibodies to double-stranded DNA, eliminated autoantibody prodn., ameliorated glomerulonephritis and prolonged survival of two mouse strains with lupus-like disease, NZB/W F1 and MRL/lpr mice.  Hence, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZtv5EvAwSRLVg90H21EOLACvtfcHk0lijGwGlPzG8Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D&md5=a53d9cfc5690c95b1454a50b40a0bdb7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1763%26sid%3Dliteratum%253Aachs%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DK.%26aulast%3DWeisel%26aufirst%3DF.%26aulast%3DMaseda%26aufirst%3DD.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DWiethe%26aufirst%3DC.%26aulast%3DWinkler%26aufirst%3DT.%2BH.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DManz%26aufirst%3DR.%2BA.%26aulast%3DVoll%26aufirst%3DR.%2BE.%26atitle%3DThe%2520proteasome%2520inhibitor%2520bortezomib%2520depletes%2520plasma%2520cells%2520and%2520protects%2520mice%2520with%2520lupus-like%2520disease%2520from%2520nephritis%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D748%26epage%3D755%26doi%3D10.1038%2Fnm1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureshkumar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasnosz, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, N. L.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation</span>. <i>Clin. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.5414/CN107156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.5414%2FCN107156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=22377258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVeisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=246-253&author=K.+K.+Sureshkumarauthor=S.+M.+Hussainauthor=R.+J.+Marcusauthor=T.+Y.+Koauthor=A.+S.+Khanauthor=K.+Tomauthor=C.+A.+Vivasauthor=G.+Parrisauthor=K.+M.+Jasnoszauthor=N.+L.+Thai&title=Proteasome+inhibition+with+bortezomib%3A+an+effective+therapy+for+severe+antibody+mediated+rejection+after+renal+transplantation&doi=10.5414%2FCN107156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation</span></div><div class="casAuthors">Sureshkumar, Kalathil K.; Hussain, Sabiha M.; Marcus, Richard J.; Ko, Tina Y.; Khan, Akhtar S.; Tom, Kusum; Vivas, Carlos A.; Parris, George; Jasnosz, Katherine M.; Thai, Ngoc L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-253</span>CODEN:
                <span class="NLM_cas:coden">CLNHBI</span>;
        ISSN:<span class="NLM_cas:issn">0301-0430</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Antibody-mediated rejection (AMR) following renal transplantation is less responsive to conventional anti-rejection therapies.  Plasmapheresis (PP), i.v. Ig, rabbit antithymocyte globulin (rATG) and rituximab deplete immature B-cells but not mature plasma cells.  The proteasome inhibitor bortezomib has activity against mature plasma cell, the source of damaging donor-specific antibody (DSA).  We present the successful use of bortezomib in 2 patients who developed AMR following kidney transplantation.  The first patient was a 54-yr-old white female who received living-unrelated kidney transplantation from her husband.  She developed severe AMR early after transplantation with rising DSA titers consistent with an anamnestic immune response by memory cells to the donor antigens.  Renal function deteriorated despite treatment with pulse methylprednisolone (MP), PP and IVIg.  After initiation of therapy with bortezomib, DSA titers became neg. and serum creatinine returned to baseline with histol. resoln. of AMR.  The second patient was a 19-yr-old white male who received deceased donor kidney transplantation and developed AMR within 2 wk, refractory to therapy with pulse MP, PP and IVIg with rising DSA.  Bortezomib use resulted in disappearance of DSA and renal function improvement.  Both patients tolerated the treatment well with stable renal function at last follow-up.  The novel mechanisms of action and preliminary results with bortezomib are encouraging, but require larger studies and longer follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk_7LDS313fLVg90H21EOLACvtfcHk0lijGwGlPzG8Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVeisrc%253D&md5=dcd5db37a70913cf21f3a76dcadf95e5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.5414%2FCN107156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCN107156%26sid%3Dliteratum%253Aachs%26aulast%3DSureshkumar%26aufirst%3DK.%2BK.%26aulast%3DHussain%26aufirst%3DS.%2BM.%26aulast%3DMarcus%26aufirst%3DR.%2BJ.%26aulast%3DKo%26aufirst%3DT.%2BY.%26aulast%3DKhan%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DK.%26aulast%3DVivas%26aufirst%3DC.%2BA.%26aulast%3DParris%26aufirst%3DG.%26aulast%3DJasnosz%26aufirst%3DK.%2BM.%26aulast%3DThai%26aufirst%3DN.%2BL.%26atitle%3DProteasome%2520inhibition%2520with%2520bortezomib%253A%2520an%2520effective%2520therapy%2520for%2520severe%2520antibody%2520mediated%2520rejection%2520after%2520renal%2520transplantation%26jtitle%3DClin.%2520Nephrol.%26date%3D2012%26volume%3D77%26spage%3D246%26epage%3D253%26doi%3D10.5414%2FCN107156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno
Gonzales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinstock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braaten, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegall, M. D.</span></span> <span> </span><span class="NLM_article-title">32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1097/TP.0000000000001330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1097%2FTP.0000000000001330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27379560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1yntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=1222-1227&author=M.+A.+Moreno%0AGonzalesauthor=M.+J.+Gandhiauthor=C.+A.+Schinstockauthor=N.+A.+Mooreauthor=B.+H.+Smithauthor=N.+Y.+Braatenauthor=M.+D.+Stegall&title=32+Doses+of+Bortezomib+for+Desensitization+Is+Not+Well+Tolerated+and+Is+Associated+With+Only+Modest+Reductions+in+Anti-HLA+Antibody&doi=10.1097%2FTP.0000000000001330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody</span></div><div class="casAuthors">Moreno Gonzales, Manuel A.; Gandhi, Manish J.; Schinstock, Carrie A.; Moore, Natalie A.; Smith, Byron H.; Braaten, Nong Y.; Stegall, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1222-1227</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given.  This study aimed to det. the safety and efficacy of 32 doses of BTZ (1.3 mg/m2 of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor.  Dose redn. was needed in 2 patients and 2 others completely discontinued therapy for adverse events.  Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P < 0.01).  No patient developed a neg. crossmatch against their original intended donor, and the calcd. panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged in all patients.  These data suggest that 32 doses of BTZ monotherapy was not well tolerated and resulted in only a modest redn. in anti-HLA antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWRQUuDccBz7Vg90H21EOLACvtfcHk0lijGwGlPzG8Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1yntbc%253D&md5=74e2dfdf735eb550a0e37d3099ad9d3d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FTP.0000000000001330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FTP.0000000000001330%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%2BGonzales%26aufirst%3DM.%2BA.%26aulast%3DGandhi%26aufirst%3DM.%2BJ.%26aulast%3DSchinstock%26aufirst%3DC.%2BA.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DBraaten%26aufirst%3DN.%2BY.%26aulast%3DStegall%26aufirst%3DM.%2BD.%26atitle%3D32%2520Doses%2520of%2520Bortezomib%2520for%2520Desensitization%2520Is%2520Not%2520Well%2520Tolerated%2520and%2520Is%2520Associated%2520With%2520Only%2520Modest%2520Reductions%2520in%2520Anti-HLA%2520Antibody%26jtitle%3DTransplantation%26date%3D2017%26volume%3D101%26spage%3D1222%26epage%3D1227%26doi%3D10.1097%2FTP.0000000000001330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Fellutamide B is a potent inhibitor of the <i>Mycobacterium tuberculosis</i> proteasome</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2010.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.abb.2010.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20558127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2itbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2010&pages=214-220&author=G.+Linauthor=D.+Liauthor=T.+Chidawanyikaauthor=C.+Nathanauthor=H.+Li&title=Fellutamide+B+is+a+potent+inhibitor+of+the+Mycobacterium+tuberculosis+proteasome&doi=10.1016%2Fj.abb.2010.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome</span></div><div class="casAuthors">Lin, Gang; Li, Dongyang; Chidawanyika, Tamutenda; Nathan, Carl; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Via high-throughput screening of a natural compd. library, we have identified a lipopeptide aldehyde, fellutamide B (1), as the most potent inhibitor of the Mycobacterium tuberculosis (Mtb) proteasome tested to date.  Kinetic studies reveal that 1 inhibits both Mtb and human proteasomes in a time-dependent manner under steady-state condition.  Remarkably, 1 inhibits the Mtb proteasome in a single-step binding mechanism with Ki = 6.8 nM, whereas it inhibits the human proteasome β5 active site following a two-step mechanism with Ki = 11.5 nM and Ki* = 0.93 nM.  Co-crystn. of 1 bound to the Mtb proteasome revealed a structural basis for the tight binding of 1 to the active sites of the Mtb proteasome.  The hemiacetal group of 1 in the Mtb proteasome takes the (R)-configuration, whereas in the yeast proteasome it takes the (S)-configuration, indicating that the pre-chiral CHO group of 1 binds to the active site Thr1 in a different orientation.  Re-examn. of the structure of the yeast proteasome in complex with 1 showed significant conformational changes at the substrate-binding cleft along the active site.  These structural differences are consistent with the different kinetic mechanisms of 1 against Mtb and human proteasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql8lEWt6GLO7Vg90H21EOLACvtfcHk0lijGwGlPzG8Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2itbzK&md5=fe2731ea82db52eb6f34beb6b0c708e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2010.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2010.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DFellutamide%2520B%2520is%2520a%2520potent%2520inhibitor%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520proteasome%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2010%26volume%3D501%26spage%3D214%26epage%3D220%26doi%3D10.1016%2Fj.abb.2010.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the <i>Mycobacterium tuberculosis</i> Proteasome</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.6b01107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b01107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyjtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=324-333&author=H.+C.+Hsuauthor=P.+K.+Singhauthor=H.+Fanauthor=R.+Wangauthor=G.+Sukenickauthor=C.+Nathanauthor=G.+Linauthor=H.+Li&title=Structural+Basis+for+the+Species-Selective+Binding+of+N%2CC-Capped+Dipeptides+to+the+Mycobacterium+tuberculosis+Proteasome&doi=10.1021%2Facs.biochem.6b01107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome</span></div><div class="casAuthors">Hsu, Hao-Chi; Singh, Pradeep K.; Fan, Hao; Wang, Rong; Sukenick, George; Nathan, Carl; Lin, Gang; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis (Mtb) 20S proteasome is vital for the pathogen to survive under nitrosative stress in vitro and to persist in mice.  To qualify for drug development, inhibitors targeting Mtb 20S must spare both the human constitutive proteasome (c-20S) and immunoproteasome (i-20S).  We recently reported members of a family of noncovalently binding dipeptide proteasome inhibitors that are highly potent and selective for Mtb 20S over human c-20S and i-20S.  To understand the structural basis of their potency and selectivity, we have studied the structure-activity relationship of six derivs. and solved their co-crystal structures with Mtb 20S.  The dipeptide inhibitors form an antiparallel β-strand with the active site β-strands.  Selectivity is conferred by several features of Mtb 20S relative to its mouse counterparts, including a larger S1 pocket, addnl. hydrogen bonds in the S3 pocket, and hydrophobic interactions in the S4 pocket.  Serine-20 and glutamine-22 of Mtb 20S interact with the dipeptides and confer Mtb-specific inhibition over c-20S and i-20S.  The Mtb 20S and mammalian i-20S have a serine-27 that interacts strongly with the dipeptides, potentially explaining the higher inhibitory activity of the dipeptides toward i-20S over c-20S.  This detailed structural knowledge will aid in optimizing the dipeptides as anti-tuberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7znxPof1C7Vg90H21EOLACvtfcHk0lgzzPNAVnXyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyjtr7K&md5=9c8a31bd018432aac4b5d36037c01c82</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b01107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b01107%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DH.%2BC.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Species-Selective%2520Binding%2520of%2520N%252CC-Capped%2520Dipeptides%2520to%2520the%2520Mycobacterium%2520tuberculosis%2520Proteasome%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D324%26epage%3D333%26doi%3D10.1021%2Facs.biochem.6b01107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Distinct specificities of <i>Mycobacterium tuberculosis</i> and mammalian proteasomes for N-acetyl tripeptide substrates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">34423</span>– <span class="NLM_lpage">34431</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805324200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1074%2Fjbc.M805324200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=18829465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=34423-34431&author=G.+Linauthor=C.+Tsuauthor=L.+Dickauthor=X.+K.+Zhouauthor=C.+Nathan&title=Distinct+specificities+of+Mycobacterium+tuberculosis+and+mammalian+proteasomes+for+N-acetyl+tripeptide+substrates&doi=10.1074%2Fjbc.M805324200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates</span></div><div class="casAuthors">Lin, Gang; Tsu, Christopher; Dick, Lawrence; Zhou, Xi K.; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">34423-34431</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics.  To lay ground-work for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we used a library of 5920 N-acetyl tripeptide-aminomethylcoumarins to contrast the substrate preferences of the recombinant Mtb proteasome wild type and open gate mutant, the Rhodococcus erythropolis proteasome, and the bovine proteasome with activator PA28.  The Mtb proteasome was distinctive in strictly preferring P1 = tryptophan, particularly in combination with P3 = glycine, proline, lysine or arginine.  Screening results were validated with Michaelis-Menten kinetic analyses of 21 oligopeptide aminomethyl-coumarin substrates.  Bortezomib, a proteasome inhibitor in clin. use, and 17 analogs varying only at P1 were used to examine the differential impact of inhibitors on human and Mtb proteasomes.  The results with the inhibitor panel confirmed those with the substrate panel in demonstrating differential preferences of Mtb and mammalian proteasomes at the P1 amino acid.  Changing P1 in bortezomib from Leu to m-CF3-Phe led to a 220-fold increase in IC50 against the human proteasome, whereas changing a P1 Ala to m-F-Phe decreased the IC50 400-fold against the Mtb proteasome.  The change of a P1 Ala to m-Cl-Phe led to an 8000-fold shift in inhibitory potency in favor of the Mtb proteasome, resulting in 8-fold selectivity.  Combinations of preferred amino acids at different sites may thus improve the species selectivity of peptide-based inhibitors that target the Mtb proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpCPunOb8tLVg90H21EOLACvtfcHk0lgzzPNAVnXyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP&md5=6f73b15a893fe094894ca3916882d834</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805324200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805324200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DDistinct%2520specificities%2520of%2520Mycobacterium%2520tuberculosis%2520and%2520mammalian%2520proteasomes%2520for%2520N-acetyl%2520tripeptide%2520substrates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D34423%26epage%3D34431%26doi%3D10.1074%2Fjbc.M805324200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Inhibitors selective for mycobacterial versus human proteasomes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nature08357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature08357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=19759536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFentLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=621-626&author=G.+Linauthor=D.+Liauthor=L.+P.+de+Carvalhoauthor=H.+Dengauthor=H.+Taoauthor=G.+Vogtauthor=K.+Wuauthor=J.+Schneiderauthor=T.+Chidawanyikaauthor=J.+D.+Warrenauthor=H.+Liauthor=C.+Nathan&title=Inhibitors+selective+for+mycobacterial+versus+human+proteasomes&doi=10.1038%2Fnature08357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors selective for mycobacterial versus human proteasomes</span></div><div class="casAuthors">Lin, Gang; Li, Dongyang; Sorio de Carvalho, Luiz Pedro; Deng, Haiteng; Tao, Hui; Vogt, Guillaume; Wu, Kangyun; Schneider, Jean; Chidawanyika, Tamutenda; Warren, J. David; Li, Huilin; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7264</span>),
    <span class="NLM_cas:pages">621-626</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many anti-infectives inhibit the synthesis of bacterial proteins, but none selectively inhibits their degrdn.  Most anti-infectives kill replicating pathogens, but few preferentially kill pathogens that have been forced into a non-replicating state by conditions in the host.  To explore these alternative approaches we sought selective inhibitors of the proteasome of Mycobacterium tuberculosis.  Given that the proteasome structure is extensively conserved, it is not surprising that inhibitors of all chem. classes tested have blocked both eukaryotic and prokaryotic proteasomes, and no inhibitor has proved substantially more potent on proteasomes of pathogens than of their hosts.  Here we show that certain oxathiazol-2-one compds. kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the M. tuberculosis proteasome by cyclocarbonylating its active site threonine.  Major conformational changes protect the inhibitor-enzyme intermediate from hydrolysis, allowing formation of an oxazolidin-2-one and preventing regeneration of active protease.  Residues outside the active site whose hydrogen bonds stabilize the crit. loop before and after it moves are extensively non-conserved.  This may account for the ability of oxathiazol-2-one compds. to inhibit the mycobacterial proteasome potently and irreversibly while largely sparing the human homolog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsldeXrXgYGbVg90H21EOLACvtfcHk0ljiVZZXm5eaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFentLjK&md5=fb55708e5d5b073dcafbe95e3f8a625b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature08357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08357%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DVogt%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DInhibitors%2520selective%2520for%2520mycobacterial%2520versus%2520human%2520proteasomes%26jtitle%3DNature%26date%3D2009%26volume%3D461%26spage%3D621%26epage%3D626%26doi%3D10.1038%2Fnature08357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okoro, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B. F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Improvement of asparagine ethylenediamines as anti-malarial <i>Plasmodium</i>-selective proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6137</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6137-6145&author=W.+Zhanauthor=J.+Visoneauthor=T.+Ouelletteauthor=J.+C.+Harrisauthor=R.+Wangauthor=H.+Zhangauthor=P.+K.+Singhauthor=J.+Ginnauthor=G.+Sukenickauthor=T.+T.+Wongauthor=J.+I.+Okoroauthor=R.+M.+Scalesauthor=P.+K.+Tumwebazeauthor=P.+J.+Rosenthalauthor=B.+F.+C.+Kafsackauthor=R.+A.+Cooperauthor=P.+T.+Meinkeauthor=L.+A.+Kirkmanauthor=G.+Lin&title=Improvement+of+asparagine+ethylenediamines+as+anti-malarial+Plasmodium-selective+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.9b00363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Visone, Joseph; Ouellette, Tierra; Harris, Jacob C.; Wang, Rong; Zhang, Hao; Singh, Pradeep K.; Ginn, John; Sukenick, George; Wong, Tzu-Tshin; Okoro, Judith I.; Scales, Ryan M.; Tumwebaze, Patrick K.; Rosenthal, Philip J.; Kafsack, Bjorn F. C.; Cooper, Roland A.; Meinke, Peter T.; Kirkman, Laura A.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6137-6145</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome (Pf20S) emerged as a target for antimalarials.  Pf20S inhibitors are active at multiple stages of the parasite life cycle and synergize with artemisinins, suggesting that Pf20S inhibitors have potential to be prophylactic, therapeutic, transmission blocking as well as useful for combination therapy.  The authors recently reported asparagine ethylenediamines (AsnEDAs) as immunoproteasome inhibitors and modified AsnEDAs as selective Pf20S inhibitors.  Here the authors report further structure-activity relation study of AsnEDAs for selective inhibition of Pf20S over human proteasomes.  Addnl., the authors show a new mutation that conferred resistance to AsnEDAs and collateral sensitivity to an inhibitor of the Pf20S β2 subunit, same as previously identified resistant mutation.  This resistance could be overcome through the use of structure-guided inhibitor design.  Collateral sensitivity to inhibitors among resp. proteasome subunits underscores the potential value of treating malaria with combinations of inhibitors of different proteasome subunits to minimize the emergence of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraItFIzHCwYbVg90H21EOLACvtfcHk0ljiVZZXm5eaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs7bO&md5=0c0f91850372915ba7cb254e8892feed</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00363%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DOuellette%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DGinn%26aufirst%3DJ.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DT.%2BT.%26aulast%3DOkoro%26aufirst%3DJ.%2BI.%26aulast%3DScales%26aufirst%3DR.%2BM.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DKafsack%26aufirst%3DB.%2BF.%2BC.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DImprovement%2520of%2520asparagine%2520ethylenediamines%2520as%2520anti-malarial%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6137%26epage%3D6145%26doi%3D10.1021%2Facs.jmedchem.9b00363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Defining the determinants of specificity of <i>Plasmodium</i> proteasome inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">11424</span>– <span class="NLM_lpage">11437</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b06656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b06656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=11424-11437&author=E.+Yooauthor=B.+H.+Stokesauthor=H.+de+Jongauthor=M.+Vanaerschotauthor=T.+Kumarauthor=N.+Lawrenceauthor=M.+Njorogeauthor=A.+Garciaauthor=R.+Van+der+Westhuyzenauthor=J.+D.+Momperauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=M.+Bogyo&title=Defining+the+determinants+of+specificity+of+Plasmodium+proteasome+inhibitors&doi=10.1021%2Fjacs.8b06656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors</span></div><div class="casAuthors">Yoo, Euna; Stokes, Barbara H.; de Jong, Hanna; Vanaerschot, Manu; Kumar, T. R. S.; Lawrence, Nina; Njoroge, Mathew; Garcia, Arnold; Van der Westhuyzen, Renier; Momper, Jeremiah D.; Ng, Caroline L.; Fidock, David A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11424-11437</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome is an emerging antimalarial target due to its essential role in all the major life cycle stages of the parasite and its contribution to the establishment of resistance to artemisinin (ART)-based therapies.  However, because of a similarly essential role for the host proteasome, the key property of any antiproteasome therapeutic is selectivity.  Several parasite-specific proteasome inhibitors have recently been reported, however, their selectivity must be improved to enable clin. development.  Here we describe screening of diverse libraries of non-natural synthetic fluorogenic substrates to identify determinants at multiple positions on the substrate that produce enhanced selectivity.  We find that selection of an optimal electrophilic "warhead" is essential to enable high selectivity that is driven by the peptide binding elements on the inhibitor.  We also find that host cell toxicity is dictated by the extent of coinhibition of the human β2 and β5 subunits.  Using this information, we identify compds. with over 3 orders of magnitude selectivity for the parasite enzyme.  Optimization of the pharmacol. properties resulted in mols. that retained high potency and selectivity, were sol., sufficiently metabolically stable and orally bioavailable.  These mols. are highly synergistic with ART and can clear parasites in a mouse model of infection, making them promising leads as antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXchyqonWDrVg90H21EOLACvtfcHk0ljiVZZXm5eaNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN&md5=990e0b5097087ff76681f901b2c8f35f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b06656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b06656%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3Dde%2BJong%26aufirst%3DH.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DT.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DVan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DMomper%26aufirst%3DJ.%2BD.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DDefining%2520the%2520determinants%2520of%2520specificity%2520of%2520Plasmodium%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D11424%26epage%3D11437%26doi%3D10.1021%2Fjacs.8b06656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedziech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzual, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindasamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendome, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doggett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6863</span>– <span class="NLM_lpage">E6870</span>, <span class="refDoi"> DOI: 10.1073/pnas.1806109115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1806109115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=29967165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6863-E6870&author=L.+A.+Kirkmanauthor=W.+Zhanauthor=J.+Visoneauthor=A.+Dziedziechauthor=P.+K.+Singhauthor=H.+Fanauthor=X.+Tongauthor=I.+Bruzualauthor=R.+Haraauthor=M.+Kawasakiauthor=T.+Imaedaauthor=R.+Okamotoauthor=K.+Satoauthor=M.+Michinoauthor=E.+F.+Alvaroauthor=L.+F.+Guiangauthor=L.+Sanzauthor=D.+J.+Motaauthor=K.+Govindasamyauthor=R.+Wangauthor=Y.+Lingauthor=P.+K.+Tumwebazeauthor=G.+Sukenickauthor=L.+Shiauthor=J.+Vendomeauthor=P.+Bhanotauthor=P.+J.+Rosenthalauthor=K.+Asoauthor=M.+A.+Foleyauthor=R.+A.+Cooperauthor=B.+Kafsackauthor=J.+S.+Doggettauthor=C.+F.+Nathanauthor=G.+Lin&title=Antimalarial+proteasome+inhibitor+reveals+collateral+sensitivity+from+intersubunit+interactions+and+fitness+cost+of+resistance&doi=10.1073%2Fpnas.1806109115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span></div><div class="casAuthors">Kirkman, Laura A.; Zhan, Wenhu; Visone, Joseph; Dziedziech, Alexis; Singh, Pradeep K.; Fan, Hao; Tong, Xinran; Bruzual, Igor; Hara, Ryoma; Kawasaki, Masanori; Imaeda, Toshihiro; Okamoto, Rei; Sato, Kenjiro; Michino, Mayako; Alvaro, Elena Fernandez; Guiang, Liselle F.; Sanz, Laura; Mota, Daniel J.; Govindasamy, Kavitha; Wang, Rong; Ling, Yan; Tumwebaze, Patrick K.; Sukenick, George; Shi, Lei; Vendome, Jeremie; Bhanot, Purnima; Rosenthal, Philip J.; Aso, Kazuyoshi; Foley, Michael A.; Cooper, Roland A.; Kafsack, Bjorn; Doggett, J. Stone; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">E6863-E6870</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe noncovalent, reversible asparagine ethylenediamine (AsnEDA) inhibitors of the Plasmodium falciparum proteasome (Pf20S) β5 subunit that spare all active subunits of human constitutive and immuno-proteasomes.  The compds. are active against erythrocytic, sexual, and liver-stage parasites, against parasites resistant to current antimalarials, and against P. falciparum strains from patients in Africa.  The β5 inhibitors synergize with a β2 inhibitor in vitro and in mice and with artemisinin.  P. falciparum selected for resistance to an AsnEDA β5 inhibitor surprisingly harbored a point mutation in the noncatalytic β6 subunit.  The β6 mutant was resistant to the species-selective Pf20S β5 inhibitor but remained sensitive to the species-nonselective β5 inhibitors bortezomib and carfilzomib.  Moreover, resistance to the Pf20S β5 inhibitor was accompanied by increased sensitivity to a Pf20S β2 inhibitor.  Finally, the β5 inhibitor-resistant mutant had a fitness cost that was exacerbated by irradn.  Thus, used in combination, multistage-active inhibitors of the Pf20S β5 and β2 subunits afford synergistic antimalarial activity with a potential to delay the emergence of resistance to artemisinins and each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBMtrslCvE7Vg90H21EOLACvtfcHk0lhm1GVkBQJWCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ&md5=6addacc779527c9e4c6a265868f088fe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806109115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806109115%26sid%3Dliteratum%253Aachs%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DDziedziech%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBruzual%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DAlvaro%26aufirst%3DE.%2BF.%26aulast%3DGuiang%26aufirst%3DL.%2BF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMota%26aufirst%3DD.%2BJ.%26aulast%3DGovindasamy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DVendome%26aufirst%3DJ.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DKafsack%26aufirst%3DB.%26aulast%3DDoggett%26aufirst%3DJ.%2BS.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DAntimalarial%2520proteasome%2520inhibitor%2520reveals%2520collateral%2520sensitivity%2520from%2520intersubunit%2520interactions%2520and%2520fitness%2520cost%2520of%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE6863%26epage%3DE6870%26doi%3D10.1073%2Fpnas.1806109115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure- and function-based design of <i>Plasmodium</i>-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+J.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+da+Fonsecaauthor=M.+Bogyo&title=Structure-+and+function-based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0lhm1GVkBQJWCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure-%2520and%2520function-based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeacock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata-Cantero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuhs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna Gaza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9323</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820175116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1820175116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=30962368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=9318-9323&author=S.+Wyllieauthor=S.+Brandauthor=M.+Thomasauthor=M.+De+Ryckerauthor=C.+W.+Chungauthor=I.+Penaauthor=R.+P.+Binghamauthor=J.+A.+Bueren-Calabuigauthor=J.+Cantizaniauthor=D.+Cebrianauthor=P.+D.+Craggsauthor=L.+Fergusonauthor=P.+Goswamiauthor=J.+Hobrathauthor=J.+Howeauthor=L.+Jeacockauthor=E.+J.+Koauthor=J.+Korczynskaauthor=L.+MacLeanauthor=S.+Manthriauthor=M.+S.+Martinezauthor=L.+Mata-Canteroauthor=S.+Monizauthor=A.+Nuhsauthor=M.+Osuna-Cabelloauthor=E.+Pintoauthor=J.+Rileyauthor=S.+Robinsonauthor=P.+Rowlandauthor=F.+R.+C.+Simeonsauthor=Y.+Shishikuraauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=E.+Viayna+Gazaauthor=R.+J.+Wallauthor=F.+Zuccottoauthor=D.+Hornauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=J.+M.+Fiandorauthor=J.+Martinauthor=D.+W.+Grayauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=K.+D.+Readauthor=M.+Marcoauthor=P.+G.+Wyatt&title=Preclinical+candidate+for+the+treatment+of+visceral+leishmaniasis+that+acts+through+proteasome+inhibition&doi=10.1073%2Fpnas.1820175116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span></div><div class="casAuthors">Wyllie, Susan; Brand, Stephen; Thomas, Michael; De Rycker, Manu; Chung, Chun-wa; Pena, Imanol; Bingham, Ryan P.; Bueren-Calabuig, Juan A.; Cantizani, Juan; Cebrian, David; Craggs, Peter D.; Ferguson, Liam; Goswami, Panchali; Hobrath, Judith; Howe, Jonathan; Jeacock, Laura; Ko, Eun-Jung; Korczynska, Justyna; MacLean, Lorna; Manthri, Sujatha; Martinez, Maria S.; Mata-Cantero, Lydia; Moniz, Sonia; NA1/4hs, Andrea; Osuna-Cabello, Maria; Pinto, Erika; Riley, Jennifer; Robinson, Sharon; Rowland, Paul; Simeons, Frederick R. C.; Shishikura, Yoko; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Gaza, Elisabet Viayna; Wall, Richard J.; Zuccotto, Fabio; Horn, David; Ferguson, Michael A. J.; Fairlamb, Alan H.; Fiandor, Jose M.; Martin, Julio; Gray, David W.; Miles, Timothy J.; Gilbert, Ian H.; Read, Kevin D.; Marco, Maria; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9318-9323</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum, is one of the major parasitic diseases worldwide.  There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting.  Here, we describe the development of a preclin. drug candidate, GSK3494245/DDD01305143/compd. 8, with potential to treat this neglected tropical disease.  The compd. series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi.  Subsequent optimization of the chem. series resulted in the development of a potent cidal compd. with activity against a range of clin. relevant L. donovani and L. infantum isolates.  Compd. 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine.  Detailed mode of action studies confirm that this compd. acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome.  High-resoln. cryo-EM structures of apo and compd. 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits.  This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our exptl. and mutagenesis data.  As a result of these comprehensive studies and due to a favorable developability and safety profile, compd. 8 is being advanced toward human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLTLZPb2MCLVg90H21EOLACvtfcHk0ljgC7snmSap2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D&md5=799defb4ef812d64ffe230c78aff3511</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820175116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820175116%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DBingham%26aufirst%3DR.%2BP.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DCebrian%26aufirst%3DD.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DGoswami%26aufirst%3DP.%26aulast%3DHobrath%26aufirst%3DJ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJeacock%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DKorczynska%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DMata-Cantero%26aufirst%3DL.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DNuhs%26aufirst%3DA.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DE.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DViayna%2BGaza%26aufirst%3DE.%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DPreclinical%2520candidate%2520for%2520the%2520treatment%2520of%2520visceral%2520leishmaniasis%2520that%2520acts%2520through%2520proteasome%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D9318%26epage%3D9323%26doi%3D10.1073%2Fpnas.1820175116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+Mathisonauthor=E.+Myburghauthor=M.+Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+inhibition+for+treatment+of+leishmaniasis%2C+Chagas+disease+and+sleeping+sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0ljgC7snmSap2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.%2BY.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520inhibition%2520for%2520treatment%2520of%2520leishmaniasis%252C%2520Chagas%2520disease%2520and%2520sleeping%2520sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getnet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirujogi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manda, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaerkady, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madugundu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelkar, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isserlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal-Rojas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahasrabuddhe, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renuse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvan, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjappa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbannayya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasamurthy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathe, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbannayya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelamanchi, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudgal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahari, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satishchandra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirdeshmukh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halushka, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span> <span> </span><span class="NLM_article-title">A draft map of the human proteome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/nature13302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature13302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24870542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslCrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=575-581&author=M.+S.+Kimauthor=S.+M.+Pintoauthor=D.+Getnetauthor=R.+S.+Nirujogiauthor=S.+S.+Mandaauthor=R.+Chaerkadyauthor=A.+K.+Madugunduauthor=D.+S.+Kelkarauthor=R.+Isserlinauthor=S.+Jainauthor=J.+K.+Thomasauthor=B.+Muthusamyauthor=P.+Leal-Rojasauthor=P.+Kumarauthor=N.+A.+Sahasrabuddheauthor=L.+Balakrishnanauthor=J.+Advaniauthor=B.+Georgeauthor=S.+Renuseauthor=L.+D.+Selvanauthor=A.+H.+Patilauthor=V.+Nanjappaauthor=A.+Radhakrishnanauthor=S.+Prasadauthor=T.+Subbannayyaauthor=R.+Rajuauthor=M.+Kumarauthor=S.+K.+Sreenivasamurthyauthor=A.+Marimuthuauthor=G.+J.+Satheauthor=S.+Chavanauthor=K.+K.+Dattaauthor=Y.+Subbannayyaauthor=A.+Sahuauthor=S.+D.+Yelamanchiauthor=S.+Jayaramauthor=P.+Rajagopalanauthor=J.+Sharmaauthor=K.+R.+Murthyauthor=N.+Syedauthor=R.+Goelauthor=A.+A.+Khanauthor=S.+Ahmadauthor=G.+Deyauthor=K.+Mudgalauthor=A.+Chatterjeeauthor=T.+C.+Huangauthor=J.+Zhongauthor=X.+Wuauthor=P.+G.+Shawauthor=D.+Freedauthor=M.+S.+Zahariauthor=K.+K.+Mukherjeeauthor=S.+Shankarauthor=A.+Mahadevanauthor=H.+Lamauthor=C.+J.+Mitchellauthor=S.+K.+Shankarauthor=P.+Satishchandraauthor=J.+T.+Schroederauthor=R.+Sirdeshmukhauthor=A.+Maitraauthor=S.+D.+Leachauthor=C.+G.+Drakeauthor=M.+K.+Halushkaauthor=T.+S.+Prasadauthor=R.+H.+Hrubanauthor=C.+L.+Kerrauthor=G.+D.+Baderauthor=C.+A.+Iacobuzio-Donahueauthor=H.+Gowdaauthor=A.+Pandey&title=A+draft+map+of+the+human+proteome&doi=10.1038%2Fnature13302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A draft map of the human proteome</span></div><div class="casAuthors">Kim, Min-Sik; Pinto, Sneha M.; Getnet, Derese; Nirujogi, Raja Sekhar; Manda, Srikanth S.; Chaerkady, Raghothama; Madugundu, Anil K.; Kelkar, Dhanashree S.; Isserlin, Ruth; Jain, Shobhit; Thomas, Joji K.; Muthusamy, Babylakshmi; Leal-Rojas, Pamela; Kumar, Praveen; Sahasrabuddhe, Nandini A.; Balakrishnan, Lavanya; Advani, Jayshree; George, Bijesh; Renuse, Santosh; Selvan, Lakshmi Dhevi N.; Patil, Arun H.; Nanjappa, Vishalakshi; Radhakrishnan, Aneesha; Prasad, Samarjeet; Subbannayya, Tejaswini; Raju, Rajesh; Kumar, Manish; Sreenivasamurthy, Sreelakshmi K.; Marimuthu, Arivusudar; Sathe, Gajanan J.; Chavan, Sandip; Datta, Keshava K.; Subbannayya, Yashwanth; Sahu, Apeksha; Yelamanchi, Soujanya D.; Jayaram, Savita; Rajagopalan, Pavithra; Sharma, Jyoti; Murthy, Krishna R.; Syed, Nazia; Goel, Renu; Khan, Aafaque A.; Ahmad, Sartaj; Dey, Gourav; Mudgal, Keshav; Chatterjee, Aditi; Huang, Tai-Chung; Zhong, Jun; Wu, Xinyan; Shaw, Patrick G.; Freed, Donald; Zahari, Muhammad S.; Mukherjee, Kanchan K.; Shankar, Subramanian; Mahadevan, Anita; Lam, Henry; Mitchell, Christopher J.; Shankar, Susarla Krishna; Satishchandra, Parthasarathy; Schroeder, John T.; Sirdeshmukh, Ravi; Maitra, Anirban; Leach, Steven D.; Drake, Charles G.; Halushka, Marc K.; Prasad, T. S. Keshava; Hruban, Ralph H.; Kerr, Candace L.; Bader, Gary D.; Iacobuzio-Donahue, Christine A.; Gowda, Harsha; Pandey, Akhilesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7502</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The availability of human genome sequence has transformed biomedical research over the past decade.  However, an equiv. map for the human proteome with direct measurements of proteins and peptides does not exist yet.  Here we present a draft map of the human proteome using high-resoln. Fourier-transform mass spectrometry.  In-depth proteomic profiling of 30 histol. normal human samples, including 17 adult tissues, 7 fetal tissues and 6 purified primary hematopoietic cells, resulted in identification of proteins encoded by 17,294 genes accounting for approx. 84% of the total annotated protein-coding genes in humans.  A unique and comprehensive strategy for proteogenomic anal. enabled us to discover a no. of novel protein-coding regions, which includes translated pseudogenes, non-coding RNAs and upstream open reading frames.  This large human proteome catalog (available as an interactive web-based resource at http://www.humanproteomemap.org) will complement available human genome and transcriptome data to accelerate biomedical research in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW2lqYhs8ULVg90H21EOLACvtfcHk0li0d0x2j--_dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslCrtrc%253D&md5=facf459fc3d9c8258fba1c1e94a378c6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature13302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13302%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DPinto%26aufirst%3DS.%2BM.%26aulast%3DGetnet%26aufirst%3DD.%26aulast%3DNirujogi%26aufirst%3DR.%2BS.%26aulast%3DManda%26aufirst%3DS.%2BS.%26aulast%3DChaerkady%26aufirst%3DR.%26aulast%3DMadugundu%26aufirst%3DA.%2BK.%26aulast%3DKelkar%26aufirst%3DD.%2BS.%26aulast%3DIsserlin%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DJ.%2BK.%26aulast%3DMuthusamy%26aufirst%3DB.%26aulast%3DLeal-Rojas%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DSahasrabuddhe%26aufirst%3DN.%2BA.%26aulast%3DBalakrishnan%26aufirst%3DL.%26aulast%3DAdvani%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DRenuse%26aufirst%3DS.%26aulast%3DSelvan%26aufirst%3DL.%2BD.%26aulast%3DPatil%26aufirst%3DA.%2BH.%26aulast%3DNanjappa%26aufirst%3DV.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DSubbannayya%26aufirst%3DT.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DSreenivasamurthy%26aufirst%3DS.%2BK.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DSathe%26aufirst%3DG.%2BJ.%26aulast%3DChavan%26aufirst%3DS.%26aulast%3DDatta%26aufirst%3DK.%2BK.%26aulast%3DSubbannayya%26aufirst%3DY.%26aulast%3DSahu%26aufirst%3DA.%26aulast%3DYelamanchi%26aufirst%3DS.%2BD.%26aulast%3DJayaram%26aufirst%3DS.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DMurthy%26aufirst%3DK.%2BR.%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DA.%2BA.%26aulast%3DAhmad%26aufirst%3DS.%26aulast%3DDey%26aufirst%3DG.%26aulast%3DMudgal%26aufirst%3DK.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DT.%2BC.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShaw%26aufirst%3DP.%2BG.%26aulast%3DFreed%26aufirst%3DD.%26aulast%3DZahari%26aufirst%3DM.%2BS.%26aulast%3DMukherjee%26aufirst%3DK.%2BK.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DMahadevan%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DShankar%26aufirst%3DS.%2BK.%26aulast%3DSatishchandra%26aufirst%3DP.%26aulast%3DSchroeder%26aufirst%3DJ.%2BT.%26aulast%3DSirdeshmukh%26aufirst%3DR.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DHalushka%26aufirst%3DM.%2BK.%26aulast%3DPrasad%26aufirst%3DT.%2BS.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DKerr%26aufirst%3DC.%2BL.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DGowda%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DA%2520draft%2520map%2520of%2520the%2520human%2520proteome%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D575%26epage%3D581%26doi%3D10.1038%2Fnature13302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span>; <span class="NLM_string-name">Lauer, C.</span>; <span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Prevention of Autoimmune Diabetes by a Selective Inhibitor of the Immunoproteasome</span>. In  <i>Wiener Klinische Wochenschrift</i>; <span class="NLM_publisher-name">Springer Wien</span>, <span class="NLM_year">2008</span>; Vol.  <span class="NLM_volume">120</span>, p  <span class="NLM_fpage">165</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=165&author=M.+Basler&author=C.+Lauer&author=M.+Groettrup&title=Wiener+Klinische+Wochenschrift"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DPrevention%2520of%2520Autoimmune%2520Diabetes%2520by%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%26btitle%3DWiener%2520Klinische%2520Wochenschrift%26pub%3DSpringer%2520Wien%26date%3D2008%26volume%3D120%26spage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1002/emmm.201303543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Femmm.201303543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24399752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=226-238&author=M.+Baslerauthor=S.+Mundtauthor=T.+Muchamuelauthor=C.+Mollauthor=J.+Jiangauthor=M.+Groettrupauthor=C.+J.+Kirk&title=Inhibition+of+the+immunoproteasome+ameliorates+experimental+autoimmune+encephalomyelitis&doi=10.1002%2Femmm.201303543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Basler, Michael; Mundt, Sarah; Muchamuel, Tony; Moll, Carlo; Jiang, Jing; Groettrup, Marcus; Kirk, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system.  The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes.  Recently, we demonstrated a novel function of immunoproteasomes in cytokine prodn. and T cell differentiation.  In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS.  ONX 0914 attenuated disease progression after active and passive induction of exptl. autoimmune encephalomyelitis (EAE), both in MOG35-55 and PLP139-151-induced EAE.  Isolation of lymphocytes from the brain or spinal cord revealed a strong redn. of cytokine-producing CD4+ cells in ONX 0914 treated mice.  Addnl., ONX 0914 treatment prevented disease exacerbation in a relapsing-remitting model.  An anal. of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice.  These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7NZVATJbqxLVg90H21EOLACvtfcHk0ljSFRmRelP4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D&md5=b092b6f79d66e9bcc23c4477cce19a67</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303543%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DMoll%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520immunoproteasome%2520ameliorates%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D226%26epage%3D238%26doi%3D10.1002%2Femmm.201303543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anolik, J. H.</span></span> <span> </span><span class="NLM_article-title">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1002/art.33333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fart.33333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=21905015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=493-503&author=H.+T.+Ichikawaauthor=T.+Conleyauthor=T.+Muchamuelauthor=J.+Jiangauthor=S.+Leeauthor=T.+Owenauthor=J.+Barnardauthor=S.+Nevarezauthor=B.+I.+Goldmanauthor=C.+J.+Kirkauthor=R.+J.+Looneyauthor=J.+H.+Anolik&title=Beneficial+effect+of+novel+proteasome+inhibitors+in+murine+lupus+via+dual+inhibition+of+type+I+interferon+and+autoantibody-secreting+cells&doi=10.1002%2Fart.33333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span></div><div class="casAuthors">Ichikawa, H. Travis; Conley, Thomas; Muchamuel, Tony; Jiang, Jing; Lee, Susan; Owen, Teresa; Barnard, Jennifer; Nevarez, Sarah; Goldman, Bruce I.; Kirk, Christopher J.; Looney, R. John; Anolik, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are crit. in disease pathogenesis.  Methods : Lupus-prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control.  Tissue was harvested and analyzed by flow cytometry using std. markers.  Nephritis was monitored by evaluation for proteinuria and by histol. anal. of kidneys.  Serum anti-double-stranded DNA (anti-dsDNA) levels were measured by ELISA (ELISA), and total IgG and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.  Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll-like receptor (TLR) agonists and proteasome inhibitors, and interferon-α (IFNα) levels were measured by ELISA and flow cytometry.  Results : Early treatment of lupus-prone mice with the dual-targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome-specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis.  Treatment had profound effects on plasma cells, with greater redns. in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels.  Notably, proteasome inhibition efficiently suppressed prodn. of IFNα by TLR-activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function.  Conclusion : Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 crit. pathways in disease pathogenesis, type I IFN activation and autoantibody prodn. by plasma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgx8A-mW0b_bVg90H21EOLACvtfcHk0ljSFRmRelP4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D&md5=1055201f4931e5c09ae292b07e26c0cc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fart.33333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33333%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%2BT.%26aulast%3DConley%26aufirst%3DT.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DT.%26aulast%3DBarnard%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%2BI.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLooney%26aufirst%3DR.%2BJ.%26aulast%3DAnolik%26aufirst%3DJ.%2BH.%26atitle%3DBeneficial%2520effect%2520of%2520novel%2520proteasome%2520inhibitors%2520in%2520murine%2520lupus%2520via%2520dual%2520inhibition%2520of%2520type%2520I%2520interferon%2520and%2520autoantibody-secreting%2520cells%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D493%26epage%3D503%26doi%3D10.1002%2Fart.33333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4193</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.4049%2Fjimmunol.1201183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=22984077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4182-4193&author=K.+W.+Kalimauthor=M.+Baslerauthor=C.+J.+Kirkauthor=M.+Groettrup&title=Immunoproteasome+subunit+LMP7+deficiency+and+inhibition+suppresses+Th1+and+Th17+but+enhances+regulatory+T+cell+differentiation&doi=10.4049%2Fjimmunol.1201183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation</span></div><div class="casAuthors">Kalim, Khalid W.; Basler, Michael; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4182-4193</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The immunoproteasome generates peptides presented on MHC class I mols. to cytotoxic T cells.  ONX 0914 (formerly called PR-957) is a selective inhibitor of the immunoproteasome subunit low mol. mass polypeptide (LMP) 7 (β5i) that attenuates disease progression in mouse models of diabetes, colitis, and arthritis.  The aim of this study was to investigate the effect of LMP7-specific inhibition on major Th cell differentiation pathways involved in the progression of autoimmune diseases in vitro and in vivo.  We used ONX 0914-treated wild-type CD4+ T cells and also LMP7-/- CD4+ T cells under different Th cell-polarizing conditions, focusing on the effector cytokines and transcription factors involved, and compared them with wild-type CD4+ T cells.  Mouse models of dextran sodium sulfate-induced colitis and a T cell transfer model of colitis were used for in vivo assessment.  Deletion or inhibition of LMP7 suppressed generation of Th17 but promoted regulatory T cell (Treg) development.  In developing Th17 cells, immunoproteasome inhibition blocked phosphorylation of STAT3, whereas in Tregs, SMAD phosphorylation was enhanced.  Addnl., LMP7 inhibition led to reduced STAT1 phosphorylation and Th1 differentiation.  These findings were confirmed in vivo as LMP7 inhibition or deficiency resulted in reduced Th1 and Th17 expansion while promoting Treg development in dextran sodium sulfate-induced colitis.  Also, in a T cell-dependent transfer model of colitis, LMP7-specific inhibition led to reduced Th1 and Th17 differentiation in vivo.  LMP7 governs Th cell lineage detn. by affecting the balance of receptor proximal signals during differentiation.  These data render LMP7 a promising drug target for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3Ux8Yelj67Vg90H21EOLACvtfcHk0ljSFRmRelP4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrtLzK&md5=00e986b09b33e6d70f26abf06b432045</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201183%26sid%3Dliteratum%253Aachs%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DImmunoproteasome%2520subunit%2520LMP7%2520deficiency%2520and%2520inhibition%2520suppresses%2520Th1%2520and%2520Th17%2520but%2520enhances%2520regulatory%2520T%2520cell%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4182%26epage%3D4193%26doi%3D10.4049%2Fjimmunol.1201183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nm.1978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnm.1978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=19525961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=781-787&author=T.+Muchamuelauthor=M.+Baslerauthor=M.+A.+Aujayauthor=E.+Suzukiauthor=K.+W.+Kalimauthor=C.+Lauerauthor=C.+Sylvainauthor=E.+R.+Ringauthor=J.+Shieldsauthor=J.+Jiangauthor=P.+Shwonekauthor=F.+Parlatiauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=C.+J.+Kirkauthor=M.+Groettrup&title=A+selective+inhibitor+of+the+immunoproteasome+subunit+LMP7+blocks+cytokine+production+and+attenuates+progression+of+experimental+arthritis&doi=10.1038%2Fnm.1978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span></div><div class="casAuthors">Muchamuel, Tony; Basler, Michael; Aujay, Monette A.; Suzuki, Erika; Kalim, Khalid W.; Lauer, Christoph; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immunoproteasome, a distinct class of proteasome found predominantly in monocytes and lymphocytes, is known to shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I).  However, a specific role for the immunoproteasome in regulating other facets of immune responses has not been established.  The authors describe here the characterization of PR-957, a selective inhibitor of low-mol. mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome.  PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo.  Selective inhibition of LMP7 by PR-957 blocked prodn. of interleukin-23 (IL-23) by activated monocytes and interferon-γ and IL-2 by T cells.  In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in redns. in cellular infiltration, cytokine prodn. and autoantibody levels.  These studies reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for targeting LMP7 in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJsuXHN4oyBbVg90H21EOLACvtfcHk0lgMJ4iZh3Dnag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D&md5=3961ba1ec6786d0318bfa2b64e5e7cfa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnm.1978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1978%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DLauer%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DE.%2BR.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520the%2520immunoproteasome%2520subunit%2520LMP7%2520blocks%2520cytokine%2520production%2520and%2520attenuates%2520progression%2520of%2520experimental%2520arthritis%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D781%26epage%3D787%26doi%3D10.1038%2Fnm.1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span>; <span class="NLM_string-name">Jiang, J.</span>; <span class="NLM_string-name">Lee, S. J.</span>; <span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">ONX-0914, A selective inhibitor of the immunoproteasome, protects against experimental autoimmune encephalomyelitis and suppresses the TH17 Response</span>. In  <i>Neurology</i>; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>, <span class="NLM_year">2011</span>; Vol.  <span class="NLM_volume">76</span>, pp  <span class="NLM_fpage">A459</span>– <span class="NLM_lpage">A460</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=A459-A460&author=T.+Muchamuel&author=J.+Jiang&author=S.+J.+Lee&author=C.+J.+Kirk&title=Neurology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26atitle%3DONX-0914%252C%2520A%2520selective%2520inhibitor%2520of%2520the%2520immunoproteasome%252C%2520protects%2520against%2520experimental%2520autoimmune%2520encephalomyelitis%2520and%2520suppresses%2520the%2520TH17%2520Response%26btitle%3DNeurology%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2011%26volume%3D76%26spage%3DA459%26epage%3DA460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vachharajani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joeris, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenike, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantazis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visekruna, A.</span></span> <span> </span><span class="NLM_article-title">Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">50447</span>– <span class="NLM_lpage">50459</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.18632%2Foncotarget.14579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28881574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50447-50459&author=N.+Vachharajaniauthor=T.+Joerisauthor=M.+Luuauthor=S.+Hartmannauthor=S.+Pautzauthor=E.+Jenikeauthor=G.+Pantazisauthor=I.+Prinzauthor=M.+J.+Hoferauthor=U.+Steinhoffauthor=A.+Visekruna&title=Prevention+of+colitis-associated+cancer+by+selective+targeting+of+immunoproteasome+subunit+LMP7&doi=10.18632%2Foncotarget.14579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7</span></div><div class="casAuthors">Vachharajani Niyati; Luu Maik; Hartmann Sabrina; Pautz Sabine; Jenike Elena; Steinhoff Ulrich; Visekruna Alexander; Joeris Thorsten; Pantazis Georgios; Hofer Markus J; Prinz Immo; Hofer Markus J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">50447-50459</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic inflammation is a well-known risk factor in development of intestinal tumorigenesis, although the exact mechanisms underlying development of colitis-associated cancer (CAC) still remain obscure.  The activity and function of immunoproteasome has been extensively analyzed in the context of inflammation and infectious diseases.  Here, we show that the proteasomal immunosubunit LMP7 plays an essential role in development of CAC.  Mice devoid of LMP7 were resistant to chronic inflammation and formation of neoplasia, and developed virtually no tumors after AOM/DSS treatment.  Our data reveal that LMP7 deficiency resulted in reduced expression of pro-tumorigenic chemokines CXCL1, CXCL2 and CXCL3 as well as adhesion molecule VCAM-1.  As a consequence, an impaired recruitment and activity of tumor-infiltrating leukocytes resulting in decreased secretion of cytokines IL-6 and TNF-α was observed.  Further, the deletion or pharmacological inhibition of LMP7 and consequent blockade of NF-κB abrogated the production of IL-17A, which possesses a strong carcinogenic activity in the gut.  Moreover, in vivo administration of the selective LMP7 inhibitor ONX-0914 led to a marked reduction of tumor numbers in wild-type (WT) mice.  Collectively, we identified the immunoproteasome as a crucial mediator of inflammation-driven neoplasia highlighting a novel potential therapeutic approach to limit colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ra5hF3i41rqxQ2mb9Pu8fW6udTcc2eZmvfNHu5mm_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1Oisw%253D%253D&md5=56e4b040eaebfa591ec3e5d9ec85355f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14579%26sid%3Dliteratum%253Aachs%26aulast%3DVachharajani%26aufirst%3DN.%26aulast%3DJoeris%26aufirst%3DT.%26aulast%3DLuu%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DPautz%26aufirst%3DS.%26aulast%3DJenike%26aufirst%3DE.%26aulast%3DPantazis%26aufirst%3DG.%26aulast%3DPrinz%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DM.%2BJ.%26aulast%3DSteinhoff%26aufirst%3DU.%26aulast%3DVisekruna%26aufirst%3DA.%26atitle%3DPrevention%2520of%2520colitis-associated%2520cancer%2520by%2520selective%2520targeting%2520of%2520immunoproteasome%2520subunit%2520LMP7%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D50447%26epage%3D50459%26doi%3D10.18632%2Foncotarget.14579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3617</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.bmcl.2014.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24913713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslKlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3614-3617&author=V.+Kasamauthor=N.+R.+Leeauthor=K.+B.+Kimauthor=C.+G.+Zhan&title=Selective+immunoproteasome+inhibitors+with+non-peptide+scaffolds+identified+from+structure-based+virtual+screening&doi=10.1016%2Fj.bmcl.2014.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening</span></div><div class="casAuthors">Kasam, Vinod; Lee, Na-Ra; Kim, Kyung-Bo; Zhan, Chang-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3614-3617</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a major component of the crucial nonlysosomal protein degrdn. pathway in the cells, the proteasome has been implicated in many diseases such as Alzheimer's disease, Huntington's disease, inflammatory bowel diseases, autoimmune diseases, multiple myeloma (MM) and other cancers.  There are two main proteasome subtypes: the constitutive proteasome which is expressed in all eukaryotic cells and the immunoproteasome which is expressed in immune cells and can be induced in other cell types.  Majority of currently available proteasome inhibitors are peptide backbone-based, having short half-lives in the body.  It is highly desirable to identify novel, immunoproteasome-selective inhibitors with non-peptide scaffolds for development of novel therapeutics.  Through combined virtual screening and exptl. studies targeting the immunoproteasome, we have identified a set of novel immunoproteasome inhibitors with diverse non-peptide scaffolds.  Some of the identified inhibitors have significant selectivity for the immunoproteasome over the constitutive proteasome.  Unlike most of the currently available proteasome inhibitors, these new inhibitors lacking electrophilic pharmacophores are not expected to form a covalent bond with proteasome after the binding.  These non-peptide scaffolds may provide a new platform for future rational drug design and discovery targeting the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2U6pRAIx7NLVg90H21EOLACvtfcHk0lgMJ4iZh3Dnag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslKlurs%253D&md5=6cf6a9bd24fd8e6986f600af903ea667</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DKasam%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520immunoproteasome%2520inhibitors%2520with%2520non-peptide%2520scaffolds%2520identified%2520from%2520structure-based%2520virtual%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3614%26epage%3D3617%26doi%3D10.1016%2Fj.bmcl.2014.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Subunit specific inhibitors of proteasomes and their potential for immunomodulation</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2014.08.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.cbpa.2014.08.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=25217863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyiurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=16-22&author=A.+F.+Kisselevauthor=M.+Groettrup&title=Subunit+specific+inhibitors+of+proteasomes+and+their+potential+for+immunomodulation&doi=10.1016%2Fj.cbpa.2014.08.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit specific inhibitors of proteasomes and their potential for immunomodulation</span></div><div class="casAuthors">Kisselev, Alexei F.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-22</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Specialized variants of the constitutive 20S proteasome in the immune system like the immunoproteasomes and the thymoproteasome contain active site-bearing subunits which differ in their cleavage priorities and substrate binding pockets.  The immunoproteasome plays a crucial role in antigen processing and for the differentiation of pro-inflammatory T helper cells which are involved in the pathogenesis of autoimmunity.  Selective inhibitors of the immunoproteasome and constitutive proteasome have recently been generated which interfere with the development and progression of autoimmune diseases.  Here we describe these inhibitors and their therapeutic potential as predicted from preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKHmwEvS8e7Vg90H21EOLACvtfcHk0litB_9BktQdWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyiurvP&md5=f5039ce8ef60506ddf14bdcb567f545c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.08.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.08.012%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DSubunit%2520specific%2520inhibitors%2520of%2520proteasomes%2520and%2520their%2520potential%2520for%2520immunomodulation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D23%26spage%3D16%26epage%3D22%26doi%3D10.1016%2Fj.cbpa.2014.08.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: An emerging therapeutic target</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2923</span>– <span class="NLM_lpage">2930</span>, <span class="refDoi"> DOI: 10.2174/156802611798281348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.2174%2F156802611798281348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=21824107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2923-2930&author=W.+Leeauthor=K.+B.+Kim&title=The+Immunoproteasome%3A+An+emerging+therapeutic+target&doi=10.2174%2F156802611798281348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome: an emerging therapeutic target</span></div><div class="casAuthors">Lee, Wooin; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2923-2930</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The proteasome, a large multisubunit protease complex, has been extensively investigated over the years, greatly enhancing our understanding of crit. roles that the proteasome plays in cells.  The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has validated the proteasome as an anticancer target.  However, the undesirable toxicities of these agents limit their broad utility.  The immunoproteasome, an alternative form of the constitutive proteasome, has recently been explored as a therapeutic target.  While the immunoproteasome, normally expressed in cells of hematopoietic origin, has been shown to be assocd. with various types of cancer and inflammatory diseases, its multifaceted function is not fully understood due to the lack of appropriate mol. probes.  In this review, recent advances in the immunoproteasome field are covered, including potential implications in disease states.  In particular, recent developments in immunoproteasome-specific inhibitors are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ejBv7fA5MbVg90H21EOLACvtfcHk0litB_9BktQdWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehur0%253D&md5=90827ffca32fb0fee1a8b72d9e3ada55</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156802611798281348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798281348%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DThe%2520Immunoproteasome%253A%2520An%2520emerging%2520therapeutic%2520target%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2923%26epage%3D2930%26doi%3D10.2174%2F156802611798281348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span>; <span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome-specific inhibitors and their application</span>. In  <i>Methods in Molecular Biology</i>; <span class="NLM_publisher-name">Humana Press,</span> <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">832</span>, pp  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">401</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=391-401&author=M.+Basler&author=M.+Groettrup&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DImmunoproteasome-specific%2520inhibitors%2520and%2520their%2520application%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26pub%3DHumana%2520Press%26date%3D2012%26volume%3D832%26spage%3D391%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubiella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">11969</span>– <span class="NLM_lpage">11973</span>, <span class="refDoi"> DOI: 10.1002/anie.201406964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fanie.201406964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOkurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=11969-11973&author=C.+Dubiellaauthor=H.+Cuiauthor=M.+Gerschauthor=A.+J.+Brouwerauthor=S.+A.+Sieberauthor=A.+Krugerauthor=R.+M.+Liskampauthor=M.+Groll&title=Selective+inhibition+of+the+immunoproteasome+by+ligand-induced+crosslinking+of+the+active+site&doi=10.1002%2Fanie.201406964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of the Immunoproteasome by Ligand-Induced Crosslinking of the Active Site</span></div><div class="casAuthors">Dubiella, Christian; Cui, Haissi; Gersch, Malte; Brouwer, Arwin J.; Sieber, Stephan A.; Krueger, Achim; Liskamp, Rob M. J.; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">11969-11973</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The concept of proteasome inhibition ranks among the latest achievements in the treatment of blood cancer and represents a promising strategy for modulating autoimmune diseases.  In this study, we describe peptidic sulfonyl fluoride inhibitors that selectively block the catalytic β5 subunit of the immunoproteasome by inducing only marginal cytotoxic effects.  Structural and mass spectrometric analyses revealed a novel reaction mechanism involving polarity inversion and irreversible crosslinking of the proteasomal active site.  We thus identified the sulfonyl fluoride headgroup for the development and optimization of immunoproteasome selective compds. and their possible application in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnN6CJub2ORrVg90H21EOLACvtfcHk0litB_9BktQdWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOkurfM&md5=00d726fdbc6f2e391f9650516b2d6c30</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201406964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201406964%26sid%3Dliteratum%253Aachs%26aulast%3DDubiella%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DSelective%2520inhibition%2520of%2520the%2520immunoproteasome%2520by%2520ligand-induced%2520crosslinking%2520of%2520the%2520active%2520site%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D11969%26epage%3D11973%26doi%3D10.1002%2Fanie.201406964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sosič, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogrizek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obreza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zigon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janezic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlinaric-Rascan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Nonpeptidic selective inhibitors of the chymotrypsin-like (beta5 i) subunit of the immunoproteasome</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5745</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1002/anie.201600190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fanie.201600190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=5745-5748&author=I.+Sosi%C4%8Dauthor=M.+Gobecauthor=B.+Brusauthor=D.+Knezauthor=M.+Zivecauthor=J.+Koncauthor=S.+Lesnikauthor=M.+Ogrizekauthor=A.+Obrezaauthor=D.+Zigonauthor=D.+Janezicauthor=I.+Mlinaric-Rascanauthor=S.+Gobec&title=Nonpeptidic+selective+inhibitors+of+the+chymotrypsin-like+%28beta5+i%29+subunit+of+the+immunoproteasome&doi=10.1002%2Fanie.201600190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5i) Subunit of the Immunoproteasome</span></div><div class="casAuthors">Sosic, Izidor; Gobec, Martina; Brus, Boris; Knez, Damijan; Zivec, Matej; Konc, Janez; Lesnik, Samo; Ogrizek, Mitja; Obreza, Ales; Zigon, Dusan; Janezic, Dusanka; Mlinaric-Rascan, Irena; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5745-5748</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Elevated expression of the immunoproteasome has been assocd. with autoimmune diseases, inflammatory diseases, and various types of cancer.  Selective inhibitors of the immunoproteasome are not only scarce, but also almost entirely restricted to peptide-based compds.  Herein, we describe nonpeptidic reversible inhibitors that selectively block the chymotrypsin-like (β5i) subunit of the human immunoproteasome in the low micromolar range.  The most potent of the reversibly acting compds. were then converted into covalent, irreversible, nonpeptidic inhibitors that retained selectivity for the β5i subunit.  In addn., these inhibitors discriminate between the immunoproteasome and the constitutive proteasome in cell-based assays.  Along with their lack of cytotoxicity, these data point to these nonpeptidic compds. being suitable for further investigation as β5i-selective probes for possible application in noncancer diseases related to the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzWe9nWrjVbVg90H21EOLACvtfcHk0ljxIUTvX9638Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yisrs%253D&md5=37d04d39e7d6ff3cf58241bc16f8bd3e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201600190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201600190%26sid%3Dliteratum%253Aachs%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DM.%26aulast%3DBrus%26aufirst%3DB.%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DZivec%26aufirst%3DM.%26aulast%3DKonc%26aufirst%3DJ.%26aulast%3DLesnik%26aufirst%3DS.%26aulast%3DOgrizek%26aufirst%3DM.%26aulast%3DObreza%26aufirst%3DA.%26aulast%3DZigon%26aufirst%3DD.%26aulast%3DJanezic%26aufirst%3DD.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DNonpeptidic%2520selective%2520inhibitors%2520of%2520the%2520chymotrypsin-like%2520%2528beta5%2520i%2529%2520subunit%2520of%2520the%2520immunoproteasome%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D5745%26epage%3D5748%26doi%3D10.1002%2Fanie.201600190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Chapelain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubiella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Structural elucidation of a non-peptidic inhibitor specific for the human immunoproteasome</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/cbic.201700021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fcbic.201700021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28098422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVKlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=523-526&author=H.+Cuiauthor=R.+Baurauthor=C.+Le+Chapelainauthor=C.+Dubiellaauthor=W.+Heinemeyerauthor=E.+M.+Huberauthor=M.+Groll&title=Structural+elucidation+of+a+non-peptidic+inhibitor+specific+for+the+human+immunoproteasome&doi=10.1002%2Fcbic.201700021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome</span></div><div class="casAuthors">Cui, Haissi; Baur, Regina; Le Chapelain, Camille; Dubiella, Christian; Heinemeyer, Wolfgang; Huber, Eva M.; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-526</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of the immunoproteasome is a promising approach towards the development of immunomodulatory drugs.  Recently, a class of substituted thiazole compds. that combine a nonpeptidic scaffold with the absence of an electrophile was reported in a patent.  Here, we investigated the mode of action of the lead compd. by using a sophisticated chimeric yeast model of the human immunoproteasome for structural studies.  The inhibitor adopts a unique orientation perpendicular to the β5i substrate-binding channel.  Distinct interactions between the inhibitor and the subpockets of the human immunoproteasome account for its isotype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvTj0zpHsy2rVg90H21EOLACvtfcHk0ljxIUTvX9638Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVKlt7k%253D&md5=01d6f4fe1901fea377d69134835488cd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700021%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DBaur%26aufirst%3DR.%26aulast%3DLe%2BChapelain%26aufirst%3DC.%26aulast%3DDubiella%26aufirst%3DC.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DStructural%2520elucidation%2520of%2520a%2520non-peptidic%2520inhibitor%2520specific%2520for%2520the%2520human%2520immunoproteasome%26jtitle%3DChemBioChem%26date%3D2017%26volume%3D18%26spage%3D523%26epage%3D526%26doi%3D10.1002%2Fcbic.201700021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0ljxIUTvX9638Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sula
Karreci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihali, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solhjou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riella, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laragione, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrat, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J.</span></span> <span> </span><span class="NLM_article-title">Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E8425</span>– <span class="NLM_lpage">E8432</span>, <span class="refDoi"> DOI: 10.1073/pnas.1618548114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1618548114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27956634" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8425-E8432&author=E.+Sula%0AKarreciauthor=H.+Fanauthor=M.+Ueharaauthor=A.+B.+Mihaliauthor=P.+K.+Singhauthor=A.+T.+Kurdiauthor=Z.+Solhjouauthor=L.+V.+Riellaauthor=I.+Ghobrialauthor=T.+Laragioneauthor=S.+Routrayauthor=J.+P.+Assakerauthor=R.+Wangauthor=G.+Sukenickauthor=L.+Shiauthor=F.+J.+Barratauthor=C.+F.+Nathanauthor=G.+Linauthor=J.+Azzi&title=Brief+treatment+with+a+highly+selective+immunoproteasome+inhibitor+promotes+long-term+cardiac+allograft+acceptance+in+mice&doi=10.1073%2Fpnas.1618548114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1618548114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1618548114%26sid%3Dliteratum%253Aachs%26aulast%3DSula%2BKarreci%26aufirst%3DE.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DM.%26aulast%3DMihali%26aufirst%3DA.%2BB.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DKurdi%26aufirst%3DA.%2BT.%26aulast%3DSolhjou%26aufirst%3DZ.%26aulast%3DRiella%26aufirst%3DL.%2BV.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DLaragione%26aufirst%3DT.%26aulast%3DRoutray%26aufirst%3DS.%26aulast%3DAssaker%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DBarrat%26aufirst%3DF.%2BJ.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DAzzi%26aufirst%3DJ.%26atitle%3DBrief%2520treatment%2520with%2520a%2520highly%2520selective%2520immunoproteasome%2520inhibitor%2520promotes%2520long-term%2520cardiac%2520allograft%2520acceptance%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE8425%26epage%3DE8432%26doi%3D10.1073%2Fpnas.1618548114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelo, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Oxathiazolones selectively inhibit the human immunoproteasome over the constitutive proteasome</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1021/ml400531d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400531d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=405-410&author=H.+Fanauthor=N.+G.+Angeloauthor=J.+D.+Warrenauthor=C.+F.+Nathanauthor=G.+Lin&title=Oxathiazolones+selectively+inhibit+the+human+immunoproteasome+over+the+constitutive+proteasome&doi=10.1021%2Fml400531d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome</span></div><div class="casAuthors">Fan, Hao; Angelo, Nicholas G.; Warren, J. David; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-410</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the constitutive proteasome hold promise for the treatment of autoimmune and inflammatory diseases and hematol. malignancies.  Here we report that oxathiazolones inhibit the immunoproteasome β5i with up to 4700-fold selectivity over the constitutive proteasome, are cell permeable, and inhibit proteasomes inside cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z_edRpQdj7Vg90H21EOLACvtfcHk0lg_tjW9rkbpcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyhsLY%253D&md5=e9dcdf8a691515c95172ab283b92a5be</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml400531d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400531d%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DAngelo%26aufirst%3DN.%2BG.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DOxathiazolones%2520selectively%2520inhibit%2520the%2520human%2520immunoproteasome%2520over%2520the%2520constitutive%2520proteasome%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D405%26epage%3D410%26doi%3D10.1021%2Fml400531d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome beta5i-selective dipeptidomimetic inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fcmdc.201600384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27561172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSgu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2127-2131&author=P.+K.+Singhauthor=H.+Fanauthor=X.+Jiangauthor=L.+Shiauthor=C.+F.+Nathanauthor=G.+Lin&title=Immunoproteasome+beta5i-selective+dipeptidomimetic+inhibitors&doi=10.1002%2Fcmdc.201600384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors</span></div><div class="casAuthors">Singh, Pradeep K.; Fan, Hao; Jiang, Xiuju; Shi, Lei; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2127-2131</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">N,C-capped dipeptides belong to a class of noncovalent proteasome inhibitors.  Herein the authors report that the insertion of a β-amino acid into N,C-capped dipeptides markedly decreases their inhibitory potency against human constitutive proteasome β5c, while maintaining potent inhibitory activity against human immunoproteasome β5i, thereby achieving thousands-fold selectivity for β5i over β5c.  Structure-activity relationship studies revealed that β5c does not tolerate the β-amino acid based dipeptidomimetics as does β5i.  In vitro, one such compd. was found to inhibit human T cell proliferation.  Compds. of this class may have potential as therapeutics for autoimmune and inflammatory diseases with less mechanism-based cytotoxicity than agents that also inhibit the constitutive proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5VZ_618QUCLVg90H21EOLACvtfcHk0lg_tjW9rkbpcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSgu7nL&md5=b3a77b4e7d66cbd41de0789d3a6ad762</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600384%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DImmunoproteasome%2520beta5i-selective%2520dipeptidomimetic%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2127%26epage%3D2131%26doi%3D10.1002%2Fcmdc.201600384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.d. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">1692</span> <span class="refDoi"> DOI: 10.1038/s41467-017-01760-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fs41467-017-01760-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=29167449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=R.d.+L.+A.+Santosauthor=L.+Baiauthor=P.+K.+Singhauthor=N.+Murakamiauthor=H.+Fanauthor=W.+Zhanauthor=Y.+Zhuauthor=X.+Jiangauthor=K.+Zhangauthor=J.+P.+Asskerauthor=C.+F.+Nathanauthor=H.+Liauthor=J.+Azziauthor=G.+Lin&title=Structure+of+human+immunoproteasome+with+a+reversible+and+noncompetitive+inhibitor+that+selectively+inhibits+activated+lymphocytes&doi=10.1038%2Fs41467-017-01760-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes</span></div><div class="casAuthors">Santos Ruda de Luna Almeida; Bai Lin; Li Huilin; Singh Pradeep K; Murakami Naoka; Assker Jean Pierre; Azzi Jamil; Fan Hao; Zhan Wenhu; Zhu Yingrong; Jiang Xiuju; Nathan Carl F; Lin Gang; Zhang Kaiming</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1692</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteasome inhibitors benefit patients with multiple myeloma and B cell-dependent autoimmune disorders but exert toxicity from inhibition of proteasomes in other cells.  Toxicity should be minimized by reversible inhibition of the immunoproteasome β5i subunit while sparing the constitutive β5c subunit.  Here we report β5i-selective inhibition by asparagine-ethylenediamine (AsnEDA)-based compounds and present the high-resolution cryo-EM structural analysis of the human immunoproteasome.  Despite inhibiting noncompetitively, an AsnEDA inhibitor binds the active site.  Hydrophobic interactions are accompanied by hydrogen bonding with β5i and β6 subunits.  The inhibitors are far more cytotoxic for myeloma and lymphoma cell lines than for hepatocarcinoma or non-activated lymphocytes.  They block human B-cell proliferation and promote apoptotic cell death selectively in antibody-secreting B cells, and to a lesser extent in activated human T cells.  Reversible, β5i-selective inhibitors may be useful for treatment of diseases involving activated or neoplastic B cells or activated T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlRnWYxiDmxxwLZxei1HN8fW6udTcc2eaTMPWmIHGxWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOmtw%253D%253D&md5=3a34624f5b07ad88384d43a22308fc7c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01760-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01760-5%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.d.%2BL.%2BA.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DMurakami%26aufirst%3DN.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DAssker%26aufirst%3DJ.%2BP.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAzzi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DStructure%2520of%2520human%2520immunoproteasome%2520with%2520a%2520reversible%2520and%2520noncompetitive%2520inhibitor%2520that%2520selectively%2520inhibits%2520activated%2520lymphocytes%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-01760-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaubourgeix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">9968</span>– <span class="NLM_lpage">9971</span>, <span class="refDoi"> DOI: 10.1021/ja400021x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja400021x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=9968-9971&author=G.+Linauthor=T.+Chidawanyikaauthor=C.+Tsuauthor=T.+Warrierauthor=J.+Vaubourgeixauthor=C.+Blackburnauthor=K.+Gigstadauthor=M.+Sintchakauthor=L.+Dickauthor=C.+Nathan&title=N%2CC-Capped+dipeptides+with+selectivity+for+mycobacterial+proteasome+over+human+proteasomes%3A+role+of+S3+and+S1+binding+pockets&doi=10.1021%2Fja400021x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">N,C-capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets</span></div><div class="casAuthors">Lin, Gang; Chidawanyika, Tamutenda; Tsu, Christopher; Warrier, Thulasi; Vaubourgeix, Julien; Blackburn, Christopher; Gigstad, Kenneth; Sintchak, Michael; Dick, Lawrence; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">9968-9971</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors identified N,C-capped dipeptides that are selective for the Mycobacterium tuberculosis proteasome over human constitutive and immunoproteasomes.  Differences in the S3 and S1 binding pockets appeared to account for the species selectivity.  The inhibitors can penetrate mycobacteria and kill nonreplicating M. tuberculosis under nitrosative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaNq6HiLQwrVg90H21EOLACvtfcHk0lifld2q83Sxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCisL0%253D&md5=2959e1ab9ece8784c35ea7bb99054ea2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja400021x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja400021x%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DWarrier%26aufirst%3DT.%26aulast%3DVaubourgeix%26aufirst%3DJ.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DN%252CC-Capped%2520dipeptides%2520with%2520selectivity%2520for%2520mycobacterial%2520proteasome%2520over%2520human%2520proteasomes%253A%2520role%2520of%2520S3%2520and%2520S1%2520binding%2520pockets%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D9968%26epage%3D9971%26doi%3D10.1021%2Fja400021x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+new+series+of+non-covalent+proteasome+inhibitors+with+exquisite+potency+and+selectivity+for+the+20S+beta5-subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0lifld2q83Sxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520new%2520series%2520of%2520non-covalent%2520proteasome%2520inhibitors%2520with%2520exquisite%2520potency%2520and%2520selectivity%2520for%2520the%252020S%2520beta5-subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melandri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span> <span> </span><span class="NLM_article-title">Kinetic characterization of the chymotryptic activity of the 20S proteasome</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3899</span>– <span class="NLM_lpage">3908</span>, <span class="refDoi"> DOI: 10.1021/bi952262x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi952262x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK28XhsFKqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=3899-3908&author=R.+L.+Steinauthor=F.+Melandriauthor=L.+Dick&title=Kinetic+characterization+of+the+chymotryptic+activity+of+the+20S+proteasome&doi=10.1021%2Fbi952262x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic characterization of the chymotryptic activity of the 20S proteasome</span></div><div class="casAuthors">Stein, Ross L.; Melandri, Francesco; Dick, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3899-908</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors report kinetic studies for the chymotryptic activity of the 20S proteasome.  Reaction progress curves that are recorded at concns. of Suc-Leu-Leu-Val-Tyr-AMC greater than about 40 μM are biphasic and characterized by initial velocities that decay by a first-order process to final, steady-state velocities.  At [Suc-Leu-Leu-Val-Tyr-AMC] > 40 μM, initial and steady-state velocities are smaller than predicted from simple, Michaelis-Menten kinetics.  The first-order rate const. for the approach to steady-state has a complex dependence on substrate concn. and decreases sigmoidally as substrate concn. increases.  These results indicate that the 20S proteasome is a hysteretic enzyme and is subject to substrate inhibition.  To explain these observations the authors propose a minimal kinetic model with two crit. mechanistic features: (1) the 20S proteasome has two cooperative active sites for Suc-Leu-Leu-Val-Tyr-AMC and (2) there are two interconvertible conformers of active 20S proteasome.  To probe this mechanism in greater detail, the authors explored the kinetic mechanism of inhibition of the 20S proteasome-catalyzed hydrolysis of Suc-Leu-Leu-Val-Tyr-AMC by the peptide aldehyde, Ac-Leu-Leu-Nle-H.  The studies reveal a nonlinear dependence of steady-state velocity on inhibitor concn. (i.e., parabolic inhibition) as well as a nonlinear dependence of the apparent inhibitor dissocn. const. on substrate concn.  Both of these observations are explained by binding of inhibitor at multiple sites on the enzyme.  Taken together, the results of this study indicate that the 20S proteasome is a conformationally flexible protein that can adjust to the binding of ligands and that has multiple and cooperative active sites.  These results support a view of the proteasome's substrate specificity in which (1) substrates are recognized and hydrolyzed by more than one active site; (2) each active site can bind substrates that possess a variety of P1 residues; and (3) the P1 residue plays a relatively minor role as a specificity determinant.  Finally, the authors interpret the results of this study to suggest that, in vivo, the 20S proteasome requires conformational plasticity for its interactions with regulatory complexes and, after it has combined with appropriate regulatory complexes, to catalyze hydrolysis of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQf-rPQS50RrVg90H21EOLACvtfcHk0lifld2q83Sxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsFKqsrg%253D&md5=5cbce45f695898e7501d57b72159d24c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbi952262x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi952262x%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DMelandri%26aufirst%3DF.%26aulast%3DDick%26aufirst%3DL.%26atitle%3DKinetic%2520characterization%2520of%2520the%2520chymotryptic%2520activity%2520of%2520the%252020S%2520proteasome%26jtitle%3DBiochemistry%26date%3D1996%26volume%3D35%26spage%3D3899%26epage%3D3908%26doi%3D10.1021%2Fbi952262x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roccaro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runnels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">4051</span>– <span class="NLM_lpage">4060</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-09-243402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1182%2Fblood-2009-09-243402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20110419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4051-4060&author=A.+M.+Roccaroauthor=A.+Saccoauthor=M.+Aujayauthor=H.+T.+Ngoauthor=A.+K.+Azabauthor=F.+Azabauthor=P.+Quangauthor=P.+Maisoauthor=J.+Runnelsauthor=K.+C.+Andersonauthor=S.+Demoauthor=I.+M.+Ghobrial&title=Selective+inhibition+of+chymotrypsin-like+activity+of+the+immunoproteasome+and+constitutive+proteasome+in+Waldenstrom+macroglobulinemia&doi=10.1182%2Fblood-2009-09-243402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span></div><div class="casAuthors">Roccaro, Aldo M.; Sacco, Antonio; Aujay, Monette; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Demo, Susan; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4051-4060</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clin. trials.  Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects.  Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematol. tumors.  We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S.  Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor κB (NF-κB) inhibition, caspase cleavage, and initiation of the unfolded protein response.  Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells.  These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBDkasuJTbVg90H21EOLACvtfcHk0li7qxhn27M9cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D&md5=6a1bdb8c763db89328adc15bc4a29f6f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243402%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DH.%2BT.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DRunnels%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520chymotrypsin-like%2520activity%2520of%2520the%2520immunoproteasome%2520and%2520constitutive%2520proteasome%2520in%2520Waldenstrom%2520macroglobulinemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4051%26epage%3D4060%26doi%3D10.1182%2Fblood-2009-09-243402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ladi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaesse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of highly selective human immunoproteasome inhibitors reveal a compensatory process that preserves immune cell viability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7032</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7032-7041&author=E.+Ladiauthor=C.+Everettauthor=C.+E.+Stivalaauthor=B.+E.+Danielsauthor=M.+R.+Durkauthor=S.+F.+Harrisauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=S.+T.+Stabenauthor=M.+Augustinauthor=M.+Blaesseauthor=S.+Steinbacherauthor=C.+Eidenschenkauthor=R.+Pappuauthor=M.+Siu&title=Design+and+evaluation+of+highly+selective+human+immunoproteasome+inhibitors+reveal+a+compensatory+process+that+preserves+immune+cell+viability&doi=10.1021%2Facs.jmedchem.9b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span></div><div class="casAuthors">Ladi, Ena; Everett, Christine; Stivala, Craig E.; Daniels, Blake E.; Durk, Matthew R.; Harris, Seth F.; Huestis, Malcolm P.; Purkey, Hans E.; Staben, Steven T.; Augustin, Martin; Blaesse, Michael; Steinbacher, Stefan; Eidenschenk, Celine; Pappu, Rajita; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7032-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pan-proteasome inhibitor bortezomib demonstrated clin. efficacy in off-label trials of Systemic Lupus Erythematosus.  One potential mechanism of this clin. benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).  However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases.  An attractive alternative is to selectively inhibit the immune cell-specific immunoproteasome to deplete pathogenic immune cells and spare non-hematopoietic cells.  Here we disclose the development of highly subunit-selective immunoproteasome inhibitors using insights obtained from the first bona fide human immunoproteasome co-crystal structures.  Evaluation of these inhibitors revealed that immunoproteasome-specific inhibition does not lead to immune cell death as anticipated and that targeting viability requires inhibition of both immuno- and constitutive proteasomes.  CRISPR/Cas9-mediated knock-out expts. confirmed upregulation of the constitutive proteasome upon disruption of the immunoproteasome, protecting cells from death.  Thus, immunoproteasome inhibition alone is not a suitable approach to deplete immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtaasYDyZZ7Vg90H21EOLACvtfcHk0li7qxhn27M9cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO&md5=21b810621134c447794d5fb88337dbd2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00509%26sid%3Dliteratum%253Aachs%26aulast%3DLadi%26aufirst%3DE.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DDaniels%26aufirst%3DB.%2BE.%26aulast%3DDurk%26aufirst%3DM.%2BR.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBlaesse%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520highly%2520selective%2520human%2520immunoproteasome%2520inhibitors%2520reveal%2520a%2520compensatory%2520process%2520that%2520preserves%2520immune%2520cell%2520viability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7032%26epage%3D7041%26doi%3D10.1021%2Facs.jmedchem.9b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pletnev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the proteasome beta2 site sensitizes triple-negative breast cancer cells to beta5 inhibitors and suppresses nrf1 activation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.chembiol.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28132893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=218-230&author=E.+S.+Weyburneauthor=O.+M.+Wilkinsauthor=Z.+Shaauthor=D.+A.+Williamsauthor=A.+A.+Pletnevauthor=G.+de+Bruinauthor=H.+S.+Overkleeftauthor=A.+L.+Goldbergauthor=M.+D.+Coleauthor=A.+F.+Kisselev&title=Inhibition+of+the+proteasome+beta2+site+sensitizes+triple-negative+breast+cancer+cells+to+beta5+inhibitors+and+suppresses+nrf1+activation&doi=10.1016%2Fj.chembiol.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation</span></div><div class="casAuthors">Weyburne, Emily S.; Wilkins, Owen M.; Sha, Zhe; Williams, David A.; Pletnev, Alexandre A.; de Bruin, Gerjan; Overkleeft, Hermann S.; Goldberg, Alfred L.; Cole, Michael D.; Kisselev, Alexei F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome inhibitors carfilzomib (Cfz) and bortezomib (Btz) are used successfully to treat multiple myeloma, but have not shown clin. efficacy in solid tumors.  Here we show that clin. achievable inhibition of the β5 site of the proteasome by Cfz and Btz does not result in loss of viability of triple-neg. breast cancer cell lines.  We use site-specific inhibitors and CRISPR-mediated genetic inactivation of β1 and β2 to demonstrate that inhibiting a second site of the proteasome, particularly the β2 site, sensitizes cell lines to Btz and Cfz in vitro and in vivo.  Inhibiting both β5 and β2 suppresses prodn. of the sol., active form of the transcription factor Nrf1 and prevents the recovery of proteasome activity through induction of new proteasomes.  These findings provide a strong rationale for the development of dual β5 and β2 inhibitors for the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLGE7V8EGrULVg90H21EOLACvtfcHk0li7qxhn27M9cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kntb4%253D&md5=04690fbff962944953339978b3a15962</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DWilkins%26aufirst%3DO.%2BM.%26aulast%3DSha%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DD.%2BA.%26aulast%3DPletnev%26aufirst%3DA.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DCole%26aufirst%3DM.%2BD.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26atitle%3DInhibition%2520of%2520the%2520proteasome%2520beta2%2520site%2520sensitizes%2520triple-negative%2520breast%2520cancer%2520cells%2520to%2520beta5%2520inhibitors%2520and%2520suppresses%2520nrf1%2520activation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D218%26epage%3D230%26doi%3D10.1016%2Fj.chembiol.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.chembiol.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=30612952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1WnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=340-351&author=A.+Besseauthor=L.+Besseauthor=M.+Krausauthor=M.+Mendez-Lopezauthor=J.+Baderauthor=B.+T.+Xinauthor=G.+de+Bruinauthor=E.+Mauritsauthor=H.+S.+Overkleeftauthor=C.+Driessen&title=Proteasome+inhibition+in+multiple+myeloma%3A+head-to-head+comparison+of+currently+available+proteasome+inhibitors&doi=10.1016%2Fj.chembiol.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors</span></div><div class="casAuthors">Besse, Andrej; Besse, Lenka; Kraus, Marianne; Mendez-Lopez, Max; Bader, Jurgen; Xin, Bo-Tao; de Bruin, Gerjan; Maurits, Elmer; Overkleeft, Herman S.; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-351.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy.  The proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified as rate-limiting and is a primary target of clin. available PIs.  The most effective pattern of subunit inhibition provided by these PIs for cytotoxic activity in MM is unknown.  A head-to-head comparison of clin. available PIs shows that in the clin. relevant setting only the co-inhibition of β1 or β2 with β5 activity achieves meaningful functional proteasome inhibition and cytotoxicity, while the selective β2/β5 inhibition of both constitutive and immunoproteasome is the most cytotoxic.  In the long-term setting, selective inhibition of β5 subunit is sufficient to induce cytotoxicity in PI-sensitive, but not in PI-resistant MM, and the β5/β2 co-inhibition is the most cytotoxic in PI-resistant MM.  These results give a rational basis for selecting individual PIs for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbOQY4rmNt7Vg90H21EOLACvtfcHk0lhUHA6s65UEZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1WnsQ%253D%253D&md5=9b16394c94377aadc35aaef69568aece</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBesse%26aufirst%3DL.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DMendez-Lopez%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DMaurits%26aufirst%3DE.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DProteasome%2520inhibition%2520in%2520multiple%2520myeloma%253A%2520head-to-head%2520comparison%2520of%2520currently%2520available%2520proteasome%2520inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D340%26epage%3D351%26doi%3D10.1016%2Fj.chembiol.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva M.  Huber</span>, <span class="hlFld-ContribAuthor ">Michael  Groll</span>. </span><span class="cited-content_cbyCitation_article-title">A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (8)
                                     , 1929. <a href="https://doi.org/10.3390/cells10081929" title="DOI URL">https://doi.org/10.3390/cells10081929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10081929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10081929%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DA%252BNut%252Bfor%252BEvery%252BBolt%25253A%252BSubunit-Selective%252BInhibitors%252Bof%252Bthe%252BImmunoproteasome%252Band%252BTheir%252BTherapeutic%252BPotential%26aulast%3DHuber%26aufirst%3DEva%2BM.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D8%26spage%3D1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Culletta</span>, <span class="hlFld-ContribAuthor ">Maria  Zappalà</span>, <span class="hlFld-ContribAuthor ">Roberta  Ettari</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Almerico</span>, <span class="hlFld-ContribAuthor ">Marco  Tutone</span>. </span><span class="cited-content_cbyCitation_article-title">Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (13)
                                     , 4046. <a href="https://doi.org/10.3390/molecules26134046" title="DOI URL">https://doi.org/10.3390/molecules26134046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26134046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26134046%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImmunoproteasome%252Band%252BNon-Covalent%252BInhibition%25253A%252BExploration%252Bby%252BAdvanced%252BMolecular%252BDynamics%252Band%252BDocking%252BMethods%26aulast%3DCulletta%26aufirst%3DGiulia%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D13%26spage%3D4046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Veronika  Molitorová</span>, <span class="hlFld-ContribAuthor ">Eliška  Pilařová</span>, <span class="hlFld-ContribAuthor ">Veronika  Vojáčková</span>, <span class="hlFld-ContribAuthor ">Eva  Řezníčková</span>, <span class="hlFld-ContribAuthor ">Klára  Svobodová</span>, <span class="hlFld-ContribAuthor ">Karel  Pauk</span>, <span class="hlFld-ContribAuthor ">Aleš  Imramovský</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">Pseudopeptides with aldehyde or vinylsulfone warheads: synthesis and antiproteasomal activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>3 </em>, 105228. <a href="https://doi.org/10.1016/j.bioorg.2021.105228" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105228%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPseudopeptides%252Bwith%252Baldehyde%252Bor%252Bvinylsulfone%252Bwarheads%25253A%252Bsynthesis%252Band%252Bantiproteasomal%252Bactivity%26aulast%3DJorda%26aufirst%3DRadek%26date%3D2021%26volume%3D3%26spage%3D105228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie Dominique  Ah Kioon</span>, <span class="hlFld-ContribAuthor ">Michael  Pierides</span>, <span class="hlFld-ContribAuthor ">Tania  Pannellini</span>, <span class="hlFld-ContribAuthor ">Gang  Lin</span>, <span class="hlFld-ContribAuthor ">Carl F.  Nathan</span>, <span class="hlFld-ContribAuthor ">Franck J.  Barrat</span>. </span><span class="cited-content_cbyCitation_article-title">Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2021,</strong> <em>206 </em>
                                    (7)
                                     , 1631-1641. <a href="https://doi.org/10.4049/jimmunol.2000951" title="DOI URL">https://doi.org/10.4049/jimmunol.2000951</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.2000951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.2000951%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DNoncytotoxic%252BInhibition%252Bof%252Bthe%252BImmunoproteasome%252BRegulates%252BHuman%252BImmune%252BCells%252BIn%252BVitro%252Band%252BSuppresses%252BCutaneous%252BInflammation%252Bin%252Bthe%252BMouse%26aulast%3DAh%2BKioon%26aufirst%3DMarie%2BDominique%26date%3D2021%26date%3D2021%26volume%3D206%26issue%3D7%26spage%3D1631%26epage%3D1641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of some reported immunoproteasome inhibitors. ONX0914 was previously named PR957.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Merck-Serono β5i-selective inhibitor 76, Ro19, and Roche compound 21 were reported in a patent review.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> HT2004, DPLG3, and PKS21221 were recently reported as β5i-selective inhibitors.<a onclick="showRef(event, 'ref35 ref36 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref38">(35,36,38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Illustration of <i>N</i>-cap, R<sub>2</sub>, R<sub>3</sub>, and <i>C</i>-cap and their binding sites in the β5 active subunits.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of β5i and β5c by select dipeptides. (A) Dose-dependent inhibition of β5i and β5c by compounds indicated in the <i>x</i>-axis. (B) <i>K</i><sub>i</sub> of PKS21265 was also determined with varying concentrations of PKS21265 and substrate suc-LLVY-AMC. The Lineweaver–Burk plot was shown on the left. The plot of slopes against the inhibitor concentration yields a <i>K</i><sub>i</sub> of 3.1 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In situ inhibition of i-20S β5i in Karpas-1106P and c-20S β5c in Hela cells and dose-dependent inhibition of T cell activation in peripheral blood mononuclear cells (PBMCs) stimulated by anti-CD3 antibody. All experiments were repeated three times. Representative results are shown and data are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Cap Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, HOBt, Hünig’s base; (b) 10% Pd on carbon, methanol, H<sub>2</sub> balloon, 98%; (c) <i>O</i>-benzylalanine hydrochloride, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), HOAt, Hünig’s base, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 59%; (d) 1-naphthylmethylamine, HATU, HOAt, Hünig’s base, DMF; (e) 20% trifluoroacetic acid (TFA) in dichloromethane (DCM); and (f) RCOOH, HATU, HOAt, Hünig’s base, DMF.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>C</i>-cap Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) 10% Pd on carbon, H<sub>2</sub> balloon, EtOH; (c) TFA, DCM; and (d) 3-phenylpropanoic acid, EDC, HOBt, Hünig’s base, DMF.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Various P2 (Methylserine) Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) TFA, DCM; (c) BOC-Asp(OBn)-OH, HATU, HOAt, Hünig’s base, DMF; (d) 3-phenylpropanoic acid, HATU, HOAt, Hünig’s base, DMF; (e) 10% Pd on carbon, methanol; (f) <i>O</i>-tert-butyl hydroxylamine, HATU, HOAt, Hünig’s base, DMF; (g) <i>tert</i>-butylamine or 3-aminooxetane, HATU, HOAt, Hünig’s base, DMF; (h) <i>tert</i>-butylamine, HATU, HOAt, Hünig’s base, DMF; and (i) 5-methylisoxazole-3-carboxylic acid, HATU, HOAt, Hünig’s base, DMF.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Various P3-P4 Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butylamine, EDC, HOBt, Hünig’s base; (b) TFA, DCM; (c) 3-phenylpropanoic acid, HATU, HOAt, Hünig’s base, DMF; (d) 10% Pd on carbon, methanol, hydrogen balloon; (e) triethylamine, DCM; and (f) HATU, HOAt, Hünig’s base, DMF.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Various P2-P3 Analogues with an <i>N</i>-cap 5-methylisoxazole-3-carboxamide</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HATU, HOAt, Hünig’s base, DMF; (b) TFA, DCM; and (c) 10% Pd on carbon, methanol, hydrogen balloon.</p></p></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/medium/jm0c01520_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds with <i>N</i>-Sulfonyl Cap</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01520/20201105/images/large/jm0c01520_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01520&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i108">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78306" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78306" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemuller, E.</span></span> <span> </span><span class="NLM_article-title">The proteasome: paradigm of a self-compartmentalizing protease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80929-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0092-8674%2800%2980929-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=9476896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK1cXhtFGisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=367-380&author=W.+Baumeisterauthor=J.+Walzauthor=F.+Zuhlauthor=E.+Seemuller&title=The+proteasome%3A+paradigm+of+a+self-compartmentalizing+protease&doi=10.1016%2FS0092-8674%2800%2980929-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: paradigm of a self-compartmentalizing protease</span></div><div class="casAuthors">Baumeister, Wolfgang; Walz, Jochen; Zuhl, Frank; Seemuller, Erika</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">367-380</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with ∼100 refs. on advances in understanding the structure of the proteasome and its mechanism of action which shaped the concept of self-compartmentalization and the proteasome became the paradigm of this form of regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tVahAhrt17Vg90H21EOLACvtfcHk0lhKBz-bmhBTWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtFGisLY%253D&md5=0a865caef4357214337a03025ba611d6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980929-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980929-0%26sid%3Dliteratum%253Aachs%26aulast%3DBaumeister%26aufirst%3DW.%26aulast%3DWalz%26aufirst%3DJ.%26aulast%3DZuhl%26aufirst%3DF.%26aulast%3DSeemuller%26aufirst%3DE.%26atitle%3DThe%2520proteasome%253A%2520paradigm%2520of%2520a%2520self-compartmentalizing%2520protease%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D367%26epage%3D380%26doi%3D10.1016%2FS0092-8674%2800%2980929-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1042/BST0350012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1042%2FBST0350012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=17212580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=12-17&author=A.+L.+Goldberg&title=Functions+of+the+proteasome%3A+from+protein+degradation+and+immune+surveillance+to+cancer+therapy&doi=10.1042%2FBST0350012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy</span></div><div class="casAuthors">Goldberg, A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-17</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Here, the author focuses on recent insights into the mechanisms and the biol. functions of the proteasome.  This large ATP-dependent proteolytic complex is the main site for protein degrdn. in mammalian cells and catalyzes the rapid degrdn. of ubiquitinated proteins, and is the source of most antigenic peptides used by the immune system to screen for viruses and cancer.  ATP is required to unfold globular proteins to open the gated channel into the 20S proteasome and to facilitate protein translation into it.  Inhibitors of its proteolytic activity are widely used as research tools and have proven effective in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopbyyvkotcZbVg90H21EOLACvtfcHk0lhKBz-bmhBTWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Ohtrg%253D&md5=5d5ad04a404f4d7e39f2bee7943afe17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1042%2FBST0350012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350012%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DFunctions%2520of%2520the%2520proteasome%253A%2520from%2520protein%2520degradation%2520and%2520immune%2520surveillance%2520to%2520cancer%2520therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D12%26epage%3D17%26doi%3D10.1042%2FBST0350012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(94)90462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0092-8674%2894%2990462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=8087844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=761-771&author=K.+L.+Rockauthor=C.+Grammauthor=L.+Rothsteinauthor=K.+Clarkauthor=R.+Steinauthor=L.+Dickauthor=D.+Hwangauthor=A.+L.+Goldberg&title=Inhibitors+of+the+proteasome+block+the+degradation+of+most+cell+proteins+and+the+generation+of+peptides+presented+on+MHC+class+I+molecules&doi=10.1016%2FS0092-8674%2894%2990462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules</span></div><div class="casAuthors">Rock, Kenneth L.; Gramm, Colette; Rothstein, Lisa; Clark, Karen; Stein, Ross; Dick, Lawrence; Hwang, Daniel; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">761-71</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Reagents that inhibit the ubiquitin-proteasome proteolytic pathway in cells have not been available.  Peptide aldehydes that inhibit major peptidase activities of the 20S and 26S proteasomes are shown to reduce the degrdn. of protein and ubiquitinated protein substrates by 26S particles.  Unlike inhibitors of lysosomal proteolysis, these compds. inhibit the degrdn. of not only abnormal and short-lived polypeptides but also long-lived proteins in intact cells.  The authors used these agents to test the importance of the proteasome in antigen presentation.  When ovalbumin is introduced into the cytosol of lymphoblasts, these inhibitors block the presentation on MHC class I mols. of an ovalbumin-derived peptide by preventing its proteolytic generation.  By preventing peptide prodn. from cell proteins, these inhibitors block the assembly of class I mols.  Therefore, the proteasome catalyzes the degrdn. of the vast majority of cell proteins and generates most peptides presented on MHC class I mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVw5InxABShLVg90H21EOLACvtfcHk0lhKBz-bmhBTWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtVarsb8%253D&md5=2960e350aedb5a0d9e04d672f96f9c4f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2894%2990462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252894%252990462-6%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DGramm%26aufirst%3DC.%26aulast%3DRothstein%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DInhibitors%2520of%2520the%2520proteasome%2520block%2520the%2520degradation%2520of%2520most%2520cell%2520proteins%2520and%2520the%2520generation%2520of%2520peptides%2520presented%2520on%2520MHC%2520class%2520I%2520molecules%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D761%26epage%3D771%26doi%3D10.1016%2FS0092-8674%2894%2990462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liepe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloetzel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishto, M.</span></span> <span> </span><span class="NLM_article-title">A large fraction of HLA class I ligands are proteasome-generated spliced peptides</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1126/science.aaf4384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1126%2Fscience.aaf4384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27846572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yltLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2016&pages=354-358&author=J.+Liepeauthor=F.+Marinoauthor=J.+Sidneyauthor=A.+Jekoauthor=D.+E.+Buntingauthor=A.+Setteauthor=P.+M.+Kloetzelauthor=M.+P.+Stumpfauthor=A.+J.+Heckauthor=M.+Mishto&title=A+large+fraction+of+HLA+class+I+ligands+are+proteasome-generated+spliced+peptides&doi=10.1126%2Fscience.aaf4384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A large fraction of HLA class I ligands are proteasome-generated spliced peptides</span></div><div class="casAuthors">Liepe, Juliane; Marino, Fabio; Sidney, John; Jeko, Anita; Bunting, Daniel E.; Sette, Alessandro; Kloetzel, Peter M.; Stumpf, Michael P. H.; Heck, Albert J. R.; Mishto, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6310</span>),
    <span class="NLM_cas:pages">354-358</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I mols. that elicit CD8+ T cell responses.  Reports of proteasome-generated spliced epitopes exist, but they have been regarded as rare events.  Here, however, we show that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance.  This pool also represents a unique set of antigens, possessing particular and distinguishing features.  We validated this observation using a range of complementary exptl. and bioinformatics approaches, as well as multiple cell types.  The widespread appearance and abundance of proteasome-catalyzed peptide splicing events has implications for immunobiol. and autoimmunity theories and may provide a previously untapped source of epitopes for use in vaccines and cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUQ5L5VkfSvrVg90H21EOLACvtfcHk0ljQ_GT62CAobw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yltLbF&md5=7c8f7a4d50e43b853488223678bc46ed</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf4384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf4384%26sid%3Dliteratum%253Aachs%26aulast%3DLiepe%26aufirst%3DJ.%26aulast%3DMarino%26aufirst%3DF.%26aulast%3DSidney%26aufirst%3DJ.%26aulast%3DJeko%26aufirst%3DA.%26aulast%3DBunting%26aufirst%3DD.%2BE.%26aulast%3DSette%26aufirst%3DA.%26aulast%3DKloetzel%26aufirst%3DP.%2BM.%26aulast%3DStumpf%26aufirst%3DM.%2BP.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DMishto%26aufirst%3DM.%26atitle%3DA%2520large%2520fraction%2520of%2520HLA%2520class%2520I%2520ligands%2520are%2520proteasome-generated%2520spliced%2520peptides%26jtitle%3DScience%26date%3D2016%26volume%3D354%26spage%3D354%26epage%3D358%26doi%3D10.1126%2Fscience.aaf4384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rock, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">York, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saric, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span> <span> </span><span class="NLM_article-title">Protein degradation and the generation of MHC class I-presented peptides</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0065-2776(02)80012-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2FS0065-2776%2802%2980012-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=12078479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD38Xoslehurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=1-70&author=K.+L.+Rockauthor=I.+A.+Yorkauthor=T.+Saricauthor=A.+L.+Goldberg&title=Protein+degradation+and+the+generation+of+MHC+class+I-presented+peptides&doi=10.1016%2FS0065-2776%2802%2980012-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein degradation and the generation of MHC class I-presented peptides</span></div><div class="casAuthors">Rock, Kenneth L.; York, Ian A.; Saric, Tomo; Goldberg, Alfred L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-70</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the past decade there has been considerable progress in understanding how MHC class I-presented peptides are generated.  The emerging theme is that the immune system has not evolved its own specialized proteolytic mechanisms but instead utilizes the phylogenetically ancient catabolic pathways that continually turnover proteins in all cells.  Three distinct proteolytic steps have now been defined in MHC class I antigen presentation.  The first step is the degrdn. of proteins by the ubiquitin-proteasome pathway into oligopeptides that either are of the correct size for presentation or are extended on their amino-termini.  In the second step, aminopeptidases trim N-extended precursors into peptides of the correct length to be presented on class I mols.  The third step involves the destruction of peptides by endo- and exopeptidases, which limits antigen presentation, but is important for preventing the accumulation of peptides and recycling them back to amino acids for protein synthesis or prodn. of energy.  The immune system has evolved several components that modify the activity of these ancient pathways in ways that enhance the generation of class I-presented peptides.  These include catalytically active subunits of the proteasome, the PA28 proteasome activator, and leucine aminopeptidase, all of which are upregulated by interferon-γ.  In addn. to these pathways that operate in all cells, dendritic cells and macrophages can also generate class I-presented peptides from proteins internalized from the extracellular fluids by degrading them in endocytic compartments or transferring them to the cytosol for degrdn. by proteasomes.  (c) 2002 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5a3DymenFa7Vg90H21EOLACvtfcHk0ljQ_GT62CAobw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xoslehurw%253D&md5=430e7b1e7fd6d4db80e51658895e0f7a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2802%2980012-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252802%252980012-8%26sid%3Dliteratum%253Aachs%26aulast%3DRock%26aufirst%3DK.%2BL.%26aulast%3DYork%26aufirst%3DI.%2BA.%26aulast%3DSaric%26aufirst%3DT.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26atitle%3DProtein%2520degradation%2520and%2520the%2520generation%2520of%2520MHC%2520class%2520I-presented%2520peptides%26jtitle%3DAdv.%2520Immunol.%26date%3D2002%26volume%3D80%26spage%3D1%26epage%3D70%26doi%3D10.1016%2FS0065-2776%2802%2980012-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maseda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalden, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voll, R. E.</span></span> <span> </span><span class="NLM_article-title">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1038/nm1763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnm1763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=18542049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=748-755&author=K.+Neubertauthor=S.+Meisterauthor=K.+Moserauthor=F.+Weiselauthor=D.+Masedaauthor=K.+Amannauthor=C.+Wietheauthor=T.+H.+Winklerauthor=J.+R.+Kaldenauthor=R.+A.+Manzauthor=R.+E.+Voll&title=The+proteasome+inhibitor+bortezomib+depletes+plasma+cells+and+protects+mice+with+lupus-like+disease+from+nephritis&doi=10.1038%2Fnm1763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</span></div><div class="casAuthors">Neubert, Kirsten; Meister, Silke; Moser, Katrin; Weisel, Florian; Maseda, Damian; Amann, Kerstin; Wiethe, Carsten; Winkler, Thomas H.; Kalden, Joachim R.; Manz, Rudolf A.; Voll, Reinhard E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">748-755</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bortezomib, a drug useful for the treatment of multiple myeloma, reduces kidney damage in animal models of lupus.  Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge.  In particular, long-lived plasma cells producing autoantibodies resist current therapeutic and exptl. approaches.  Recently, we showed that the sensitivity of myeloma cells toward proteasome inhibitors directly correlates with their Ig synthesis rates.  Therefore, we hypothesized that normal plasma cells are also hypersensitive to proteasome inhibition owing to their extremely high amt. of protein biosynthesis.  Here we show that the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma, eliminates both short- and long-lived plasma cells by activation of the terminal unfolded protein response.  Treatment with bortezomib depleted plasma cells producing antibodies to double-stranded DNA, eliminated autoantibody prodn., ameliorated glomerulonephritis and prolonged survival of two mouse strains with lupus-like disease, NZB/W F1 and MRL/lpr mice.  Hence, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZtv5EvAwSRLVg90H21EOLACvtfcHk0lgPnqgmmT1uTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotF2lurw%253D&md5=a53d9cfc5690c95b1454a50b40a0bdb7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm1763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1763%26sid%3Dliteratum%253Aachs%26aulast%3DNeubert%26aufirst%3DK.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DMoser%26aufirst%3DK.%26aulast%3DWeisel%26aufirst%3DF.%26aulast%3DMaseda%26aufirst%3DD.%26aulast%3DAmann%26aufirst%3DK.%26aulast%3DWiethe%26aufirst%3DC.%26aulast%3DWinkler%26aufirst%3DT.%2BH.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DManz%26aufirst%3DR.%2BA.%26aulast%3DVoll%26aufirst%3DR.%2BE.%26atitle%3DThe%2520proteasome%2520inhibitor%2520bortezomib%2520depletes%2520plasma%2520cells%2520and%2520protects%2520mice%2520with%2520lupus-like%2520disease%2520from%2520nephritis%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D748%26epage%3D755%26doi%3D10.1038%2Fnm1763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureshkumar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasnosz, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, N. L.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation</span>. <i>Clin. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.5414/CN107156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.5414%2FCN107156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=22377258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVeisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=246-253&author=K.+K.+Sureshkumarauthor=S.+M.+Hussainauthor=R.+J.+Marcusauthor=T.+Y.+Koauthor=A.+S.+Khanauthor=K.+Tomauthor=C.+A.+Vivasauthor=G.+Parrisauthor=K.+M.+Jasnoszauthor=N.+L.+Thai&title=Proteasome+inhibition+with+bortezomib%3A+an+effective+therapy+for+severe+antibody+mediated+rejection+after+renal+transplantation&doi=10.5414%2FCN107156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation</span></div><div class="casAuthors">Sureshkumar, Kalathil K.; Hussain, Sabiha M.; Marcus, Richard J.; Ko, Tina Y.; Khan, Akhtar S.; Tom, Kusum; Vivas, Carlos A.; Parris, George; Jasnosz, Katherine M.; Thai, Ngoc L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-253</span>CODEN:
                <span class="NLM_cas:coden">CLNHBI</span>;
        ISSN:<span class="NLM_cas:issn">0301-0430</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Antibody-mediated rejection (AMR) following renal transplantation is less responsive to conventional anti-rejection therapies.  Plasmapheresis (PP), i.v. Ig, rabbit antithymocyte globulin (rATG) and rituximab deplete immature B-cells but not mature plasma cells.  The proteasome inhibitor bortezomib has activity against mature plasma cell, the source of damaging donor-specific antibody (DSA).  We present the successful use of bortezomib in 2 patients who developed AMR following kidney transplantation.  The first patient was a 54-yr-old white female who received living-unrelated kidney transplantation from her husband.  She developed severe AMR early after transplantation with rising DSA titers consistent with an anamnestic immune response by memory cells to the donor antigens.  Renal function deteriorated despite treatment with pulse methylprednisolone (MP), PP and IVIg.  After initiation of therapy with bortezomib, DSA titers became neg. and serum creatinine returned to baseline with histol. resoln. of AMR.  The second patient was a 19-yr-old white male who received deceased donor kidney transplantation and developed AMR within 2 wk, refractory to therapy with pulse MP, PP and IVIg with rising DSA.  Bortezomib use resulted in disappearance of DSA and renal function improvement.  Both patients tolerated the treatment well with stable renal function at last follow-up.  The novel mechanisms of action and preliminary results with bortezomib are encouraging, but require larger studies and longer follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk_7LDS313fLVg90H21EOLACvtfcHk0lgPnqgmmT1uTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVeisrc%253D&md5=dcd5db37a70913cf21f3a76dcadf95e5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.5414%2FCN107156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCN107156%26sid%3Dliteratum%253Aachs%26aulast%3DSureshkumar%26aufirst%3DK.%2BK.%26aulast%3DHussain%26aufirst%3DS.%2BM.%26aulast%3DMarcus%26aufirst%3DR.%2BJ.%26aulast%3DKo%26aufirst%3DT.%2BY.%26aulast%3DKhan%26aufirst%3DA.%2BS.%26aulast%3DTom%26aufirst%3DK.%26aulast%3DVivas%26aufirst%3DC.%2BA.%26aulast%3DParris%26aufirst%3DG.%26aulast%3DJasnosz%26aufirst%3DK.%2BM.%26aulast%3DThai%26aufirst%3DN.%2BL.%26atitle%3DProteasome%2520inhibition%2520with%2520bortezomib%253A%2520an%2520effective%2520therapy%2520for%2520severe%2520antibody%2520mediated%2520rejection%2520after%2520renal%2520transplantation%26jtitle%3DClin.%2520Nephrol.%26date%3D2012%26volume%3D77%26spage%3D246%26epage%3D253%26doi%3D10.5414%2FCN107156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno
Gonzales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinstock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braaten, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegall, M. D.</span></span> <span> </span><span class="NLM_article-title">32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1097/TP.0000000000001330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1097%2FTP.0000000000001330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27379560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1yntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=1222-1227&author=M.+A.+Moreno%0AGonzalesauthor=M.+J.+Gandhiauthor=C.+A.+Schinstockauthor=N.+A.+Mooreauthor=B.+H.+Smithauthor=N.+Y.+Braatenauthor=M.+D.+Stegall&title=32+Doses+of+Bortezomib+for+Desensitization+Is+Not+Well+Tolerated+and+Is+Associated+With+Only+Modest+Reductions+in+Anti-HLA+Antibody&doi=10.1097%2FTP.0000000000001330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody</span></div><div class="casAuthors">Moreno Gonzales, Manuel A.; Gandhi, Manish J.; Schinstock, Carrie A.; Moore, Natalie A.; Smith, Byron H.; Braaten, Nong Y.; Stegall, Mark D.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1222-1227</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given.  This study aimed to det. the safety and efficacy of 32 doses of BTZ (1.3 mg/m2 of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor.  Dose redn. was needed in 2 patients and 2 others completely discontinued therapy for adverse events.  Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P < 0.01).  No patient developed a neg. crossmatch against their original intended donor, and the calcd. panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged in all patients.  These data suggest that 32 doses of BTZ monotherapy was not well tolerated and resulted in only a modest redn. in anti-HLA antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWRQUuDccBz7Vg90H21EOLACvtfcHk0ljzA2aSKMIpLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1yntbc%253D&md5=74e2dfdf735eb550a0e37d3099ad9d3d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FTP.0000000000001330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FTP.0000000000001330%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%2BGonzales%26aufirst%3DM.%2BA.%26aulast%3DGandhi%26aufirst%3DM.%2BJ.%26aulast%3DSchinstock%26aufirst%3DC.%2BA.%26aulast%3DMoore%26aufirst%3DN.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DBraaten%26aufirst%3DN.%2BY.%26aulast%3DStegall%26aufirst%3DM.%2BD.%26atitle%3D32%2520Doses%2520of%2520Bortezomib%2520for%2520Desensitization%2520Is%2520Not%2520Well%2520Tolerated%2520and%2520Is%2520Associated%2520With%2520Only%2520Modest%2520Reductions%2520in%2520Anti-HLA%2520Antibody%26jtitle%3DTransplantation%26date%3D2017%26volume%3D101%26spage%3D1222%26epage%3D1227%26doi%3D10.1097%2FTP.0000000000001330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Fellutamide B is a potent inhibitor of the <i>Mycobacterium tuberculosis</i> proteasome</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2010.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.abb.2010.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20558127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2itbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2010&pages=214-220&author=G.+Linauthor=D.+Liauthor=T.+Chidawanyikaauthor=C.+Nathanauthor=H.+Li&title=Fellutamide+B+is+a+potent+inhibitor+of+the+Mycobacterium+tuberculosis+proteasome&doi=10.1016%2Fj.abb.2010.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome</span></div><div class="casAuthors">Lin, Gang; Li, Dongyang; Chidawanyika, Tamutenda; Nathan, Carl; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Via high-throughput screening of a natural compd. library, we have identified a lipopeptide aldehyde, fellutamide B (1), as the most potent inhibitor of the Mycobacterium tuberculosis (Mtb) proteasome tested to date.  Kinetic studies reveal that 1 inhibits both Mtb and human proteasomes in a time-dependent manner under steady-state condition.  Remarkably, 1 inhibits the Mtb proteasome in a single-step binding mechanism with Ki = 6.8 nM, whereas it inhibits the human proteasome β5 active site following a two-step mechanism with Ki = 11.5 nM and Ki* = 0.93 nM.  Co-crystn. of 1 bound to the Mtb proteasome revealed a structural basis for the tight binding of 1 to the active sites of the Mtb proteasome.  The hemiacetal group of 1 in the Mtb proteasome takes the (R)-configuration, whereas in the yeast proteasome it takes the (S)-configuration, indicating that the pre-chiral CHO group of 1 binds to the active site Thr1 in a different orientation.  Re-examn. of the structure of the yeast proteasome in complex with 1 showed significant conformational changes at the substrate-binding cleft along the active site.  These structural differences are consistent with the different kinetic mechanisms of 1 against Mtb and human proteasomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql8lEWt6GLO7Vg90H21EOLACvtfcHk0ljzA2aSKMIpLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2itbzK&md5=fe2731ea82db52eb6f34beb6b0c708e1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2010.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2010.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DFellutamide%2520B%2520is%2520a%2520potent%2520inhibitor%2520of%2520the%2520Mycobacterium%2520tuberculosis%2520proteasome%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2010%26volume%3D501%26spage%3D214%26epage%3D220%26doi%3D10.1016%2Fj.abb.2010.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the <i>Mycobacterium tuberculosis</i> Proteasome</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.6b01107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b01107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyjtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=324-333&author=H.+C.+Hsuauthor=P.+K.+Singhauthor=H.+Fanauthor=R.+Wangauthor=G.+Sukenickauthor=C.+Nathanauthor=G.+Linauthor=H.+Li&title=Structural+Basis+for+the+Species-Selective+Binding+of+N%2CC-Capped+Dipeptides+to+the+Mycobacterium+tuberculosis+Proteasome&doi=10.1021%2Facs.biochem.6b01107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome</span></div><div class="casAuthors">Hsu, Hao-Chi; Singh, Pradeep K.; Fan, Hao; Wang, Rong; Sukenick, George; Nathan, Carl; Lin, Gang; Li, Huilin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis (Mtb) 20S proteasome is vital for the pathogen to survive under nitrosative stress in vitro and to persist in mice.  To qualify for drug development, inhibitors targeting Mtb 20S must spare both the human constitutive proteasome (c-20S) and immunoproteasome (i-20S).  We recently reported members of a family of noncovalently binding dipeptide proteasome inhibitors that are highly potent and selective for Mtb 20S over human c-20S and i-20S.  To understand the structural basis of their potency and selectivity, we have studied the structure-activity relationship of six derivs. and solved their co-crystal structures with Mtb 20S.  The dipeptide inhibitors form an antiparallel β-strand with the active site β-strands.  Selectivity is conferred by several features of Mtb 20S relative to its mouse counterparts, including a larger S1 pocket, addnl. hydrogen bonds in the S3 pocket, and hydrophobic interactions in the S4 pocket.  Serine-20 and glutamine-22 of Mtb 20S interact with the dipeptides and confer Mtb-specific inhibition over c-20S and i-20S.  The Mtb 20S and mammalian i-20S have a serine-27 that interacts strongly with the dipeptides, potentially explaining the higher inhibitory activity of the dipeptides toward i-20S over c-20S.  This detailed structural knowledge will aid in optimizing the dipeptides as anti-tuberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7znxPof1C7Vg90H21EOLACvtfcHk0li4F9o-I9UsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyjtr7K&md5=9c8a31bd018432aac4b5d36037c01c82</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b01107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b01107%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DH.%2BC.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DNathan%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Species-Selective%2520Binding%2520of%2520N%252CC-Capped%2520Dipeptides%2520to%2520the%2520Mycobacterium%2520tuberculosis%2520Proteasome%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D324%26epage%3D333%26doi%3D10.1021%2Facs.biochem.6b01107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Distinct specificities of <i>Mycobacterium tuberculosis</i> and mammalian proteasomes for N-acetyl tripeptide substrates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">34423</span>– <span class="NLM_lpage">34431</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805324200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1074%2Fjbc.M805324200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=18829465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=34423-34431&author=G.+Linauthor=C.+Tsuauthor=L.+Dickauthor=X.+K.+Zhouauthor=C.+Nathan&title=Distinct+specificities+of+Mycobacterium+tuberculosis+and+mammalian+proteasomes+for+N-acetyl+tripeptide+substrates&doi=10.1074%2Fjbc.M805324200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates</span></div><div class="casAuthors">Lin, Gang; Tsu, Christopher; Dick, Lawrence; Zhou, Xi K.; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">34423-34431</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics.  To lay ground-work for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we used a library of 5920 N-acetyl tripeptide-aminomethylcoumarins to contrast the substrate preferences of the recombinant Mtb proteasome wild type and open gate mutant, the Rhodococcus erythropolis proteasome, and the bovine proteasome with activator PA28.  The Mtb proteasome was distinctive in strictly preferring P1 = tryptophan, particularly in combination with P3 = glycine, proline, lysine or arginine.  Screening results were validated with Michaelis-Menten kinetic analyses of 21 oligopeptide aminomethyl-coumarin substrates.  Bortezomib, a proteasome inhibitor in clin. use, and 17 analogs varying only at P1 were used to examine the differential impact of inhibitors on human and Mtb proteasomes.  The results with the inhibitor panel confirmed those with the substrate panel in demonstrating differential preferences of Mtb and mammalian proteasomes at the P1 amino acid.  Changing P1 in bortezomib from Leu to m-CF3-Phe led to a 220-fold increase in IC50 against the human proteasome, whereas changing a P1 Ala to m-F-Phe decreased the IC50 400-fold against the Mtb proteasome.  The change of a P1 Ala to m-Cl-Phe led to an 8000-fold shift in inhibitory potency in favor of the Mtb proteasome, resulting in 8-fold selectivity.  Combinations of preferred amino acids at different sites may thus improve the species selectivity of peptide-based inhibitors that target the Mtb proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpCPunOb8tLVg90H21EOLACvtfcHk0li4F9o-I9UsRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP&md5=6f73b15a893fe094894ca3916882d834</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805324200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805324200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DDistinct%2520specificities%2520of%2520Mycobacterium%2520tuberculosis%2520and%2520mammalian%2520proteasomes%2520for%2520N-acetyl%2520tripeptide%2520substrates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D34423%26epage%3D34431%26doi%3D10.1074%2Fjbc.M805324200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Carvalho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Inhibitors selective for mycobacterial versus human proteasomes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>461</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nature08357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature08357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=19759536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFentLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=2009&pages=621-626&author=G.+Linauthor=D.+Liauthor=L.+P.+de+Carvalhoauthor=H.+Dengauthor=H.+Taoauthor=G.+Vogtauthor=K.+Wuauthor=J.+Schneiderauthor=T.+Chidawanyikaauthor=J.+D.+Warrenauthor=H.+Liauthor=C.+Nathan&title=Inhibitors+selective+for+mycobacterial+versus+human+proteasomes&doi=10.1038%2Fnature08357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors selective for mycobacterial versus human proteasomes</span></div><div class="casAuthors">Lin, Gang; Li, Dongyang; Sorio de Carvalho, Luiz Pedro; Deng, Haiteng; Tao, Hui; Vogt, Guillaume; Wu, Kangyun; Schneider, Jean; Chidawanyika, Tamutenda; Warren, J. David; Li, Huilin; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">461</span>
        (<span class="NLM_cas:issue">7264</span>),
    <span class="NLM_cas:pages">621-626</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many anti-infectives inhibit the synthesis of bacterial proteins, but none selectively inhibits their degrdn.  Most anti-infectives kill replicating pathogens, but few preferentially kill pathogens that have been forced into a non-replicating state by conditions in the host.  To explore these alternative approaches we sought selective inhibitors of the proteasome of Mycobacterium tuberculosis.  Given that the proteasome structure is extensively conserved, it is not surprising that inhibitors of all chem. classes tested have blocked both eukaryotic and prokaryotic proteasomes, and no inhibitor has proved substantially more potent on proteasomes of pathogens than of their hosts.  Here we show that certain oxathiazol-2-one compds. kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the M. tuberculosis proteasome by cyclocarbonylating its active site threonine.  Major conformational changes protect the inhibitor-enzyme intermediate from hydrolysis, allowing formation of an oxazolidin-2-one and preventing regeneration of active protease.  Residues outside the active site whose hydrogen bonds stabilize the crit. loop before and after it moves are extensively non-conserved.  This may account for the ability of oxathiazol-2-one compds. to inhibit the mycobacterial proteasome potently and irreversibly while largely sparing the human homolog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsldeXrXgYGbVg90H21EOLACvtfcHk0lh11ZkaPZjFGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFentLjK&md5=fb55708e5d5b073dcafbe95e3f8a625b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature08357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08357%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DD.%26aulast%3Dde%2BCarvalho%26aufirst%3DL.%2BP.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DVogt%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DInhibitors%2520selective%2520for%2520mycobacterial%2520versus%2520human%2520proteasomes%26jtitle%3DNature%26date%3D2009%26volume%3D461%26spage%3D621%26epage%3D626%26doi%3D10.1038%2Fnature08357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okoro, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scales, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B. F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Improvement of asparagine ethylenediamines as anti-malarial <i>Plasmodium</i>-selective proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6137</span>– <span class="NLM_lpage">6145</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6137-6145&author=W.+Zhanauthor=J.+Visoneauthor=T.+Ouelletteauthor=J.+C.+Harrisauthor=R.+Wangauthor=H.+Zhangauthor=P.+K.+Singhauthor=J.+Ginnauthor=G.+Sukenickauthor=T.+T.+Wongauthor=J.+I.+Okoroauthor=R.+M.+Scalesauthor=P.+K.+Tumwebazeauthor=P.+J.+Rosenthalauthor=B.+F.+C.+Kafsackauthor=R.+A.+Cooperauthor=P.+T.+Meinkeauthor=L.+A.+Kirkmanauthor=G.+Lin&title=Improvement+of+asparagine+ethylenediamines+as+anti-malarial+Plasmodium-selective+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.9b00363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Visone, Joseph; Ouellette, Tierra; Harris, Jacob C.; Wang, Rong; Zhang, Hao; Singh, Pradeep K.; Ginn, John; Sukenick, George; Wong, Tzu-Tshin; Okoro, Judith I.; Scales, Ryan M.; Tumwebaze, Patrick K.; Rosenthal, Philip J.; Kafsack, Bjorn F. C.; Cooper, Roland A.; Meinke, Peter T.; Kirkman, Laura A.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6137-6145</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome (Pf20S) emerged as a target for antimalarials.  Pf20S inhibitors are active at multiple stages of the parasite life cycle and synergize with artemisinins, suggesting that Pf20S inhibitors have potential to be prophylactic, therapeutic, transmission blocking as well as useful for combination therapy.  The authors recently reported asparagine ethylenediamines (AsnEDAs) as immunoproteasome inhibitors and modified AsnEDAs as selective Pf20S inhibitors.  Here the authors report further structure-activity relation study of AsnEDAs for selective inhibition of Pf20S over human proteasomes.  Addnl., the authors show a new mutation that conferred resistance to AsnEDAs and collateral sensitivity to an inhibitor of the Pf20S β2 subunit, same as previously identified resistant mutation.  This resistance could be overcome through the use of structure-guided inhibitor design.  Collateral sensitivity to inhibitors among resp. proteasome subunits underscores the potential value of treating malaria with combinations of inhibitors of different proteasome subunits to minimize the emergence of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraItFIzHCwYbVg90H21EOLACvtfcHk0lgc9wqBULHgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaqs7bO&md5=0c0f91850372915ba7cb254e8892feed</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00363%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DOuellette%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DGinn%26aufirst%3DJ.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DT.%2BT.%26aulast%3DOkoro%26aufirst%3DJ.%2BI.%26aulast%3DScales%26aufirst%3DR.%2BM.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DKafsack%26aufirst%3DB.%2BF.%2BC.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DImprovement%2520of%2520asparagine%2520ethylenediamines%2520as%2520anti-malarial%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6137%26epage%3D6145%26doi%3D10.1021%2Facs.jmedchem.9b00363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Defining the determinants of specificity of <i>Plasmodium</i> proteasome inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">11424</span>– <span class="NLM_lpage">11437</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b06656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b06656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=11424-11437&author=E.+Yooauthor=B.+H.+Stokesauthor=H.+de+Jongauthor=M.+Vanaerschotauthor=T.+Kumarauthor=N.+Lawrenceauthor=M.+Njorogeauthor=A.+Garciaauthor=R.+Van+der+Westhuyzenauthor=J.+D.+Momperauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=M.+Bogyo&title=Defining+the+determinants+of+specificity+of+Plasmodium+proteasome+inhibitors&doi=10.1021%2Fjacs.8b06656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors</span></div><div class="casAuthors">Yoo, Euna; Stokes, Barbara H.; de Jong, Hanna; Vanaerschot, Manu; Kumar, T. R. S.; Lawrence, Nina; Njoroge, Mathew; Garcia, Arnold; Van der Westhuyzen, Renier; Momper, Jeremiah D.; Ng, Caroline L.; Fidock, David A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11424-11437</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome is an emerging antimalarial target due to its essential role in all the major life cycle stages of the parasite and its contribution to the establishment of resistance to artemisinin (ART)-based therapies.  However, because of a similarly essential role for the host proteasome, the key property of any antiproteasome therapeutic is selectivity.  Several parasite-specific proteasome inhibitors have recently been reported, however, their selectivity must be improved to enable clin. development.  Here we describe screening of diverse libraries of non-natural synthetic fluorogenic substrates to identify determinants at multiple positions on the substrate that produce enhanced selectivity.  We find that selection of an optimal electrophilic "warhead" is essential to enable high selectivity that is driven by the peptide binding elements on the inhibitor.  We also find that host cell toxicity is dictated by the extent of coinhibition of the human β2 and β5 subunits.  Using this information, we identify compds. with over 3 orders of magnitude selectivity for the parasite enzyme.  Optimization of the pharmacol. properties resulted in mols. that retained high potency and selectivity, were sol., sufficiently metabolically stable and orally bioavailable.  These mols. are highly synergistic with ART and can clear parasites in a mouse model of infection, making them promising leads as antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXchyqonWDrVg90H21EOLACvtfcHk0lgc9wqBULHgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN&md5=990e0b5097087ff76681f901b2c8f35f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b06656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b06656%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3Dde%2BJong%26aufirst%3DH.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DT.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DVan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DMomper%26aufirst%3DJ.%2BD.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DDefining%2520the%2520determinants%2520of%2520specificity%2520of%2520Plasmodium%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D11424%26epage%3D11437%26doi%3D10.1021%2Fjacs.8b06656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedziech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzual, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindasamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendome, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doggett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6863</span>– <span class="NLM_lpage">E6870</span>, <span class="refDoi"> DOI: 10.1073/pnas.1806109115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1806109115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=29967165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6863-E6870&author=L.+A.+Kirkmanauthor=W.+Zhanauthor=J.+Visoneauthor=A.+Dziedziechauthor=P.+K.+Singhauthor=H.+Fanauthor=X.+Tongauthor=I.+Bruzualauthor=R.+Haraauthor=M.+Kawasakiauthor=T.+Imaedaauthor=R.+Okamotoauthor=K.+Satoauthor=M.+Michinoauthor=E.+F.+Alvaroauthor=L.+F.+Guiangauthor=L.+Sanzauthor=D.+J.+Motaauthor=K.+Govindasamyauthor=R.+Wangauthor=Y.+Lingauthor=P.+K.+Tumwebazeauthor=G.+Sukenickauthor=L.+Shiauthor=J.+Vendomeauthor=P.+Bhanotauthor=P.+J.+Rosenthalauthor=K.+Asoauthor=M.+A.+Foleyauthor=R.+A.+Cooperauthor=B.+Kafsackauthor=J.+S.+Doggettauthor=C.+F.+Nathanauthor=G.+Lin&title=Antimalarial+proteasome+inhibitor+reveals+collateral+sensitivity+from+intersubunit+interactions+and+fitness+cost+of+resistance&doi=10.1073%2Fpnas.1806109115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span></div><div class="casAuthors">Kirkman, Laura A.; Zhan, Wenhu; Visone, Joseph; Dziedziech, Alexis; Singh, Pradeep K.; Fan, Hao; Tong, Xinran; Bruzual, Igor; Hara, Ryoma; Kawasaki, Masanori; Imaeda, Toshihiro; Okamoto, Rei; Sato, Kenjiro; Michino, Mayako; Alvaro, Elena Fernandez; Guiang, Liselle F.; Sanz, Laura; Mota, Daniel J.; Govindasamy, Kavitha; Wang, Rong; Ling, Yan; Tumwebaze, Patrick K.; Sukenick, George; Shi, Lei; Vendome, Jeremie; Bhanot, Purnima; Rosenthal, Philip J.; Aso, Kazuyoshi; Foley, Michael A.; Cooper, Roland A.; Kafsack, Bjorn; Doggett, J. Stone; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">E6863-E6870</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe noncovalent, reversible asparagine ethylenediamine (AsnEDA) inhibitors of the Plasmodium falciparum proteasome (Pf20S) β5 subunit that spare all active subunits of human constitutive and immuno-proteasomes.  The compds. are active against erythrocytic, sexual, and liver-stage parasites, against parasites resistant to current antimalarials, and against P. falciparum strains from patients in Africa.  The β5 inhibitors synergize with a β2 inhibitor in vitro and in mice and with artemisinin.  P. falciparum selected for resistance to an AsnEDA β5 inhibitor surprisingly harbored a point mutation in the noncatalytic β6 subunit.  The β6 mutant was resistant to the species-selective Pf20S β5 inhibitor but remained sensitive to the species-nonselective β5 inhibitors bortezomib and carfilzomib.  Moreover, resistance to the Pf20S β5 inhibitor was accompanied by increased sensitivity to a Pf20S β2 inhibitor.  Finally, the β5 inhibitor-resistant mutant had a fitness cost that was exacerbated by irradn.  Thus, used in combination, multistage-active inhibitors of the Pf20S β5 and β2 subunits afford synergistic antimalarial activity with a potential to delay the emergence of resistance to artemisinins and each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBMtrslCvE7Vg90H21EOLACvtfcHk0liWK7PskPnhEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ&md5=6addacc779527c9e4c6a265868f088fe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806109115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806109115%26sid%3Dliteratum%253Aachs%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DDziedziech%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBruzual%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DAlvaro%26aufirst%3DE.%2BF.%26aulast%3DGuiang%26aufirst%3DL.%2BF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMota%26aufirst%3DD.%2BJ.%26aulast%3DGovindasamy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DVendome%26aufirst%3DJ.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DKafsack%26aufirst%3DB.%26aulast%3DDoggett%26aufirst%3DJ.%2BS.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DAntimalarial%2520proteasome%2520inhibitor%2520reveals%2520collateral%2520sensitivity%2520from%2520intersubunit%2520interactions%2520and%2520fitness%2520cost%2520of%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE6863%26epage%3DE6870%26doi%3D10.1073%2Fpnas.1806109115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure- and function-based design of <i>Plasmodium</i>-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+J.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+da+Fonsecaauthor=M.+Bogyo&title=Structure-+and+function-based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0liWK7PskPnhEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure-%2520and%2520function-based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeacock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata-Cantero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuhs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna Gaza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9323</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820175116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1820175116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=30962368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=9318-9323&author=S.+Wyllieauthor=S.+Brandauthor=M.+Thomasauthor=M.+De+Ryckerauthor=C.+W.+Chungauthor=I.+Penaauthor=R.+P.+Binghamauthor=J.+A.+Bueren-Calabuigauthor=J.+Cantizaniauthor=D.+Cebrianauthor=P.+D.+Craggsauthor=L.+Fergusonauthor=P.+Goswamiauthor=J.+Hobrathauthor=J.+Howeauthor=L.+Jeacockauthor=E.+J.+Koauthor=J.+Korczynskaauthor=L.+MacLeanauthor=S.+Manthriauthor=M.+S.+Martinezauthor=L.+Mata-Canteroauthor=S.+Monizauthor=A.+Nuhsauthor=M.+Osuna-Cabelloauthor=E.+Pintoauthor=J.+Rileyauthor=S.+Robinsonauthor=P.+Rowlandauthor=F.+R.+C.+Simeonsauthor=Y.+Shishikuraauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=E.+Viayna+Gazaauthor=R.+J.+Wallauthor=F.+Zuccottoauthor=D.+Hornauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=J.+M.+Fiandorauthor=J.+Martinauthor=D.+W.+Grayauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=K.+D.+Readauthor=M.+Marcoauthor=P.+G.+Wyatt&title=Preclinical+candidate+for+the+treatment+of+visceral+leishmaniasis+that+acts+through+proteasome+inhibition&doi=10.1073%2Fpnas.1820175116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span></div><div class="casAuthors">Wyllie, Susan; Brand, Stephen; Thomas, Michael; De Rycker, Manu; Chung, Chun-wa; Pena, Imanol; Bingham, Ryan P.; Bueren-Calabuig, Juan A.; Cantizani, Juan; Cebrian, David; Craggs, Peter D.; Ferguson, Liam; Goswami, Panchali; Hobrath, Judith; Howe, Jonathan; Jeacock, Laura; Ko, Eun-Jung; Korczynska, Justyna; MacLean, Lorna; Manthri, Sujatha; Martinez, Maria S.; Mata-Cantero, Lydia; Moniz, Sonia; NA1/4hs, Andrea; Osuna-Cabello, Maria; Pinto, Erika; Riley, Jennifer; Robinson, Sharon; Rowland, Paul; Simeons, Frederick R. C.; Shishikura, Yoko; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Gaza, Elisabet Viayna; Wall, Richard J.; Zuccotto, Fabio; Horn, David; Ferguson, Michael A. J.; Fairlamb, Alan H.; Fiandor, Jose M.; Martin, Julio; Gray, David W.; Miles, Timothy J.; Gilbert, Ian H.; Read, Kevin D.; Marco, Maria; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9318-9323</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum, is one of the major parasitic diseases worldwide.  There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting.  Here, we describe the development of a preclin. drug candidate, GSK3494245/DDD01305143/compd. 8, with potential to treat this neglected tropical disease.  The compd. series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi.  Subsequent optimization of the chem. series resulted in the development of a potent cidal compd. with activity against a range of clin. relevant L. donovani and L. infantum isolates.  Compd. 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine.  Detailed mode of action studies confirm that this compd. acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome.  High-resoln. cryo-EM structures of apo and compd. 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits.  This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our exptl. and mutagenesis data.  As a result of these comprehensive studies and due to a favorable developability and safety profile, compd. 8 is being advanced toward human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLTLZPb2MCLVg90H21EOLACvtfcHk0lh8PJvVep19rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D&md5=799defb4ef812d64ffe230c78aff3511</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820175116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820175116%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DBingham%26aufirst%3DR.%2BP.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DCebrian%26aufirst%3DD.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DGoswami%26aufirst%3DP.%26aulast%3DHobrath%26aufirst%3DJ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJeacock%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DKorczynska%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DMata-Cantero%26aufirst%3DL.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DNuhs%26aufirst%3DA.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DE.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DViayna%2BGaza%26aufirst%3DE.%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DPreclinical%2520candidate%2520for%2520the%2520treatment%2520of%2520visceral%2520leishmaniasis%2520that%2520acts%2520through%2520proteasome%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D9318%26epage%3D9323%26doi%3D10.1073%2Fpnas.1820175116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+Mathisonauthor=E.+Myburghauthor=M.+Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+inhibition+for+treatment+of+leishmaniasis%2C+Chagas+disease+and+sleeping+sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0ljIXiJlc1XV7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.%2BY.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520inhibition%2520for%2520treatment%2520of%2520leishmaniasis%252C%2520Chagas%2520disease%2520and%2520sleeping%2520sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getnet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirujogi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manda, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaerkady, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madugundu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelkar, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isserlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal-Rojas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahasrabuddhe, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renuse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvan, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanjappa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbannayya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasamurthy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathe, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbannayya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelamanchi, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudgal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahari, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satishchandra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirdeshmukh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halushka, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruban, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span> <span> </span><span class="NLM_article-title">A draft map of the human proteome</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/nature13302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnature13302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24870542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXoslCrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=575-581&author=M.+S.+Kimauthor=S.+M.+Pintoauthor=D.+Getnetauthor=R.+S.+Nirujogiauthor=S.+S.+Mandaauthor=R.+Chaerkadyauthor=A.+K.+Madugunduauthor=D.+S.+Kelkarauthor=R.+Isserlinauthor=S.+Jainauthor=J.+K.+Thomasauthor=B.+Muthusamyauthor=P.+Leal-Rojasauthor=P.+Kumarauthor=N.+A.+Sahasrabuddheauthor=L.+Balakrishnanauthor=J.+Advaniauthor=B.+Georgeauthor=S.+Renuseauthor=L.+D.+Selvanauthor=A.+H.+Patilauthor=V.+Nanjappaauthor=A.+Radhakrishnanauthor=S.+Prasadauthor=T.+Subbannayyaauthor=R.+Rajuauthor=M.+Kumarauthor=S.+K.+Sreenivasamurthyauthor=A.+Marimuthuauthor=G.+J.+Satheauthor=S.+Chavanauthor=K.+K.+Dattaauthor=Y.+Subbannayyaauthor=A.+Sahuauthor=S.+D.+Yelamanchiauthor=S.+Jayaramauthor=P.+Rajagopalanauthor=J.+Sharmaauthor=K.+R.+Murthyauthor=N.+Syedauthor=R.+Goelauthor=A.+A.+Khanauthor=S.+Ahmadauthor=G.+Deyauthor=K.+Mudgalauthor=A.+Chatterjeeauthor=T.+C.+Huangauthor=J.+Zhongauthor=X.+Wuauthor=P.+G.+Shawauthor=D.+Freedauthor=M.+S.+Zahariauthor=K.+K.+Mukherjeeauthor=S.+Shankarauthor=A.+Mahadevanauthor=H.+Lamauthor=C.+J.+Mitchellauthor=S.+K.+Shankarauthor=P.+Satishchandraauthor=J.+T.+Schroederauthor=R.+Sirdeshmukhauthor=A.+Maitraauthor=S.+D.+Leachauthor=C.+G.+Drakeauthor=M.+K.+Halushkaauthor=T.+S.+Prasadauthor=R.+H.+Hrubanauthor=C.+L.+Kerrauthor=G.+D.+Baderauthor=C.+A.+Iacobuzio-Donahueauthor=H.+Gowdaauthor=A.+Pandey&title=A+draft+map+of+the+human+proteome&doi=10.1038%2Fnature13302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A draft map of the human proteome</span></div><div class="casAuthors">Kim, Min-Sik; Pinto, Sneha M.; Getnet, Derese; Nirujogi, Raja Sekhar; Manda, Srikanth S.; Chaerkady, Raghothama; Madugundu, Anil K.; Kelkar, Dhanashree S.; Isserlin, Ruth; Jain, Shobhit; Thomas, Joji K.; Muthusamy, Babylakshmi; Leal-Rojas, Pamela; Kumar, Praveen; Sahasrabuddhe, Nandini A.; Balakrishnan, Lavanya; Advani, Jayshree; George, Bijesh; Renuse, Santosh; Selvan, Lakshmi Dhevi N.; Patil, Arun H.; Nanjappa, Vishalakshi; Radhakrishnan, Aneesha; Prasad, Samarjeet; Subbannayya, Tejaswini; Raju, Rajesh; Kumar, Manish; Sreenivasamurthy, Sreelakshmi K.; Marimuthu, Arivusudar; Sathe, Gajanan J.; Chavan, Sandip; Datta, Keshava K.; Subbannayya, Yashwanth; Sahu, Apeksha; Yelamanchi, Soujanya D.; Jayaram, Savita; Rajagopalan, Pavithra; Sharma, Jyoti; Murthy, Krishna R.; Syed, Nazia; Goel, Renu; Khan, Aafaque A.; Ahmad, Sartaj; Dey, Gourav; Mudgal, Keshav; Chatterjee, Aditi; Huang, Tai-Chung; Zhong, Jun; Wu, Xinyan; Shaw, Patrick G.; Freed, Donald; Zahari, Muhammad S.; Mukherjee, Kanchan K.; Shankar, Subramanian; Mahadevan, Anita; Lam, Henry; Mitchell, Christopher J.; Shankar, Susarla Krishna; Satishchandra, Parthasarathy; Schroeder, John T.; Sirdeshmukh, Ravi; Maitra, Anirban; Leach, Steven D.; Drake, Charles G.; Halushka, Marc K.; Prasad, T. S. Keshava; Hruban, Ralph H.; Kerr, Candace L.; Bader, Gary D.; Iacobuzio-Donahue, Christine A.; Gowda, Harsha; Pandey, Akhilesh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7502</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The availability of human genome sequence has transformed biomedical research over the past decade.  However, an equiv. map for the human proteome with direct measurements of proteins and peptides does not exist yet.  Here we present a draft map of the human proteome using high-resoln. Fourier-transform mass spectrometry.  In-depth proteomic profiling of 30 histol. normal human samples, including 17 adult tissues, 7 fetal tissues and 6 purified primary hematopoietic cells, resulted in identification of proteins encoded by 17,294 genes accounting for approx. 84% of the total annotated protein-coding genes in humans.  A unique and comprehensive strategy for proteogenomic anal. enabled us to discover a no. of novel protein-coding regions, which includes translated pseudogenes, non-coding RNAs and upstream open reading frames.  This large human proteome catalog (available as an interactive web-based resource at http://www.humanproteomemap.org) will complement available human genome and transcriptome data to accelerate biomedical research in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNW2lqYhs8ULVg90H21EOLACvtfcHk0lgC_1Oezapm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXoslCrtrc%253D&md5=facf459fc3d9c8258fba1c1e94a378c6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnature13302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13302%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DPinto%26aufirst%3DS.%2BM.%26aulast%3DGetnet%26aufirst%3DD.%26aulast%3DNirujogi%26aufirst%3DR.%2BS.%26aulast%3DManda%26aufirst%3DS.%2BS.%26aulast%3DChaerkady%26aufirst%3DR.%26aulast%3DMadugundu%26aufirst%3DA.%2BK.%26aulast%3DKelkar%26aufirst%3DD.%2BS.%26aulast%3DIsserlin%26aufirst%3DR.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DJ.%2BK.%26aulast%3DMuthusamy%26aufirst%3DB.%26aulast%3DLeal-Rojas%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DSahasrabuddhe%26aufirst%3DN.%2BA.%26aulast%3DBalakrishnan%26aufirst%3DL.%26aulast%3DAdvani%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DRenuse%26aufirst%3DS.%26aulast%3DSelvan%26aufirst%3DL.%2BD.%26aulast%3DPatil%26aufirst%3DA.%2BH.%26aulast%3DNanjappa%26aufirst%3DV.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DSubbannayya%26aufirst%3DT.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DSreenivasamurthy%26aufirst%3DS.%2BK.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DSathe%26aufirst%3DG.%2BJ.%26aulast%3DChavan%26aufirst%3DS.%26aulast%3DDatta%26aufirst%3DK.%2BK.%26aulast%3DSubbannayya%26aufirst%3DY.%26aulast%3DSahu%26aufirst%3DA.%26aulast%3DYelamanchi%26aufirst%3DS.%2BD.%26aulast%3DJayaram%26aufirst%3DS.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DMurthy%26aufirst%3DK.%2BR.%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DGoel%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DA.%2BA.%26aulast%3DAhmad%26aufirst%3DS.%26aulast%3DDey%26aufirst%3DG.%26aulast%3DMudgal%26aufirst%3DK.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DT.%2BC.%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShaw%26aufirst%3DP.%2BG.%26aulast%3DFreed%26aufirst%3DD.%26aulast%3DZahari%26aufirst%3DM.%2BS.%26aulast%3DMukherjee%26aufirst%3DK.%2BK.%26aulast%3DShankar%26aufirst%3DS.%26aulast%3DMahadevan%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DMitchell%26aufirst%3DC.%2BJ.%26aulast%3DShankar%26aufirst%3DS.%2BK.%26aulast%3DSatishchandra%26aufirst%3DP.%26aulast%3DSchroeder%26aufirst%3DJ.%2BT.%26aulast%3DSirdeshmukh%26aufirst%3DR.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DHalushka%26aufirst%3DM.%2BK.%26aulast%3DPrasad%26aufirst%3DT.%2BS.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DKerr%26aufirst%3DC.%2BL.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DGowda%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DA.%26atitle%3DA%2520draft%2520map%2520of%2520the%2520human%2520proteome%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D575%26epage%3D581%26doi%3D10.1038%2Fnature13302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span>; <span class="NLM_string-name">Lauer, C.</span>; <span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Prevention of Autoimmune Diabetes by a Selective Inhibitor of the Immunoproteasome</span>. In  <i>Wiener Klinische Wochenschrift</i>; <span class="NLM_publisher-name">Springer Wien</span>, <span class="NLM_year">2008</span>; Vol.  <span class="NLM_volume">120</span>, p  <span class="NLM_fpage">165</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=165&author=M.+Basler&author=C.+Lauer&author=M.+Groettrup&title=Wiener+Klinische+Wochenschrift"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DPrevention%2520of%2520Autoimmune%2520Diabetes%2520by%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Immunoproteasome%26btitle%3DWiener%2520Klinische%2520Wochenschrift%26pub%3DSpringer%2520Wien%26date%3D2008%26volume%3D120%26spage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1002/emmm.201303543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Femmm.201303543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24399752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=226-238&author=M.+Baslerauthor=S.+Mundtauthor=T.+Muchamuelauthor=C.+Mollauthor=J.+Jiangauthor=M.+Groettrupauthor=C.+J.+Kirk&title=Inhibition+of+the+immunoproteasome+ameliorates+experimental+autoimmune+encephalomyelitis&doi=10.1002%2Femmm.201303543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Basler, Michael; Mundt, Sarah; Muchamuel, Tony; Moll, Carlo; Jiang, Jing; Groettrup, Marcus; Kirk, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system.  The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes.  Recently, we demonstrated a novel function of immunoproteasomes in cytokine prodn. and T cell differentiation.  In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS.  ONX 0914 attenuated disease progression after active and passive induction of exptl. autoimmune encephalomyelitis (EAE), both in MOG35-55 and PLP139-151-induced EAE.  Isolation of lymphocytes from the brain or spinal cord revealed a strong redn. of cytokine-producing CD4+ cells in ONX 0914 treated mice.  Addnl., ONX 0914 treatment prevented disease exacerbation in a relapsing-remitting model.  An anal. of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice.  These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7NZVATJbqxLVg90H21EOLACvtfcHk0lgC_1Oezapm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWkur4%253D&md5=b092b6f79d66e9bcc23c4477cce19a67</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Femmm.201303543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201303543%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DMundt%26aufirst%3DS.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DMoll%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520immunoproteasome%2520ameliorates%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D226%26epage%3D238%26doi%3D10.1002%2Femmm.201303543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looney, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anolik, J. H.</span></span> <span> </span><span class="NLM_article-title">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1002/art.33333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fart.33333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=21905015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=493-503&author=H.+T.+Ichikawaauthor=T.+Conleyauthor=T.+Muchamuelauthor=J.+Jiangauthor=S.+Leeauthor=T.+Owenauthor=J.+Barnardauthor=S.+Nevarezauthor=B.+I.+Goldmanauthor=C.+J.+Kirkauthor=R.+J.+Looneyauthor=J.+H.+Anolik&title=Beneficial+effect+of+novel+proteasome+inhibitors+in+murine+lupus+via+dual+inhibition+of+type+I+interferon+and+autoantibody-secreting+cells&doi=10.1002%2Fart.33333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells</span></div><div class="casAuthors">Ichikawa, H. Travis; Conley, Thomas; Muchamuel, Tony; Jiang, Jing; Lee, Susan; Owen, Teresa; Barnard, Jennifer; Nevarez, Sarah; Goldman, Bruce I.; Kirk, Christopher J.; Looney, R. John; Anolik, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">493-503</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are crit. in disease pathogenesis.  Methods : Lupus-prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control.  Tissue was harvested and analyzed by flow cytometry using std. markers.  Nephritis was monitored by evaluation for proteinuria and by histol. anal. of kidneys.  Serum anti-double-stranded DNA (anti-dsDNA) levels were measured by ELISA (ELISA), and total IgG and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.  Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll-like receptor (TLR) agonists and proteasome inhibitors, and interferon-α (IFNα) levels were measured by ELISA and flow cytometry.  Results : Early treatment of lupus-prone mice with the dual-targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome-specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis.  Treatment had profound effects on plasma cells, with greater redns. in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels.  Notably, proteasome inhibition efficiently suppressed prodn. of IFNα by TLR-activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function.  Conclusion : Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 crit. pathways in disease pathogenesis, type I IFN activation and autoantibody prodn. by plasma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgx8A-mW0b_bVg90H21EOLACvtfcHk0lgpbmBxnnLb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrurk%253D&md5=1055201f4931e5c09ae292b07e26c0cc</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fart.33333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33333%26sid%3Dliteratum%253Aachs%26aulast%3DIchikawa%26aufirst%3DH.%2BT.%26aulast%3DConley%26aufirst%3DT.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DT.%26aulast%3DBarnard%26aufirst%3DJ.%26aulast%3DNevarez%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DB.%2BI.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLooney%26aufirst%3DR.%2BJ.%26aulast%3DAnolik%26aufirst%3DJ.%2BH.%26atitle%3DBeneficial%2520effect%2520of%2520novel%2520proteasome%2520inhibitors%2520in%2520murine%2520lupus%2520via%2520dual%2520inhibition%2520of%2520type%2520I%2520interferon%2520and%2520autoantibody-secreting%2520cells%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D493%26epage%3D503%26doi%3D10.1002%2Fart.33333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">4182</span>– <span class="NLM_lpage">4193</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.4049%2Fjimmunol.1201183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=22984077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4182-4193&author=K.+W.+Kalimauthor=M.+Baslerauthor=C.+J.+Kirkauthor=M.+Groettrup&title=Immunoproteasome+subunit+LMP7+deficiency+and+inhibition+suppresses+Th1+and+Th17+but+enhances+regulatory+T+cell+differentiation&doi=10.4049%2Fjimmunol.1201183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation</span></div><div class="casAuthors">Kalim, Khalid W.; Basler, Michael; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4182-4193</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The immunoproteasome generates peptides presented on MHC class I mols. to cytotoxic T cells.  ONX 0914 (formerly called PR-957) is a selective inhibitor of the immunoproteasome subunit low mol. mass polypeptide (LMP) 7 (β5i) that attenuates disease progression in mouse models of diabetes, colitis, and arthritis.  The aim of this study was to investigate the effect of LMP7-specific inhibition on major Th cell differentiation pathways involved in the progression of autoimmune diseases in vitro and in vivo.  We used ONX 0914-treated wild-type CD4+ T cells and also LMP7-/- CD4+ T cells under different Th cell-polarizing conditions, focusing on the effector cytokines and transcription factors involved, and compared them with wild-type CD4+ T cells.  Mouse models of dextran sodium sulfate-induced colitis and a T cell transfer model of colitis were used for in vivo assessment.  Deletion or inhibition of LMP7 suppressed generation of Th17 but promoted regulatory T cell (Treg) development.  In developing Th17 cells, immunoproteasome inhibition blocked phosphorylation of STAT3, whereas in Tregs, SMAD phosphorylation was enhanced.  Addnl., LMP7 inhibition led to reduced STAT1 phosphorylation and Th1 differentiation.  These findings were confirmed in vivo as LMP7 inhibition or deficiency resulted in reduced Th1 and Th17 expansion while promoting Treg development in dextran sodium sulfate-induced colitis.  Also, in a T cell-dependent transfer model of colitis, LMP7-specific inhibition led to reduced Th1 and Th17 differentiation in vivo.  LMP7 governs Th cell lineage detn. by affecting the balance of receptor proximal signals during differentiation.  These data render LMP7 a promising drug target for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3Ux8Yelj67Vg90H21EOLACvtfcHk0lgpbmBxnnLb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrtLzK&md5=00e986b09b33e6d70f26abf06b432045</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201183%26sid%3Dliteratum%253Aachs%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DImmunoproteasome%2520subunit%2520LMP7%2520deficiency%2520and%2520inhibition%2520suppresses%2520Th1%2520and%2520Th17%2520but%2520enhances%2520regulatory%2520T%2520cell%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4182%26epage%3D4193%26doi%3D10.4049%2Fjimmunol.1201183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalim, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylvain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwonek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nm.1978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fnm.1978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=19525961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=781-787&author=T.+Muchamuelauthor=M.+Baslerauthor=M.+A.+Aujayauthor=E.+Suzukiauthor=K.+W.+Kalimauthor=C.+Lauerauthor=C.+Sylvainauthor=E.+R.+Ringauthor=J.+Shieldsauthor=J.+Jiangauthor=P.+Shwonekauthor=F.+Parlatiauthor=S.+D.+Demoauthor=M.+K.+Bennettauthor=C.+J.+Kirkauthor=M.+Groettrup&title=A+selective+inhibitor+of+the+immunoproteasome+subunit+LMP7+blocks+cytokine+production+and+attenuates+progression+of+experimental+arthritis&doi=10.1038%2Fnm.1978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</span></div><div class="casAuthors">Muchamuel, Tony; Basler, Michael; Aujay, Monette A.; Suzuki, Erika; Kalim, Khalid W.; Lauer, Christoph; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">781-787</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immunoproteasome, a distinct class of proteasome found predominantly in monocytes and lymphocytes, is known to shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I).  However, a specific role for the immunoproteasome in regulating other facets of immune responses has not been established.  The authors describe here the characterization of PR-957, a selective inhibitor of low-mol. mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome.  PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo.  Selective inhibition of LMP7 by PR-957 blocked prodn. of interleukin-23 (IL-23) by activated monocytes and interferon-γ and IL-2 by T cells.  In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in redns. in cellular infiltration, cytokine prodn. and autoantibody levels.  These studies reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for targeting LMP7 in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJsuXHN4oyBbVg90H21EOLACvtfcHk0lgd6qSk6g-X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShtLs%253D&md5=3961ba1ec6786d0318bfa2b64e5e7cfa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnm.1978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1978%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DKalim%26aufirst%3DK.%2BW.%26aulast%3DLauer%26aufirst%3DC.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DE.%2BR.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520the%2520immunoproteasome%2520subunit%2520LMP7%2520blocks%2520cytokine%2520production%2520and%2520attenuates%2520progression%2520of%2520experimental%2520arthritis%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D781%26epage%3D787%26doi%3D10.1038%2Fnm.1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muchamuel, T.</span>; <span class="NLM_string-name">Jiang, J.</span>; <span class="NLM_string-name">Lee, S. J.</span>; <span class="NLM_string-name">Kirk, C. J.</span></span> <span> </span><span class="NLM_article-title">ONX-0914, A selective inhibitor of the immunoproteasome, protects against experimental autoimmune encephalomyelitis and suppresses the TH17 Response</span>. In  <i>Neurology</i>; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>, <span class="NLM_year">2011</span>; Vol.  <span class="NLM_volume">76</span>, pp  <span class="NLM_fpage">A459</span>– <span class="NLM_lpage">A460</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=A459-A460&author=T.+Muchamuel&author=J.+Jiang&author=S.+J.+Lee&author=C.+J.+Kirk&title=Neurology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMuchamuel%26aufirst%3DT.%26atitle%3DONX-0914%252C%2520A%2520selective%2520inhibitor%2520of%2520the%2520immunoproteasome%252C%2520protects%2520against%2520experimental%2520autoimmune%2520encephalomyelitis%2520and%2520suppresses%2520the%2520TH17%2520Response%26btitle%3DNeurology%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2011%26volume%3D76%26spage%3DA459%26epage%3DA460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vachharajani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joeris, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenike, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantazis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visekruna, A.</span></span> <span> </span><span class="NLM_article-title">Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">50447</span>– <span class="NLM_lpage">50459</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.18632%2Foncotarget.14579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28881574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A280%3ADC%252BC1cbls1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=50447-50459&author=N.+Vachharajaniauthor=T.+Joerisauthor=M.+Luuauthor=S.+Hartmannauthor=S.+Pautzauthor=E.+Jenikeauthor=G.+Pantazisauthor=I.+Prinzauthor=M.+J.+Hoferauthor=U.+Steinhoffauthor=A.+Visekruna&title=Prevention+of+colitis-associated+cancer+by+selective+targeting+of+immunoproteasome+subunit+LMP7&doi=10.18632%2Foncotarget.14579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7</span></div><div class="casAuthors">Vachharajani Niyati; Luu Maik; Hartmann Sabrina; Pautz Sabine; Jenike Elena; Steinhoff Ulrich; Visekruna Alexander; Joeris Thorsten; Pantazis Georgios; Hofer Markus J; Prinz Immo; Hofer Markus J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">50447-50459</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic inflammation is a well-known risk factor in development of intestinal tumorigenesis, although the exact mechanisms underlying development of colitis-associated cancer (CAC) still remain obscure.  The activity and function of immunoproteasome has been extensively analyzed in the context of inflammation and infectious diseases.  Here, we show that the proteasomal immunosubunit LMP7 plays an essential role in development of CAC.  Mice devoid of LMP7 were resistant to chronic inflammation and formation of neoplasia, and developed virtually no tumors after AOM/DSS treatment.  Our data reveal that LMP7 deficiency resulted in reduced expression of pro-tumorigenic chemokines CXCL1, CXCL2 and CXCL3 as well as adhesion molecule VCAM-1.  As a consequence, an impaired recruitment and activity of tumor-infiltrating leukocytes resulting in decreased secretion of cytokines IL-6 and TNF-α was observed.  Further, the deletion or pharmacological inhibition of LMP7 and consequent blockade of NF-κB abrogated the production of IL-17A, which possesses a strong carcinogenic activity in the gut.  Moreover, in vivo administration of the selective LMP7 inhibitor ONX-0914 led to a marked reduction of tumor numbers in wild-type (WT) mice.  Collectively, we identified the immunoproteasome as a crucial mediator of inflammation-driven neoplasia highlighting a novel potential therapeutic approach to limit colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ra5hF3i41rqxQ2mb9Pu8fW6udTcc2earOvbtF6jPBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbls1Oisw%253D%253D&md5=56e4b040eaebfa591ec3e5d9ec85355f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14579%26sid%3Dliteratum%253Aachs%26aulast%3DVachharajani%26aufirst%3DN.%26aulast%3DJoeris%26aufirst%3DT.%26aulast%3DLuu%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DS.%26aulast%3DPautz%26aufirst%3DS.%26aulast%3DJenike%26aufirst%3DE.%26aulast%3DPantazis%26aufirst%3DG.%26aulast%3DPrinz%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DM.%2BJ.%26aulast%3DSteinhoff%26aufirst%3DU.%26aulast%3DVisekruna%26aufirst%3DA.%26atitle%3DPrevention%2520of%2520colitis-associated%2520cancer%2520by%2520selective%2520targeting%2520of%2520immunoproteasome%2520subunit%2520LMP7%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D50447%26epage%3D50459%26doi%3D10.18632%2Foncotarget.14579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C. G.</span></span> <span> </span><span class="NLM_article-title">Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3617</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.bmcl.2014.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=24913713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslKlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3614-3617&author=V.+Kasamauthor=N.+R.+Leeauthor=K.+B.+Kimauthor=C.+G.+Zhan&title=Selective+immunoproteasome+inhibitors+with+non-peptide+scaffolds+identified+from+structure-based+virtual+screening&doi=10.1016%2Fj.bmcl.2014.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening</span></div><div class="casAuthors">Kasam, Vinod; Lee, Na-Ra; Kim, Kyung-Bo; Zhan, Chang-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3614-3617</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a major component of the crucial nonlysosomal protein degrdn. pathway in the cells, the proteasome has been implicated in many diseases such as Alzheimer's disease, Huntington's disease, inflammatory bowel diseases, autoimmune diseases, multiple myeloma (MM) and other cancers.  There are two main proteasome subtypes: the constitutive proteasome which is expressed in all eukaryotic cells and the immunoproteasome which is expressed in immune cells and can be induced in other cell types.  Majority of currently available proteasome inhibitors are peptide backbone-based, having short half-lives in the body.  It is highly desirable to identify novel, immunoproteasome-selective inhibitors with non-peptide scaffolds for development of novel therapeutics.  Through combined virtual screening and exptl. studies targeting the immunoproteasome, we have identified a set of novel immunoproteasome inhibitors with diverse non-peptide scaffolds.  Some of the identified inhibitors have significant selectivity for the immunoproteasome over the constitutive proteasome.  Unlike most of the currently available proteasome inhibitors, these new inhibitors lacking electrophilic pharmacophores are not expected to form a covalent bond with proteasome after the binding.  These non-peptide scaffolds may provide a new platform for future rational drug design and discovery targeting the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2U6pRAIx7NLVg90H21EOLACvtfcHk0lhFoPQv2J7dHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslKlurs%253D&md5=6cf6a9bd24fd8e6986f600af903ea667</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DKasam%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26atitle%3DSelective%2520immunoproteasome%2520inhibitors%2520with%2520non-peptide%2520scaffolds%2520identified%2520from%2520structure-based%2520virtual%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3614%26epage%3D3617%26doi%3D10.1016%2Fj.bmcl.2014.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Subunit specific inhibitors of proteasomes and their potential for immunomodulation</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2014.08.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.cbpa.2014.08.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=25217863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyiurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=16-22&author=A.+F.+Kisselevauthor=M.+Groettrup&title=Subunit+specific+inhibitors+of+proteasomes+and+their+potential+for+immunomodulation&doi=10.1016%2Fj.cbpa.2014.08.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit specific inhibitors of proteasomes and their potential for immunomodulation</span></div><div class="casAuthors">Kisselev, Alexei F.; Groettrup, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-22</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Specialized variants of the constitutive 20S proteasome in the immune system like the immunoproteasomes and the thymoproteasome contain active site-bearing subunits which differ in their cleavage priorities and substrate binding pockets.  The immunoproteasome plays a crucial role in antigen processing and for the differentiation of pro-inflammatory T helper cells which are involved in the pathogenesis of autoimmunity.  Selective inhibitors of the immunoproteasome and constitutive proteasome have recently been generated which interfere with the development and progression of autoimmune diseases.  Here we describe these inhibitors and their therapeutic potential as predicted from preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTKHmwEvS8e7Vg90H21EOLACvtfcHk0lhFoPQv2J7dHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyiurvP&md5=f5039ce8ef60506ddf14bdcb567f545c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.08.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.08.012%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DGroettrup%26aufirst%3DM.%26atitle%3DSubunit%2520specific%2520inhibitors%2520of%2520proteasomes%2520and%2520their%2520potential%2520for%2520immunomodulation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D23%26spage%3D16%26epage%3D22%26doi%3D10.1016%2Fj.cbpa.2014.08.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">The Immunoproteasome: An emerging therapeutic target</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2923</span>– <span class="NLM_lpage">2930</span>, <span class="refDoi"> DOI: 10.2174/156802611798281348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.2174%2F156802611798281348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=21824107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2923-2930&author=W.+Leeauthor=K.+B.+Kim&title=The+Immunoproteasome%3A+An+emerging+therapeutic+target&doi=10.2174%2F156802611798281348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoproteasome: an emerging therapeutic target</span></div><div class="casAuthors">Lee, Wooin; Kim, Kyung Bo</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2923-2930</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The proteasome, a large multisubunit protease complex, has been extensively investigated over the years, greatly enhancing our understanding of crit. roles that the proteasome plays in cells.  The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has validated the proteasome as an anticancer target.  However, the undesirable toxicities of these agents limit their broad utility.  The immunoproteasome, an alternative form of the constitutive proteasome, has recently been explored as a therapeutic target.  While the immunoproteasome, normally expressed in cells of hematopoietic origin, has been shown to be assocd. with various types of cancer and inflammatory diseases, its multifaceted function is not fully understood due to the lack of appropriate mol. probes.  In this review, recent advances in the immunoproteasome field are covered, including potential implications in disease states.  In particular, recent developments in immunoproteasome-specific inhibitors are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ejBv7fA5MbVg90H21EOLACvtfcHk0lhFoPQv2J7dHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehur0%253D&md5=90827ffca32fb0fee1a8b72d9e3ada55</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156802611798281348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798281348%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DThe%2520Immunoproteasome%253A%2520An%2520emerging%2520therapeutic%2520target%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2923%26epage%3D2930%26doi%3D10.2174%2F156802611798281348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span>; <span class="NLM_string-name">Groettrup, M.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome-specific inhibitors and their application</span>. In  <i>Methods in Molecular Biology</i>; <span class="NLM_publisher-name">Humana Press,</span> <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">832</span>, pp  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">401</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=391-401&author=M.+Basler&author=M.+Groettrup&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasler%26aufirst%3DM.%26atitle%3DImmunoproteasome-specific%2520inhibitors%2520and%2520their%2520application%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26pub%3DHumana%2520Press%26date%3D2012%26volume%3D832%26spage%3D391%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubiella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieber, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">11969</span>– <span class="NLM_lpage">11973</span>, <span class="refDoi"> DOI: 10.1002/anie.201406964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fanie.201406964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOkurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=11969-11973&author=C.+Dubiellaauthor=H.+Cuiauthor=M.+Gerschauthor=A.+J.+Brouwerauthor=S.+A.+Sieberauthor=A.+Krugerauthor=R.+M.+Liskampauthor=M.+Groll&title=Selective+inhibition+of+the+immunoproteasome+by+ligand-induced+crosslinking+of+the+active+site&doi=10.1002%2Fanie.201406964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of the Immunoproteasome by Ligand-Induced Crosslinking of the Active Site</span></div><div class="casAuthors">Dubiella, Christian; Cui, Haissi; Gersch, Malte; Brouwer, Arwin J.; Sieber, Stephan A.; Krueger, Achim; Liskamp, Rob M. J.; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">11969-11973</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The concept of proteasome inhibition ranks among the latest achievements in the treatment of blood cancer and represents a promising strategy for modulating autoimmune diseases.  In this study, we describe peptidic sulfonyl fluoride inhibitors that selectively block the catalytic β5 subunit of the immunoproteasome by inducing only marginal cytotoxic effects.  Structural and mass spectrometric analyses revealed a novel reaction mechanism involving polarity inversion and irreversible crosslinking of the proteasomal active site.  We thus identified the sulfonyl fluoride headgroup for the development and optimization of immunoproteasome selective compds. and their possible application in autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnN6CJub2ORrVg90H21EOLACvtfcHk0lgZ-CH4vodbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOkurfM&md5=00d726fdbc6f2e391f9650516b2d6c30</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201406964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201406964%26sid%3Dliteratum%253Aachs%26aulast%3DDubiella%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DGersch%26aufirst%3DM.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DSieber%26aufirst%3DS.%2BA.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DSelective%2520inhibition%2520of%2520the%2520immunoproteasome%2520by%2520ligand-induced%2520crosslinking%2520of%2520the%2520active%2520site%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D11969%26epage%3D11973%26doi%3D10.1002%2Fanie.201406964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sosič, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogrizek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obreza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zigon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janezic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlinaric-Rascan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Nonpeptidic selective inhibitors of the chymotrypsin-like (beta5 i) subunit of the immunoproteasome</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5745</span>– <span class="NLM_lpage">5748</span>, <span class="refDoi"> DOI: 10.1002/anie.201600190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fanie.201600190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=5745-5748&author=I.+Sosi%C4%8Dauthor=M.+Gobecauthor=B.+Brusauthor=D.+Knezauthor=M.+Zivecauthor=J.+Koncauthor=S.+Lesnikauthor=M.+Ogrizekauthor=A.+Obrezaauthor=D.+Zigonauthor=D.+Janezicauthor=I.+Mlinaric-Rascanauthor=S.+Gobec&title=Nonpeptidic+selective+inhibitors+of+the+chymotrypsin-like+%28beta5+i%29+subunit+of+the+immunoproteasome&doi=10.1002%2Fanie.201600190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5i) Subunit of the Immunoproteasome</span></div><div class="casAuthors">Sosic, Izidor; Gobec, Martina; Brus, Boris; Knez, Damijan; Zivec, Matej; Konc, Janez; Lesnik, Samo; Ogrizek, Mitja; Obreza, Ales; Zigon, Dusan; Janezic, Dusanka; Mlinaric-Rascan, Irena; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5745-5748</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Elevated expression of the immunoproteasome has been assocd. with autoimmune diseases, inflammatory diseases, and various types of cancer.  Selective inhibitors of the immunoproteasome are not only scarce, but also almost entirely restricted to peptide-based compds.  Herein, we describe nonpeptidic reversible inhibitors that selectively block the chymotrypsin-like (β5i) subunit of the human immunoproteasome in the low micromolar range.  The most potent of the reversibly acting compds. were then converted into covalent, irreversible, nonpeptidic inhibitors that retained selectivity for the β5i subunit.  In addn., these inhibitors discriminate between the immunoproteasome and the constitutive proteasome in cell-based assays.  Along with their lack of cytotoxicity, these data point to these nonpeptidic compds. being suitable for further investigation as β5i-selective probes for possible application in noncancer diseases related to the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzWe9nWrjVbVg90H21EOLACvtfcHk0lgZ-CH4vodbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yisrs%253D&md5=37d04d39e7d6ff3cf58241bc16f8bd3e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201600190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201600190%26sid%3Dliteratum%253Aachs%26aulast%3DSosi%25C4%258D%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DM.%26aulast%3DBrus%26aufirst%3DB.%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DZivec%26aufirst%3DM.%26aulast%3DKonc%26aufirst%3DJ.%26aulast%3DLesnik%26aufirst%3DS.%26aulast%3DOgrizek%26aufirst%3DM.%26aulast%3DObreza%26aufirst%3DA.%26aulast%3DZigon%26aufirst%3DD.%26aulast%3DJanezic%26aufirst%3DD.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DNonpeptidic%2520selective%2520inhibitors%2520of%2520the%2520chymotrypsin-like%2520%2528beta5%2520i%2529%2520subunit%2520of%2520the%2520immunoproteasome%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D5745%26epage%3D5748%26doi%3D10.1002%2Fanie.201600190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Chapelain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubiella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Structural elucidation of a non-peptidic inhibitor specific for the human immunoproteasome</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/cbic.201700021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fcbic.201700021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28098422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVKlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=523-526&author=H.+Cuiauthor=R.+Baurauthor=C.+Le+Chapelainauthor=C.+Dubiellaauthor=W.+Heinemeyerauthor=E.+M.+Huberauthor=M.+Groll&title=Structural+elucidation+of+a+non-peptidic+inhibitor+specific+for+the+human+immunoproteasome&doi=10.1002%2Fcbic.201700021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome</span></div><div class="casAuthors">Cui, Haissi; Baur, Regina; Le Chapelain, Camille; Dubiella, Christian; Heinemeyer, Wolfgang; Huber, Eva M.; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-526</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of the immunoproteasome is a promising approach towards the development of immunomodulatory drugs.  Recently, a class of substituted thiazole compds. that combine a nonpeptidic scaffold with the absence of an electrophile was reported in a patent.  Here, we investigated the mode of action of the lead compd. by using a sophisticated chimeric yeast model of the human immunoproteasome for structural studies.  The inhibitor adopts a unique orientation perpendicular to the β5i substrate-binding channel.  Distinct interactions between the inhibitor and the subpockets of the human immunoproteasome account for its isotype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvTj0zpHsy2rVg90H21EOLACvtfcHk0lgZ-CH4vodbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVKlt7k%253D&md5=01d6f4fe1901fea377d69134835488cd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700021%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DBaur%26aufirst%3DR.%26aulast%3DLe%2BChapelain%26aufirst%3DC.%26aulast%3DDubiella%26aufirst%3DC.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DStructural%2520elucidation%2520of%2520a%2520non-peptidic%2520inhibitor%2520specific%2520for%2520the%2520human%2520immunoproteasome%26jtitle%3DChemBioChem%26date%3D2017%26volume%3D18%26spage%3D523%26epage%3D526%26doi%3D10.1002%2Fcbic.201700021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0lhzXHyDxQ1mMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sula
Karreci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihali, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solhjou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riella, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laragione, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrat, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J.</span></span> <span> </span><span class="NLM_article-title">Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E8425</span>– <span class="NLM_lpage">E8432</span>, <span class="refDoi"> DOI: 10.1073/pnas.1618548114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1073%2Fpnas.1618548114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27956634" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E8425-E8432&author=E.+Sula%0AKarreciauthor=H.+Fanauthor=M.+Ueharaauthor=A.+B.+Mihaliauthor=P.+K.+Singhauthor=A.+T.+Kurdiauthor=Z.+Solhjouauthor=L.+V.+Riellaauthor=I.+Ghobrialauthor=T.+Laragioneauthor=S.+Routrayauthor=J.+P.+Assakerauthor=R.+Wangauthor=G.+Sukenickauthor=L.+Shiauthor=F.+J.+Barratauthor=C.+F.+Nathanauthor=G.+Linauthor=J.+Azzi&title=Brief+treatment+with+a+highly+selective+immunoproteasome+inhibitor+promotes+long-term+cardiac+allograft+acceptance+in+mice&doi=10.1073%2Fpnas.1618548114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1618548114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1618548114%26sid%3Dliteratum%253Aachs%26aulast%3DSula%2BKarreci%26aufirst%3DE.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DM.%26aulast%3DMihali%26aufirst%3DA.%2BB.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DKurdi%26aufirst%3DA.%2BT.%26aulast%3DSolhjou%26aufirst%3DZ.%26aulast%3DRiella%26aufirst%3DL.%2BV.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DLaragione%26aufirst%3DT.%26aulast%3DRoutray%26aufirst%3DS.%26aulast%3DAssaker%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DBarrat%26aufirst%3DF.%2BJ.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DAzzi%26aufirst%3DJ.%26atitle%3DBrief%2520treatment%2520with%2520a%2520highly%2520selective%2520immunoproteasome%2520inhibitor%2520promotes%2520long-term%2520cardiac%2520allograft%2520acceptance%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE8425%26epage%3DE8432%26doi%3D10.1073%2Fpnas.1618548114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelo, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Oxathiazolones selectively inhibit the human immunoproteasome over the constitutive proteasome</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1021/ml400531d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400531d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=405-410&author=H.+Fanauthor=N.+G.+Angeloauthor=J.+D.+Warrenauthor=C.+F.+Nathanauthor=G.+Lin&title=Oxathiazolones+selectively+inhibit+the+human+immunoproteasome+over+the+constitutive+proteasome&doi=10.1021%2Fml400531d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome</span></div><div class="casAuthors">Fan, Hao; Angelo, Nicholas G.; Warren, J. David; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">405-410</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the constitutive proteasome hold promise for the treatment of autoimmune and inflammatory diseases and hematol. malignancies.  Here we report that oxathiazolones inhibit the immunoproteasome β5i with up to 4700-fold selectivity over the constitutive proteasome, are cell permeable, and inhibit proteasomes inside cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z_edRpQdj7Vg90H21EOLACvtfcHk0lhzgtTu1KXqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyhsLY%253D&md5=e9dcdf8a691515c95172ab283b92a5be</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml400531d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400531d%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DH.%26aulast%3DAngelo%26aufirst%3DN.%2BG.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DOxathiazolones%2520selectively%2520inhibit%2520the%2520human%2520immunoproteasome%2520over%2520the%2520constitutive%2520proteasome%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D405%26epage%3D410%26doi%3D10.1021%2Fml400531d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasome beta5i-selective dipeptidomimetic inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2131</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1002%2Fcmdc.201600384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=27561172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSgu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2127-2131&author=P.+K.+Singhauthor=H.+Fanauthor=X.+Jiangauthor=L.+Shiauthor=C.+F.+Nathanauthor=G.+Lin&title=Immunoproteasome+beta5i-selective+dipeptidomimetic+inhibitors&doi=10.1002%2Fcmdc.201600384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors</span></div><div class="casAuthors">Singh, Pradeep K.; Fan, Hao; Jiang, Xiuju; Shi, Lei; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2127-2131</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">N,C-capped dipeptides belong to a class of noncovalent proteasome inhibitors.  Herein the authors report that the insertion of a β-amino acid into N,C-capped dipeptides markedly decreases their inhibitory potency against human constitutive proteasome β5c, while maintaining potent inhibitory activity against human immunoproteasome β5i, thereby achieving thousands-fold selectivity for β5i over β5c.  Structure-activity relationship studies revealed that β5c does not tolerate the β-amino acid based dipeptidomimetics as does β5i.  In vitro, one such compd. was found to inhibit human T cell proliferation.  Compds. of this class may have potential as therapeutics for autoimmune and inflammatory diseases with less mechanism-based cytotoxicity than agents that also inhibit the constitutive proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5VZ_618QUCLVg90H21EOLACvtfcHk0lhzgtTu1KXqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSgu7nL&md5=b3a77b4e7d66cbd41de0789d3a6ad762</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600384%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DImmunoproteasome%2520beta5i-selective%2520dipeptidomimetic%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2127%26epage%3D2131%26doi%3D10.1002%2Fcmdc.201600384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.d. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assker, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">1692</span> <span class="refDoi"> DOI: 10.1038/s41467-017-01760-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1038%2Fs41467-017-01760-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=29167449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=R.d.+L.+A.+Santosauthor=L.+Baiauthor=P.+K.+Singhauthor=N.+Murakamiauthor=H.+Fanauthor=W.+Zhanauthor=Y.+Zhuauthor=X.+Jiangauthor=K.+Zhangauthor=J.+P.+Asskerauthor=C.+F.+Nathanauthor=H.+Liauthor=J.+Azziauthor=G.+Lin&title=Structure+of+human+immunoproteasome+with+a+reversible+and+noncompetitive+inhibitor+that+selectively+inhibits+activated+lymphocytes&doi=10.1038%2Fs41467-017-01760-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes</span></div><div class="casAuthors">Santos Ruda de Luna Almeida; Bai Lin; Li Huilin; Singh Pradeep K; Murakami Naoka; Assker Jean Pierre; Azzi Jamil; Fan Hao; Zhan Wenhu; Zhu Yingrong; Jiang Xiuju; Nathan Carl F; Lin Gang; Zhang Kaiming</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1692</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Proteasome inhibitors benefit patients with multiple myeloma and B cell-dependent autoimmune disorders but exert toxicity from inhibition of proteasomes in other cells.  Toxicity should be minimized by reversible inhibition of the immunoproteasome β5i subunit while sparing the constitutive β5c subunit.  Here we report β5i-selective inhibition by asparagine-ethylenediamine (AsnEDA)-based compounds and present the high-resolution cryo-EM structural analysis of the human immunoproteasome.  Despite inhibiting noncompetitively, an AsnEDA inhibitor binds the active site.  Hydrophobic interactions are accompanied by hydrogen bonding with β5i and β6 subunits.  The inhibitors are far more cytotoxic for myeloma and lymphoma cell lines than for hepatocarcinoma or non-activated lymphocytes.  They block human B-cell proliferation and promote apoptotic cell death selectively in antibody-secreting B cells, and to a lesser extent in activated human T cells.  Reversible, β5i-selective inhibitors may be useful for treatment of diseases involving activated or neoplastic B cells or activated T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlRnWYxiDmxxwLZxei1HN8fW6udTcc2eZjEXO7UkJ6CLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOmtw%253D%253D&md5=3a34624f5b07ad88384d43a22308fc7c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01760-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01760-5%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.d.%2BL.%2BA.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DMurakami%26aufirst%3DN.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DAssker%26aufirst%3DJ.%2BP.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAzzi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DStructure%2520of%2520human%2520immunoproteasome%2520with%2520a%2520reversible%2520and%2520noncompetitive%2520inhibitor%2520that%2520selectively%2520inhibits%2520activated%2520lymphocytes%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-01760-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidawanyika, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaubourgeix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">9968</span>– <span class="NLM_lpage">9971</span>, <span class="refDoi"> DOI: 10.1021/ja400021x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja400021x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=9968-9971&author=G.+Linauthor=T.+Chidawanyikaauthor=C.+Tsuauthor=T.+Warrierauthor=J.+Vaubourgeixauthor=C.+Blackburnauthor=K.+Gigstadauthor=M.+Sintchakauthor=L.+Dickauthor=C.+Nathan&title=N%2CC-Capped+dipeptides+with+selectivity+for+mycobacterial+proteasome+over+human+proteasomes%3A+role+of+S3+and+S1+binding+pockets&doi=10.1021%2Fja400021x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">N,C-capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets</span></div><div class="casAuthors">Lin, Gang; Chidawanyika, Tamutenda; Tsu, Christopher; Warrier, Thulasi; Vaubourgeix, Julien; Blackburn, Christopher; Gigstad, Kenneth; Sintchak, Michael; Dick, Lawrence; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">9968-9971</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors identified N,C-capped dipeptides that are selective for the Mycobacterium tuberculosis proteasome over human constitutive and immunoproteasomes.  Differences in the S3 and S1 binding pockets appeared to account for the species selectivity.  The inhibitors can penetrate mycobacteria and kill nonreplicating M. tuberculosis under nitrosative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaNq6HiLQwrVg90H21EOLACvtfcHk0lg66bh3F7edeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCisL0%253D&md5=2959e1ab9ece8784c35ea7bb99054ea2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja400021x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja400021x%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DChidawanyika%26aufirst%3DT.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DWarrier%26aufirst%3DT.%26aulast%3DVaubourgeix%26aufirst%3DJ.%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DN%252CC-Capped%2520dipeptides%2520with%2520selectivity%2520for%2520mycobacterial%2520proteasome%2520over%2520human%2520proteasomes%253A%2520role%2520of%2520S3%2520and%2520S1%2520binding%2520pockets%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D9968%26epage%3D9971%26doi%3D10.1021%2Fja400021x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+new+series+of+non-covalent+proteasome+inhibitors+with+exquisite+potency+and+selectivity+for+the+20S+beta5-subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0lg66bh3F7edeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520new%2520series%2520of%2520non-covalent%2520proteasome%2520inhibitors%2520with%2520exquisite%2520potency%2520and%2520selectivity%2520for%2520the%252020S%2520beta5-subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melandri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span> <span> </span><span class="NLM_article-title">Kinetic characterization of the chymotryptic activity of the 20S proteasome</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3899</span>– <span class="NLM_lpage">3908</span>, <span class="refDoi"> DOI: 10.1021/bi952262x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi952262x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADyaK28XhsFKqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=3899-3908&author=R.+L.+Steinauthor=F.+Melandriauthor=L.+Dick&title=Kinetic+characterization+of+the+chymotryptic+activity+of+the+20S+proteasome&doi=10.1021%2Fbi952262x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic characterization of the chymotryptic activity of the 20S proteasome</span></div><div class="casAuthors">Stein, Ross L.; Melandri, Francesco; Dick, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3899-908</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors report kinetic studies for the chymotryptic activity of the 20S proteasome.  Reaction progress curves that are recorded at concns. of Suc-Leu-Leu-Val-Tyr-AMC greater than about 40 μM are biphasic and characterized by initial velocities that decay by a first-order process to final, steady-state velocities.  At [Suc-Leu-Leu-Val-Tyr-AMC] > 40 μM, initial and steady-state velocities are smaller than predicted from simple, Michaelis-Menten kinetics.  The first-order rate const. for the approach to steady-state has a complex dependence on substrate concn. and decreases sigmoidally as substrate concn. increases.  These results indicate that the 20S proteasome is a hysteretic enzyme and is subject to substrate inhibition.  To explain these observations the authors propose a minimal kinetic model with two crit. mechanistic features: (1) the 20S proteasome has two cooperative active sites for Suc-Leu-Leu-Val-Tyr-AMC and (2) there are two interconvertible conformers of active 20S proteasome.  To probe this mechanism in greater detail, the authors explored the kinetic mechanism of inhibition of the 20S proteasome-catalyzed hydrolysis of Suc-Leu-Leu-Val-Tyr-AMC by the peptide aldehyde, Ac-Leu-Leu-Nle-H.  The studies reveal a nonlinear dependence of steady-state velocity on inhibitor concn. (i.e., parabolic inhibition) as well as a nonlinear dependence of the apparent inhibitor dissocn. const. on substrate concn.  Both of these observations are explained by binding of inhibitor at multiple sites on the enzyme.  Taken together, the results of this study indicate that the 20S proteasome is a conformationally flexible protein that can adjust to the binding of ligands and that has multiple and cooperative active sites.  These results support a view of the proteasome's substrate specificity in which (1) substrates are recognized and hydrolyzed by more than one active site; (2) each active site can bind substrates that possess a variety of P1 residues; and (3) the P1 residue plays a relatively minor role as a specificity determinant.  Finally, the authors interpret the results of this study to suggest that, in vivo, the 20S proteasome requires conformational plasticity for its interactions with regulatory complexes and, after it has combined with appropriate regulatory complexes, to catalyze hydrolysis of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQf-rPQS50RrVg90H21EOLACvtfcHk0lh1k8N72qyu0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsFKqsrg%253D&md5=5cbce45f695898e7501d57b72159d24c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbi952262x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi952262x%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DR.%2BL.%26aulast%3DMelandri%26aufirst%3DF.%26aulast%3DDick%26aufirst%3DL.%26atitle%3DKinetic%2520characterization%2520of%2520the%2520chymotryptic%2520activity%2520of%2520the%252020S%2520proteasome%26jtitle%3DBiochemistry%26date%3D1996%26volume%3D35%26spage%3D3899%26epage%3D3908%26doi%3D10.1021%2Fbi952262x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roccaro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azab, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runnels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">4051</span>– <span class="NLM_lpage">4060</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-09-243402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1182%2Fblood-2009-09-243402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=20110419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4051-4060&author=A.+M.+Roccaroauthor=A.+Saccoauthor=M.+Aujayauthor=H.+T.+Ngoauthor=A.+K.+Azabauthor=F.+Azabauthor=P.+Quangauthor=P.+Maisoauthor=J.+Runnelsauthor=K.+C.+Andersonauthor=S.+Demoauthor=I.+M.+Ghobrial&title=Selective+inhibition+of+chymotrypsin-like+activity+of+the+immunoproteasome+and+constitutive+proteasome+in+Waldenstrom+macroglobulinemia&doi=10.1182%2Fblood-2009-09-243402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia</span></div><div class="casAuthors">Roccaro, Aldo M.; Sacco, Antonio; Aujay, Monette; Ngo, Hai T.; Azab, Abdel Kareem; Azab, Feda; Quang, Phong; Maiso, Patricia; Runnels, Judith; Anderson, Kenneth C.; Demo, Susan; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4051-4060</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been successfully tested in clin. trials.  Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects.  Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteasome 20S (c20S) and immunoproteasome 20S (i20S) represents a sufficient and successful strategy to induce antineoplastic effect in hematol. tumors.  We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S.  Primary WM cells express higher level of i20S compared with c20S, and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells, as well as of apoptosis through c-Jun N-terminal kinase activation, nuclear factor κB (NF-κB) inhibition, caspase cleavage, and initiation of the unfolded protein response.  Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived interleukin-6 (IL-6) and insulin-like growth factor 1 (IGF-1) secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase (p-ERK) activation in WM cells.  These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBDkasuJTbVg90H21EOLACvtfcHk0lh1k8N72qyu0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Ggsb0%253D&md5=6a1bdb8c763db89328adc15bc4a29f6f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243402%26sid%3Dliteratum%253Aachs%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DAujay%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DH.%2BT.%26aulast%3DAzab%26aufirst%3DA.%2BK.%26aulast%3DAzab%26aufirst%3DF.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DRunnels%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DDemo%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520chymotrypsin-like%2520activity%2520of%2520the%2520immunoproteasome%2520and%2520constitutive%2520proteasome%2520in%2520Waldenstrom%2520macroglobulinemia%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4051%26epage%3D4060%26doi%3D10.1182%2Fblood-2009-09-243402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ladi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stivala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaesse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidenschenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span> <span> </span><span class="NLM_article-title">Design and evaluation of highly selective human immunoproteasome inhibitors reveal a compensatory process that preserves immune cell viability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7032</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7032-7041&author=E.+Ladiauthor=C.+Everettauthor=C.+E.+Stivalaauthor=B.+E.+Danielsauthor=M.+R.+Durkauthor=S.+F.+Harrisauthor=M.+P.+Huestisauthor=H.+E.+Purkeyauthor=S.+T.+Stabenauthor=M.+Augustinauthor=M.+Blaesseauthor=S.+Steinbacherauthor=C.+Eidenschenkauthor=R.+Pappuauthor=M.+Siu&title=Design+and+evaluation+of+highly+selective+human+immunoproteasome+inhibitors+reveal+a+compensatory+process+that+preserves+immune+cell+viability&doi=10.1021%2Facs.jmedchem.9b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability</span></div><div class="casAuthors">Ladi, Ena; Everett, Christine; Stivala, Craig E.; Daniels, Blake E.; Durk, Matthew R.; Harris, Seth F.; Huestis, Malcolm P.; Purkey, Hans E.; Staben, Steven T.; Augustin, Martin; Blaesse, Michael; Steinbacher, Stefan; Eidenschenk, Celine; Pappu, Rajita; Siu, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7032-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pan-proteasome inhibitor bortezomib demonstrated clin. efficacy in off-label trials of Systemic Lupus Erythematosus.  One potential mechanism of this clin. benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells).  However, bortezomib is cytotoxic against non-immune cells which limits its use for autoimmune diseases.  An attractive alternative is to selectively inhibit the immune cell-specific immunoproteasome to deplete pathogenic immune cells and spare non-hematopoietic cells.  Here we disclose the development of highly subunit-selective immunoproteasome inhibitors using insights obtained from the first bona fide human immunoproteasome co-crystal structures.  Evaluation of these inhibitors revealed that immunoproteasome-specific inhibition does not lead to immune cell death as anticipated and that targeting viability requires inhibition of both immuno- and constitutive proteasomes.  CRISPR/Cas9-mediated knock-out expts. confirmed upregulation of the constitutive proteasome upon disruption of the immunoproteasome, protecting cells from death.  Thus, immunoproteasome inhibition alone is not a suitable approach to deplete immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtaasYDyZZ7Vg90H21EOLACvtfcHk0lgJx93v84sINg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbnO&md5=21b810621134c447794d5fb88337dbd2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00509%26sid%3Dliteratum%253Aachs%26aulast%3DLadi%26aufirst%3DE.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DStivala%26aufirst%3DC.%2BE.%26aulast%3DDaniels%26aufirst%3DB.%2BE.%26aulast%3DDurk%26aufirst%3DM.%2BR.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DHuestis%26aufirst%3DM.%2BP.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBlaesse%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DEidenschenk%26aufirst%3DC.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSiu%26aufirst%3DM.%26atitle%3DDesign%2520and%2520evaluation%2520of%2520highly%2520selective%2520human%2520immunoproteasome%2520inhibitors%2520reveal%2520a%2520compensatory%2520process%2520that%2520preserves%2520immune%2520cell%2520viability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7032%26epage%3D7041%26doi%3D10.1021%2Facs.jmedchem.9b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pletnev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the proteasome beta2 site sensitizes triple-negative breast cancer cells to beta5 inhibitors and suppresses nrf1 activation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.chembiol.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=28132893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=218-230&author=E.+S.+Weyburneauthor=O.+M.+Wilkinsauthor=Z.+Shaauthor=D.+A.+Williamsauthor=A.+A.+Pletnevauthor=G.+de+Bruinauthor=H.+S.+Overkleeftauthor=A.+L.+Goldbergauthor=M.+D.+Coleauthor=A.+F.+Kisselev&title=Inhibition+of+the+proteasome+beta2+site+sensitizes+triple-negative+breast+cancer+cells+to+beta5+inhibitors+and+suppresses+nrf1+activation&doi=10.1016%2Fj.chembiol.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation</span></div><div class="casAuthors">Weyburne, Emily S.; Wilkins, Owen M.; Sha, Zhe; Williams, David A.; Pletnev, Alexandre A.; de Bruin, Gerjan; Overkleeft, Hermann S.; Goldberg, Alfred L.; Cole, Michael D.; Kisselev, Alexei F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome inhibitors carfilzomib (Cfz) and bortezomib (Btz) are used successfully to treat multiple myeloma, but have not shown clin. efficacy in solid tumors.  Here we show that clin. achievable inhibition of the β5 site of the proteasome by Cfz and Btz does not result in loss of viability of triple-neg. breast cancer cell lines.  We use site-specific inhibitors and CRISPR-mediated genetic inactivation of β1 and β2 to demonstrate that inhibiting a second site of the proteasome, particularly the β2 site, sensitizes cell lines to Btz and Cfz in vitro and in vivo.  Inhibiting both β5 and β2 suppresses prodn. of the sol., active form of the transcription factor Nrf1 and prevents the recovery of proteasome activity through induction of new proteasomes.  These findings provide a strong rationale for the development of dual β5 and β2 inhibitors for the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLGE7V8EGrULVg90H21EOLACvtfcHk0lgJx93v84sINg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kntb4%253D&md5=04690fbff962944953339978b3a15962</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DWilkins%26aufirst%3DO.%2BM.%26aulast%3DSha%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DD.%2BA.%26aulast%3DPletnev%26aufirst%3DA.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DGoldberg%26aufirst%3DA.%2BL.%26aulast%3DCole%26aufirst%3DM.%2BD.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26atitle%3DInhibition%2520of%2520the%2520proteasome%2520beta2%2520site%2520sensitizes%2520triple-negative%2520breast%2520cancer%2520cells%2520to%2520beta5%2520inhibitors%2520and%2520suppresses%2520nrf1%2520activation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D218%26epage%3D230%26doi%3D10.1016%2Fj.chembiol.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=10.1016%2Fj.chembiol.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=30612952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1WnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=340-351&author=A.+Besseauthor=L.+Besseauthor=M.+Krausauthor=M.+Mendez-Lopezauthor=J.+Baderauthor=B.+T.+Xinauthor=G.+de+Bruinauthor=E.+Mauritsauthor=H.+S.+Overkleeftauthor=C.+Driessen&title=Proteasome+inhibition+in+multiple+myeloma%3A+head-to-head+comparison+of+currently+available+proteasome+inhibitors&doi=10.1016%2Fj.chembiol.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors</span></div><div class="casAuthors">Besse, Andrej; Besse, Lenka; Kraus, Marianne; Mendez-Lopez, Max; Bader, Jurgen; Xin, Bo-Tao; de Bruin, Gerjan; Maurits, Elmer; Overkleeft, Herman S.; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-351.e3</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy.  The proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified as rate-limiting and is a primary target of clin. available PIs.  The most effective pattern of subunit inhibition provided by these PIs for cytotoxic activity in MM is unknown.  A head-to-head comparison of clin. available PIs shows that in the clin. relevant setting only the co-inhibition of β1 or β2 with β5 activity achieves meaningful functional proteasome inhibition and cytotoxicity, while the selective β2/β5 inhibition of both constitutive and immunoproteasome is the most cytotoxic.  In the long-term setting, selective inhibition of β5 subunit is sufficient to induce cytotoxicity in PI-sensitive, but not in PI-resistant MM, and the β5/β2 co-inhibition is the most cytotoxic in PI-resistant MM.  These results give a rational basis for selecting individual PIs for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbOQY4rmNt7Vg90H21EOLACvtfcHk0lgkVsqCEb__Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1WnsQ%253D%253D&md5=9b16394c94377aadc35aaef69568aece</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBesse%26aufirst%3DL.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DMendez-Lopez%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DMaurits%26aufirst%3DE.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DProteasome%2520inhibition%2520in%2520multiple%2520myeloma%253A%2520head-to-head%2520comparison%2520of%2520currently%2520available%2520proteasome%2520inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D340%26epage%3D351%26doi%3D10.1016%2Fj.chembiol.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i104"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01520">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88578"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01520?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01520</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis and compound characterization of all new compounds, and tables (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_001.pdf">jm0c01520_si_001.pdf (10.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01520/suppl_file/jm0c01520_si_002.csv">jm0c01520_si_002.csv (5.02 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01520&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01520%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01520" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b51e9afe1964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
